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2-21 azino-di-(3-ethyl benzothiazolin 
sulphone-6 diammonium salt)
Acridinium ester
Anti-human IgG labelled with acridinium ester
IgG (containing anti-TPO) labelled with acridinium ester
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The presence of antibodies to thyroid peroxidase (i.e. TPOAb) in human serum has 
been measured using an immunoradiometric assay (IRMA), an enzyme- 
immunometric assay, and three other immunoassay systems which incorporated 
the chemiluminescent label acridinium ester (AE).
The IRMA successfully utilised a commercial preparation of TPO labelled with [125I] 
and magnetic particles coupled to Protein A (Staphylococcus aureus) (MPA), with 
the latter separation medium used in an enzyme-immunometric assay which 
incorporated TPO labelled with horse-radish peroxidase (HRP-TPO). TPO was 
also labelled with AE and used in a chemiluminometric assay with magnetic 
particles coupled to human anti-IgG (MAb-Anti-IgG). The latter assay exhibited an 
improved response, as compared with the non-viable enzyme-immunometric 
assay, but was inferior to the IRMA lacking the required sensitivity and precision for 
a viable, clinical assay.
A competitive assay system was also investigated which utilised human anti-TPO 
(obtained from a purified preparation of IgG) labelled with acridinium ester (Acrid- 
IgG), TPO labelled with biotin (Biotin-TPO) and magnetic streptavidin-labelled 
'Dynabeads®1 , as the separation medium. This immunoassay produced a similar 
'blanket' response as produced in the enzyme-immunometric assay. The coated- 
tube assay involved the immobilisation of TPO onto plastic tubes and the use of a 
commercial preparation of sheep anti-human IgG labelled with AE (Acrid-Anti-IgG). 
This system proved to be the most viable of all the non-radioactive assays, with the 
results comparing favourably with the established ELISA with a correlation 
coefficient (r) of 0.96 and P = <0.001, (using the 'least squares linear regression 
after logarithmic conversion of the data). A good correlation was also demonstrated 
in the Deming and the Passing & Bablok plots. The coated-tube assay also 
compared favourably with indirect agglutination (r) = 0.80, P = <0.001. 
The results indicated that the less pure source of TPO used in the non-radioactive 
assays, could only be successfully applied to the measurement of TPOAb, when 
immobilised onto a solid-phase support such as the ELISA micro-titre plate or onto 
plastic tubes, but not in the more random, assay systems which utilised magnetic 
particles as the separation phase. The solid-phase, coated-tube chemiluminometric 





1.1 The Thyroid Gland
Disease of the thyroid gland is common and, although not usually life 
threatening, is quite prevalent in the general population and can be quite 
debilitating in some circumstances, affecting both the physical and mental 
well-being of the sufferer. Thyroid disease was indicated as early as the 19th 
century in the medical literature, as shown by the patient in Figure 1.
Figure 1 A 19th century photograph of a patient with autoimmune Graves' disease.
Photograph courtesy of the Royal College of Physicians of Edinburgh [Becton 
Dickinson (U.K.) Ltd.].
The adult thyroid gland is a highly vascular structure of about 25g in weight, 
and consists of two conical lobes joined by an isthmus and is located 
anterolaterally to the trachea, just behind its junction with the larynx (Williams 
& Goodburn, 1983). The main functions of the gland are concerned with the 
trapping of iodide (by active transport from the blood); the concentrating (and 
subsequent conversion to iodine) of iodide ions; the synthesis of thyroid 
hormones [thyroxine (T4), tri-iodothyronine (T3) and reverse tri-iodothyronine
(r-Ta)], (via phenolic coupling) by the follicular cells (Doniach, 1967); their 
storage in the follicular colloid, and their subsequent release into the 
bloodstream. The formation of mono-iodotyrosine (MIT) or di-iodotyrosine 
(DIT), which combine to form the thyroid hormones, T3 and T4 , occurs via the 
iodination of thyroglobulin (Tg), catalysed by thyroid peroxidase (TPO) 
(Williams & Goodburn, 1983) [see Figure 2].
Thioureylenes and excess I'
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Figure 2 A schematic diagram showing the synthesis of thyroid hormones by the 
thyroid follicular cell. (Tg = thyroglobulin, T = tyrosine, 
MIT = monoiodotyrosine, DIT = di-iodotyrosine, T3 = tri-iodothyronine, 
L = lysosome and p = pseudopod).
[Taken from Pharmacology by Rang, Dale and Ritter, 1995, Churchill Livingstone, New 
York].
The inorganic iodide absorbed from the diet is actively taken up by the 
thyroid gland where, in the presence of hydrogen peroxide (H2O2) and TPO, 
it is converted to iodine (Banga et a/., 1991). In cell-free systems the 
peroxidase can be shown to produce molecular iodine (I2):
2r + H2O2 + 2I-T   -> I 2 + 2H2O (Williams & Goodburn, 1983).
The two-electron oxidation of TPO by H2O2 produces an oxoferryl porphyrin 
pi-cation radical compound I, which is the catalytic species that effects iodide 
ion oxidation; this compound isomerises spontaneously to produce a protein 
radical compound, which is thought to catalyse the phenolic coupling reaction 
of the thyroid hormones (Doerge & Divi, 1995). In the living cell the iodination 
of thyroglobulin occurs on the surface of the thyroid peroxidase enzyme (a 
complex, transmembrane protein) located on the apical membrane of the 
thyrocyte (Banga et a/., 1991).
The free thyroid hormones (the biologically active components), are essential 
for growth and development, and have a central role in cell metabolism and 
the rate of metabolic processes (Henneman et a/., 1994), including effects on 
heat production, neuromuscular activity and protein synthesis (Williams & 
Goodburn, 1983). The glycoprotein, thyrotropin (thyroid stimulating hormone, 
TSH) initiates all pathways involved in the synthesis of the thyroid hormones 
(Henneman et a/., 1994), and together with the tri-peptide thyrotrophin 
releasing hormone, TRH, (L-pyroglutamyl-L-histidyl-L-proline amide), which is 
produced in the hypothalamus, is involved in the thyroid negative feedback, 





Figure 3 Secretion, metabolism and control of thyroid hormones. 
Solid lines - secretion and metabolism of hormones; 
Dotted lines - negative feedback mechanisms.
[Taken from 'Clinical Chemistry in Diagnosis and Treatment' by Zilva and Pannall, 1984, 
4th Edition, Lloyd-Luke (Medical Books) Ltd., London].
1.2 Autoimmune Thyroid Disease (AITD)
The thyroid gland can be affected by the same spectrum of disease 
processes that can strike other organs and tissues, including autoimmune 
disease (Williams & Goodburn, 1983). The aetiology and pathology of thyroid 
disease is more complex than initially comprehended and increased interest 
has been focused on the autoimmune variants of disease and its 
implications. The clinical aspects of autoimmune thyroid disease (AITD) are 
diverse, with the thyroid gland being much more prone to autoimmune 
disease than other endocrine glands (Williams & Goodburn, 1983).
The function of the immune system is to identify and eliminate foreign protein 
antigens from the body, controlled through a process known as tolerance 
(Roitt et a/., 1996; Janeway & Travers, 1996). The breakdown in tolerance 
and immunoregulation results in autoimmunity, with the generation of 
humoral and/or cell mediated activity directed against a self protein resulting 
in tissue destruction (Roitt et a/., 1996; Janeway & Travers, 1996).
The prevalence of AITD in the general population is quite high (Banga et al., 
1991), affecting approximately 5% of the population (Weetman & McGregor., 
1994), and consequently has been intensively studied (Williams & Goodburn, 
1983). Although the pathology of these diseases is well-documented, their 
origins are unclear (Weetman & McGregor, 1994). Autoimmune thyroid 
disorders include Graves' disease (GD), Hashimoto's thyroiditis (HT), post- 
partum thyroiditis (PPT), primary myxoedema, and focal lymphocytic 
thyroiditis.
Individuals with AITD demonstrate an increased incidence of other 
autoimmune disease, such as systemic lupus erythmatosis (SLE) and 
Addison's disease (Williams & Goodburn, 1983), and particularly diabetes 
mellitus (DM), and pernicious anaemia (PA) (Banga et a/., 1991), indicating 
the polyclonal activation of the autoimmune reaction in organ-specific 
autoimmune diseases (Morita et a/., 1995). Paggi et a/. (1994) showed an 
increased incidence of anticardiolipin antibodies [associated with systemic 
lupus erythematosus (SLE)], in patients with AITD. Similarly, Morita et al. 
(1995) showed a high prevalence of anti-nuclear antibody (ANA), anti- 
smooth muscle antibody (SMA) and anti-ssDNA antibody in some individuals 
with AITD.
Weetman et al. (1983) stated that microsomal autoantibodies (TPOAb) were 
found in 11.6% of patients with rheumatoid arthritis (RA) and also an 
increased frequency of thyroid autoantibodies has been reported in 
Alzheimer patients (Mariotti et al., 1995). This could indicate a possible 
overlap in the pathogenicity of these conditions (Morita et al., 1995), but may 
merely represent a non-specific marker of immune disregulation (Mariotti et 
al., 1995).
Patients with AITD present with a spectrum of clinical disease, from immune 
destruction as in Hashimoto's thyroiditis (HT), which leads to hypothyroidism, 
to excessive stimulation which results in Graves' disease (GD) and 
hyperthyroidism (Banga et al., 1991). GD and HT are both considered to be
organ-specific autoimmune diseases (Morita et a/., 1995), and are examples 
of type II autoimmune polyglandular syndrome (APS) (Riley, 1995).
Hypothyroidism presents with non-specific symptoms such as lethargy, mild 
depression, variation in menstruation and weight increase, together with the 
classic features which consist of bradycardia, dry skin and hair loss, with the 
myotonic ankle jerk being the most discriminatory clinical feature (Lazarus, 
1996).
GD in contrast, is associated with hyperthyroidism, which includes the 
symptoms of sweating, palpitations, irritability, insomnia, mood swings, 
tremor, ocular signs (exophthalmopathy), smooth skin, heat intolerance, 
nervousness and tachycardia, together with a generalised increase in 
metabolic rate (Williams & Goodburn, 1983).
1.2.1 Hashimoto's Thyroiditis (HT)
Hashimoto's thyroiditis (HT) was first described in 1912 and is the most 
common organ-specific autoimmune disease in man (Roitt et a/., 1989), and 
is the most prevalent cause of primary thyroid failure (Lazarus, 1996). HT is 
a T cell mediated disease (Rieu et a/., 1994) and is characterised by 
infiltration of the gland by lymphocytes, with gradual destruction of the gland 
(Tomer, 1997). The gland is lobulated (Lazarus, 1996), enlarged and 
horseshoe-shaped, with a firm, rubbery consistency (Williams & Goodburn, 
1983).
The peak incidence occurs between 50 and 60 years of age and the disease 
is more common in women and Caucasians (Volpe, 1989a). The incidence is 
thought to have increased in recent years due to a greater intake of dietary 
iodine (Weetman & McGregor, 1994). The thyroid's functional state may vary 
through the course of Hashimoto's disease (Rieu et a/., 1994). Most 
characteristically, although patients may remain euthyroid for many years, 
approximately 10% will ultimately become hypothyroid (Gorin & Lamberg, 
1975). Other associated hormonal deficiencies may contribute to the clinical 
picture (e.g. features of hypogonadism) (Lazarus, 1996).
1.2.2 Graves'Disease (GD)
Graves' disease (GD), also known as Parry's disease, von Basedow's 
disease, exophthalmic goitre and toxic diffuse goitre, is an autoimmune 
disease (Weetman & McGregor, 1994; Volpe, 1994), which (as in HT), is 
characterised histologically by lymphocyte infiltration of the thyroid (Cavan et 
a/., 1994) and is associated with a diffusely enlarged, non-nodular gland 
(Williams & Goodburn, 1983). GD is again more prevalent in females (4-5 
times more), and increases with age (Volpe, 1989b). In HT, animal models 
have contributed to an improved understanding of the disease, however, an 
equivalent model is not currently available for GD (Weetman & McGregor, 
1994). GD best fits a polygenic, multifactorial model of disease in which 
genetically susceptible individuals are exposed to a constitutional or 
environmental insult. This provocation can then result in the activation of the 
immune response and trigger the B cell production of thyroid-receptor 
autoantibodies (TRAb), which can lead directly to the induction of 
hyperthyroid GD (Weetman & McGregor, 1994).
Both GD and HT are characterised by the presence of autoantibodies 
against the thyroid tissue-specific components thyroid peroxidase (TPO) (i.e. 
TPOAb) and thyroglobulin (Tg) (i.e. TgAb). GD is also characterised by the 
presence of TSH receptor autoantibodies (TRAb) (Volpe, 1989b; Banga et 
a/., 1991; Weetman & McGregor, 1994), such as TSH binding inhibitory 
immunoglobulin (TBII) and thyroid stimulating antibodies (TSAb), [also called 
thyroid-stimulating immunoglobulin (TSI)] (Miles et a/., 1998). The latter was 
initially discovered by Adams and Purves in 1956 and termed Long Acting 
Thyroid Stimulator (LATS) (Williams & Goodburn, 1983).
1.2.3 Post-partum Thyroiditis (PPT)
Post-partum thyroiditis (PPT) is a transient, destructive, autoimmune 
syndrome, similar to Hashimoto's thyroiditis (Parkes et a/., 1994). PPT 
affects 4-7% (Jansson et a/., 1988; Gerstein, 1990), 5-9% (Othman et a/., 
1990), 4-6% (Weetman, 1994) of apparently healthy women in the first year
after delivery. The syndrome is characterised biochemically by an episode of 
hypothyroidism or sequential episodes of both hyper and hypo-thyroidism 
(Parkesefa/., 1994).
An elevated level of thyroid peroxidase autoantibodies (TPOAb) during early 
pregnancy is generally considered to be the best predictor of PPT (Jansson 
et a/., 1984; Weetman, 1992; Creagh et a/., 1994; Weetman & McGregor, 
1994). Symptoms of PPT appear in some 50% of women who have positive 
TPOAb levels at 16 weeks gestation (Lazurus & Othman, 1991; Creagh et 
a/., 1994; Lazurus et a/., 1996). In 20 - 30% of the women who develop PPT, 
the hypothyroid state becomes permanent (Jansson et a/., 1984; Othman et 
a/., 1990; Creagh et a/., 1994; Lazurus et a/., 1996).
An association between depression and post-partum thyroiditis certainly 
exists in the hypothyroid state, but severe psychiatric symptoms are 
uncommon (Harris et a/., 1992; Pop et a/., 1995). PPT has been associated 
with decreased foetal size and lower birth weight (Weetman & McGregor, 
1994) and later impaired child development (Pop et a/., 1995), and also with 
the devastating consequences of increased infant mortality rate and 
spontaneous abortion (Burrow, 1993; Pop et a/., 1995).
1.3 Factors Implicated in Autoimmune Thyroid Disease (AITD)
Genetic predisposition, together with ill-defined environmental and 
endogenous factors, determines susceptibility to AITD (Weetman & 
McGregor, 1994). AITD clearly increases with age (especially) in the female 
population (Fong et a/., 1981; Roti et a/., 1992; Weetman, 1992; Mariotti et 
a/., 1995; Sunbeck et a/., 1995). The hormone oestrogen has been 
associated with the exacerbation of AITD, in contrast to testosterone which 
has been associated with the amelioration of AITD (Weetman, 1991). 
Prolactin may also have a role because asymptomatic autoimmune thyroiditis 
is more common in hyperprolactinaemic disorders (Ferrari et a/., 1983). 
AITD is also known to present during puberty, pregnancy, postpartum period
(Weetman, 1991) and the menopause (Williams & Goodburn, 1983; 
Vanderpump et a/., 1995).
GD is diagnosed more frequently in the warmer months of the year, which 
could possibly be due to the increased heat-intolerance experienced 
(Weetman & McGregor, 1994; Westphal, 1994). Seasonal variation could 
also be attributed to an associated increase in iodine intake, which has also 
been implicated in the onset and severity of GD (Weetman & McGregor, 
1994), and the enhancement of thyroid autoimmunity in genetically 
susceptible individuals (Prentice et al., 1990). Sudden changes in iodine 
intake may be more important for the development of thyroiditis and thyroid 
autoantibodies than prolonged exposure to a high but constant iodine intake 
(Weetman & McGregor, 1994).
Stress has been associated with the onset of thyroid disease (Kanner et al., 
1981; Leclere & Weryha, 1989; Weetman & McGregor, 1994; Kung, 1995). 
Recent studies have demonstrated a shared antigenicity of the human stress 
protein (hsp70) with thyroid peroxidase (Youde & Parkes, 1996a).
The administration of various cytokines [i.e. alpha-interferon (a-IFN)] is a 
clearly established iatrogenic cause for AITD (Weetman & McGregor, 1994). 
Clinical studies have suggested that lithium may dispose individuals to the 
development of AITD (Calabrese et a/., 1985; Lazurus et a/., 1986) and 
Graves' disease can develop in patients on long-term therapy (Barclay ef a/., 
1994). However, studies by Lee et al. (1992) on a Hong Kong population in 
contrast, indicated that thyroid autoantibodies were not as prevalent in their 
lithium patients, possibly attributable to ethnic (genetic) differences, and 
indicated the multifactorial mechanisms of lithium-associated thyroid 
abnormalities. Cyclosporin (CS) a potent immunosuppressive agent has 
been shown to aggravate and/or induce relapse in AITD (Prud'homme et al., 
1991).
Infection with microorganisms has been linked to the initiation of autoimmune 
thyroid disease, although definitive roles for their involvement have not been 
proven (Weetman & McGregor, 1994). These include Yersinia enterocolitica
associated with food poisoning (Weiss et a/., 1983); congenital rubella 
syndrome linked with thyroid disease (Clarke et a/., 1984); hepatitis C and 
Graves' disease (Leri et a/., 1992); influenza, Coxsackie, adenovirus and 
mumps (Weetman & Borysiewicz, 1990); and the Epstein-Barr virus (EBV) 
(Coyleefa/., 1989).
The major histocompatibility complex (MHC) of genes, called HLA (Human 
Leucocyte Antigen) in man, controls (in part) immune responsiveness to a 
variety of foreign and self antigens (Weetman, 1992). Individuals with certain 
HLA profiles seem prone to various forms of thyroid disease (Cavan et a/., 
1994; Nicholson et a/., 1994). GD is associated with particular HLA types, but 
the associations are relatively weak and inconsistent between populations 
(Weetman, 1992), and it seems that the HLA genes may be important in 
conferring protection against GD (Cavan et a/., 1994). The available data 
suggest strongly that a non-MHC genetic factor plays an important role in 
susceptibility (Weetman & McGregor, 1994). Thyroid autoimmunity has been 
associated with familial Alzheimer's disease and Down's syndrome, 
suggesting the influence of an unknown genetic factor on chromosome 21 
(Ewins et a/., 1991). Thyroid abnormalities in Down's syndrome however, 
appear to be heterogeneous in origin and are not always associated with 
autoimmunity (Ewins et a/., 1991). AITD has also been associated with 
Turner's syndrome (Williams & Goodburn, 1983).
1.4 The Major Autoantigens
Thyroid peroxidase (TPO), formerly known as the microsomal antigen, 
together with thyroglobulin (Tg) and the TSH-receptor (TSH-R) are the three 
major autoantigens involved in AITD. Undoubtedly, the major advance in 
thyroid autoimmunity in the last decade was the cloning and sequencing of 
the three thyroid autoantigens, contributing to a detailed characterisation of 
the autoantibodies (Weetman & McGregor, 1994). All of these autoantigens 
play essential roles in thyroid hormone synthesis [see Figure 4 for 










Figure 4 A schematic diagram showing the structures of the three major autoantigens 
involved in Graves' disease and Hashimoto thyroiditis [O'Connor & Davies, 
1990].
1.4.1 Thyroid Peroxidase (TPO)
Thyroid peroxidase (TPO) has been described as a small membrane-bound 
glycoprotein of 100-105 kilodaltons (kDa), which contained a haem group 
with a central role in tyrosyl residue iodination and coupling (Banga et a/., 
1984; Weetman & McGregor, 1994). Subsequent immunoprecipitation and 
Western blotting studies confirmed the molecular weight of TPO to be 103- 
110 kDa under reducing conditions and from 117 kDa under non-reducing 
conditions (Banga et a/., 1991). However, McLachlan & Rapoport, 1995, 
claimed that TPO is a membrane-bound glycoprotein comprising two 
identical approximately 100 kDa subunits. The 93 kDa extracellular region of 
TPO can be purified in limited amounts from thyroid tissue and it is this 
region which is particularly suitable for the studies of the associated human 
TPO autoantibodies (McLachlan & Rapoport, 1995). X-Ray crystallography
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has shown that TPO is composed mainly of alpha-helical structure with little 
beta-sheet structure (Banga et al., 1991).
The antigen was first recognised by immunofluorescent studies some 40 
years ago by Trotter et al. (1957). The antigen was located to the microsomal 
fraction of the thyroid gland (Roitt & Doniach, 1958) and later linked to the 
smooth-surface vesicles of the microsomal fraction of the thyroid gland 
(Belyavin & Trotter, 1959; Roitt et a/., 1964). Khoury et at. (1984) later 
provided evidence that in AITD, microsomal autoantibodies were present in 
the apical portion of follicular cells, the probable site of TPO-catalysed 
iodination, which was similarly demonstrated by Aliquer et al. (1989).
The nature of this antigen remained unknown for more than 20 years after its 
discovery, but it become clear that the thyroid microsomal antigen was very 
closely related to, if not identical with thyroid peroxidase (TPO) (Doniach et 
al., 1982; Portmann et al., 1985; Ruf et al., 1985; Kotani et al., 1986; 
Nakajima et al., 1987; Yokoyama et al., 1989; Roti et al., 1992). It has now 
been shown to be identical to thyroid peroxidase (TPO) (Aliquer et al., 1989; 
Banga ef al., 1991). The coding sequence for the human thyroid peroxidase 
(hTPO) complementary DMA (cDNA) comprises 2799 nucleotides and codes 
for a 933 amino acid protein with five potential N-glycosylation sites. A typical 
hydrophobic sequence of 25 residues is found towards the C-terminus of the 
molecule. This traverses the plasma membrane and anchors the enzyme to 
the apical surface of the thyroid follicular cell (Banga et al., 1991). Two forms 
of TPO referred to as TPO-1 (larger) and TPO-2 (smaller) have been 
described (Banga ef al., 1991).
The autoimmune response to TPO is heterogeneous and polyclonal in nature 
(Banga et al., 1991). Epitopes of TPO have been found to be both 
conformational and linear (Ludgate et al., 1989; Finke ef al., 1990). Kohno et 
al. (1986) concluded that at least three epitopes of TPO were recognised by 
serum autoantibodies in their study, but up to six autoantigenic epitopes have 
been recognised by others (Hamada et al., 1987; Weetman et al., 1987; 
Doble et al., 1988; Banga et al., 1991). Ruf et al. (1989) mapped four 
antigenic domains (A.B.C and D) on the TPO molecule, with seven epitopes
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(recognised by monoclonal antibodies), localised in the four antigenic 
domains. The variable outcome in results can probably be attributed to the 
different investigative techniques employed.
One particular epitope, an 85 amino acid segment of TPO, is known as C2 
(Ludgate et al., 1989). This sequence harbours a major epitope recognised in 
the serum of patients with both GD and HT. It has been suggested that TPO 
and Tg may share common epitopes (Kohno et al., 1988; Banga et a/., 
1991), and Weetman & McGregor (1994) state that there is some 
conformational similarity between TPO and Tg. If this proves to be the case, 
it will unveil novel explanations for the simultaneous presence of high levels 
of Tg and TPO autoantibodies in the majority of AITD patients (Banga et al., 
1991). Weetman & McGregor (1984) and Ruf et al. (1993) also reported the 
identification of a new category of thyroid-specific autoantibody interacting 
with both Tg and TPO (TGPO autoantibodies).
1.5 Thyroid Peroxidase Autoantibodies (TPOAb)
Thyroid peroxidase autoantibodies (TPOAb), [formerly termed microsomal 
autoantibodies (MicAb)], are considered to be a more specific indicator of 
AITD than thyroglobulin autoantibodies (TgAb). Early studies demonstrated 
the presence of TPOAb in virtually all cases of HT (Trotter et al., 1957; 
Belyavin & Trotter, 1959), while only some 70% of patients had TgAb (Roitt 
et al., 1956). More recently, TgAb have been found in no more than 50% of 
lymphocytic thyroiditis patients and 25% of GD patients, whereas TPOAb are 
found in over 90% of both groups of patients (Banga et al., 1991). A positive 
correlation between TPOAb and the intensity of the intrathyroidal 
autoimmune process in GD has been described (Paschke et al., 1993). 
However, Mariotti et al. (1990) found no simple relationship between TPOAb 
and thyroid status in their study.
The TPOAb was discovered in the serum of patients with HT due to 
differences between the precipitation and complement-fixing reactions of
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TPOAb as compared with TgAb. The TPOAb were capable of complement 
fixation, unlike TgAb (Belyavin & Trotter, 1959).
The TPOAb have an IgG subclass distribution similar to those against Tg 
(Parkes et at, 1984; Banga et at, 1991; Weetman & McGregor, 1994; 
McLachlan & Rapoport, 1995). Preliminary studies indicated a predominance 
of subclasses lgG1 and lgG4 in patients' sera (Parkes et at, 1984). 
However, in a review by Banga et at, 1991, they state that subsequent 
studies by Weetman ef at (1989) demonstrated the significant presence of 
lgG2 subclass TPOAb, with a higher affinity for TPO than lgG1 and lgG4. 
This could therefore represent the biologically important subclass in this 
disease (Banga ef a/., 1991). Guo et at (1997) also provided evidence for 
the presence of TPOAb of IgE class in AITD.
The thyroid receptor autoantibodies (TRAb) are directly pathogenic, whereas 
the involvement of TgAb and TPOAb in the pathogenesis of the disease has 
been unclear, and they have been considered to be innocent bystanders, 
reflecting the cellular destruction of the underlying gland, and used as 
diagnostic markers (Riley, 1995). However, there is growing evidence to 
suggest that disease-associated TgAb may play a role in the initiation of 
autoimmune thyroiditis (Tomer, 1997). The TPOAb are complement fixing 
and this raises the possibility that they may also play a role in the 
pathogenesis of thyroid follicular cell destruction in lymphocytic thyroiditis 
(Banga et at, 1991). Preliminary studies by Parkes et at (1993) indicated 
that thyroid damage during the post-partum period may be mediated via the 
complement system.
1.6 Prevalence of Thyroid Peroxidase Autoantibodies in the Normal 
Population
It is generally agreed that circulating thyroid autoantibodies are the hallmark 
of AITD (Yoshida et at, 1978; Weetman & McGregor 1984; Mariotti et at, 
1990; Fan et at, 1994; McLachlan & Rapoport, 1995; Sundbeck et at, 1995), 
but low levels of TPOAb [and TgAb (Tomer, 1997)] are detected in
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apparently normal individuals, which could indicate a predisposition to the 
development of disease. It is not clear which individuals will be affected by 
disease (Hidaka et a/., 1994), but a recent follow-up study indicated a 
continuing risk of developing thyroid failure in euthyroid persons, with positive 
thyroid autoantibodies with a female/male ratio of about 5 to 1 (Vanderpump 
etal., 1995).
A study by Yoshida et a/. (1978) indicated a very high prevalence of 
individuals with asymptomatic autoimmune thyroid diseases in the normal 
population. However, widely differing figures have been quoted, varying from 
3.6-8.4% of apparently normal adults (Roti et a/., 1992; Sundbeck et a/., 
1995), to 7% (Tunbridge et a/., 1977), 8.4% (Mariotti et a/., 1990), 10% 
(Groves et a/., 1990), and 15% (Weetman & McGregor 1992). The observed 
increase in percentage values in more recent studies is probably a reflection 
of the improved sensitivity of assays.
The age-dependent increase in the prevalence of positive TgAb and TPOAb 
is a well established phenomenon, recognised since the early 1960s (Hackett 
& Beech 1960; Hijmans et a/., 1984), with TPOAb having been detected in 
8% of children (Roti et a/., 1992). However, some reports indicate decreasing 
prevalence of TPOAb at ages greater than 60 years, thus indicating the need 
for a better understanding of the diagnostic and prognostic significance of 
increased TPOAb concentrations in the elderly (Sundbeck et a/., 1995).
There is an increased prevalence of TPOAb in the female population with 
Roti et a/. (1992), quoting values of 2.3% in elderly men as opposed to 
10.2% in elderly women. In the Wickham study in North-East England, MicAb 
were detectable in 7.9% of young women (aged 18-24) rising to 13.7% at 
age 45-54 years (Tunbridge et a/., 1977), with values of 14.9% and 24.2% 
quoted for the age-groups (18-24) and (55-64) years respectively, in women 
blood-donors by Prentice et a/. (1990).
Different reports of the prevalence of autoantibodies in both diseased and 
apparently normal individuals may be attributable to the use of different study 
designs, decision limits and subject populations (i.e. variation due to regional
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differences, including ethnic background, iodine intake, gender ratio and 
age). In addition, TPOAb are heterogeneous so that different methods (i.e. of 
sensitivity and specificity) may have given different results in different thyroid 
disorders (Sundbeck et a/., 1995).
1.7 Methods for Measuring Thyroid Autoantibodies
Autoantibodies present in biological fluids are identified exclusively by highly 
specific and sensitive immunochemical techniques, which involve the 
detection of a complex formed between the antibody and a target antigen 
(using antibodies or antigens labelled with various markers), which is 
presented in tissues, cells, a crude tissue extract, or in a purified form (Miles 
et a/., 1998). Methods for measuring MicAb/TPOAb, TgAb, and TRAb, have 
improved over the last decade. However, more accurate and sensitive 
methods, together with high sample throughput are increasingly needed for 
identifying patients with autoimmune thyroid disease (AITD) and individuals 
at high risk for the possible onset of thyroid autoimmunity e.g. pregnant and 
postpartum females [especially in females with Type 1 Diabetes Mellitus 
(Bech et a/., 1991)], and individuals with a family history of these diseases.
In most cases TPOAb measurement is sufficient, and it is generally agreed 
that TPOAb appears to be a more sensitive indicator of AITD than TgAb 
(Banga et a/., 1991) and the more clinically relevant (Miles et a/., 1998). The 
measurement of TgAb however, is pertinent for disclosing possible 
interference in the methods for measuring Tg as a tumour marker in thyroid 
carcinoma (Feldt-Rasmussen, 1996). Many investigators have mentioned the 
usefulness of TRAb measurement in the diagnosis of GD (Kasagi et a/., 
1987; Chiovato et a/., 1994; Mukata et a/., 1994) and as an indicator of 
individuals at high risk of developing PPT (Hidaka et a/., 1994). However, as 
TRAb methodologies have been technically complex and relatively 
insensitive, with no recommended methods, accepted standards or quality 
assurance schemes for their measurement they have not been widely 
adopted for routine use (Feldt-Rasmussen, 1996; Miles et a/., 1998).
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1.8 Methods for the Detection and Measurement of
MicrosomaI/Thyroid Peroxidase Autoantibodies (MicAb/TPOAb)
New molecular and biochemical techniques, together with the improvement 
in separation procedures have all contributed to more precise antigen 
identification and to the availability of highly purified antigen preparations of 
thyroglobulin (Tg) and thyroid microsomal antigen [thyroid peroxidase (TPO)] 
from the thyroid gland (Miles et a/., 1998). In earlier methodologies such as 
indirect immunofluorescence (IMF) and passive haemagglutination (PH), the 
crude microsomal antigen preparation was used (usually contaminated with 
Tg) (Feldt-Rasmussen, 1996) and the autoantibodies detected were initially 
termed microsomal autoantibodies (MicAb). Later assays utilised more 
purified preparations (including monoclonal antibodies to TPO and 
recombinant TPO preparations) and were termed thyroid peroxidase 
autoantibodies (TPOAb).
Thyroid MicAb/TPOAb (and TgAb) have both been traditionally detected or 
measured using the same methodologies. The assay of thyroid peroxidase 
autoantibodies by various methods has been used in the diagnosis of AITD 
since they were first described by Roitt et al. (1956). The earlier methods 
provided a means of detection of the autoantibody only i.e. 
immunoprecipitation, complement fixation (CF) and indirect 
imunofluorescence (IMF) (the latter a histological technique used as an 
autoantibody screen). The semi-quantitative particle agglutination technique 
was then devised, which was mainly superseded by quantitative procedures 
such as Radioimmunoassay (RIA), Immunoradiometric assay (IRMA), 
Enzyme-linked immunosorbent assay (ELISA) and more recently 
Chemiluminescent immunoassay (CIA). The earlier methods will only be 




In immunochemical reactions, addition of an increasing amount of antigen to 
a constant amount of antibody will result in increasing precipitation which 
reaches a plateau and then diminishes (Heidelberger & Kendall, 1935). The 
fundamental aspect of immunoprecipitation provided the basis for the 
quantitative immunoassay method called the 'precipitin' test, described by 
Heidelberger and Kendall in 1929 and 1935 (Edwards, 1985), and was used 
by Roitt et a/. (1956) for detecting thyroid autoantibodies in Hashimoto's 
thyroiditis (Anderson et a/., 1957), and in 'primary' myxoedema and sub- 
acute thyroiditis (Doniach & Roitt, 1957). The formed immunoprecipitate was 
removed by centrifugation, and the protein content of the precipitate assayed 
by optical density or nitrogen determination (micro-Kjeldahl). The decrease in 
precipitation at higher antigen concentrations due to the formation of smaller, 
more soluble complexes, gave rise to the 'prozone' effect due to antigen 
excess, which produced false negative results (Miles et a/., 1998).
Various immunoprecipitation procedures involving diffusion or electrophoretic 
migration were subsequently developed, using gels as the reaction medium 
[i.e. single radial immunodiffusion (SRID), and double immunodiffusion]. 
Immunodiffusion was used for the routine estimation of larger proteins such 
as the immunoglobulins and in the detection of TgAb. However, the 
technique was non-quantitative, lacked sensitivity, with a slow end-point 
development and was prone to give rise to spurious results due to 
haemolysis, lipaemia and bacterial contamination (Williams & Goodburn, 
1983; Edwards, 1985). Techniques based on electrophoretic separation and 
visualisation (i.e. immunoblotting) were more rapid and are extensively used 
in current research procedures.
The concentration of formed immunocomplexes can be measured using light 
scattering principles (i.e. nephelometry or turbidimetry) (Edwards, 1985). This 
principle was exploited by Harchhali et a/., 1994, who applied microparticle- 
enhanced nephelometry to the detection of human thyroid peroxidase 
autoantibodies in AITD (Harchhali et a/., 1994).
18
1.8.2 Complement Fixation (CF)
Red blood cells have been used as labels for monitoring and quantifying the 
immune reaction since the beginning of this century, with early descriptions 
of the complement fixation process in 1901 (Edwards, 1985). Complement 
factors bind to some immunoglobulins when aggregated or when antibodies 
are combined with their specific antigens (Edwards, 1985). Trotter et al. 
(1957), Anderson et al. (1957), Roitt & Doniach (1958) and Belyavin & 
Trotter (1959) demonstrated the ability of MicAb (TPOAb) to fix complement, 
with these findings confirmed by Irvine (1960), who demonstrated that serum 
from patients with Hashimoto's disease was cytotoxic for thyroid cells in vitro 
in the presence of complement (Cayzer, et al., 1978). It was also found by 
Forbes et al. (1962), and subsequently by Khoury et al. (1981) that exposure 
of primary cultures of thyroid cells in vitro to TPOAb in the presence of 
complement led to lysis of the cells (Banga et al., 1991).
The early complement fixation methods used for the detection of thyroid 
autoantibodies (as described by Anderson ef a/., 1957; Anderson et al., 
1959; Belyavin & Trotter, 1959), involved the incubation for 1 hour at 37°C, 
of suitable dilutions of (heat-inactivated) serum with complement extracted 
from guinea pig serum. The complement used had been titrated in the 
presence of antigen against the sensitised haemolytic system, in order to 
determine the dilution at which 50% red blood cell (RBC) haemolysis 
occurred [termed 1 minimum haemolytic dose (1MHD)] (Parkes et al., 1991). 
The antigen (saline extracts of human thyroid) was also added, with the 
optimal dilution usually found by 'chessboard' titration with dilutions of 
positive autoantibody sera of known titre, as described by Belyavin, (1953) 
(Roitt & Doniach, 1958). This was carried out to identify the highest 
autoantibody titre which did not exhibit the 'prozone' effect (Parkes et al., 
1991).
The residual (unreacted) complement was then detected with the addition of 
a suitable haemolytic system [e.g. a 3% suspension of sheep red cells 
sensitised with immune horse serum (Anderson ef a/., 1959)]. The degree of 
lysis (activated via the complement cascade system) was then observed
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after a further incubation period [see Figure 5 for the schematic 
representation of method principle].
'Sensitised' RBC 'Lysed' RBC
Figure 5 The TPO-TPOAb complex fixes serum complement (CF). Residual
complement then causes the lysis of the sensitised red blood cells (RBCs).
Earlier methods could not discriminate between the species of antibody 
which interacted with the complement system, however, Parkes et a/. (1991) 
devised a semi-quantitative micro-method for the differentiation of 
microsomal (TPO) autoantibodies depending on their degree of complement 
fixation. The method involved the use of sheep erythrocytes ('sensitised' with 
rabbit anti-sheep RBC serum) for the detection and titration of complement 
fixation by autoantibodies directed against human thyroid membranes in the 
serum of patients with AITD (Parkes et a/., 1991).
20
1.8.3 Indirect Immunofluorescence (IMF)
The secondary thyroid autoantibodies, MicAb/TPOAb and TgAb, were both 
identified by reaction against tissues or tissue organelles, most often 
subjectively using indirect immunofluorescence (IMF) microscopy, a relatively 
simple and inexpensive technique (Miles et a/., 1998). A composite block of 
rodent tissues included liver, stomach, kidney and thyroid was used for the 
so-called 'autoimmune screen' to detect a number of both organ-specific and 
non-organ specific autoantibodies (Miles et a/., 1998).
Each antibody was associated with distinctive patterns of fluorescence on 
human thyroid tissue and the use of a composite tissue block was necessary 
as anti-mitochondrial antibody demonstrated a similar immunofluorescent 
staining pattern on thyroid tissue, but could be distinguished from thyroid 
antibodies by reaction with the other tissues, e.g. liver (Miles et a/., 1998). 
Interference from heterophilic antibodies was also evident, with this 
remaining a pertinent factor in current, sophisticated immunoassays.
Although the immunofluorescence technique was highly sensitive and 
specific, trained personnel were required to prepare frozen tissue sections 
[which required a suitable freezing microtome (cryostat)], and also be 
competent in immunofluorescence microscopy (Ng et a/., 1987). 
Furthermore, being time-consuming and non-quantitative, with the subjective 
reading of results, it was not amenable to automation and consequently, 
unsuitable for large-scale screening. As a result immunofluorescence 
techniques were largely superseded by agglutination [see Figure 6 for the 




(conjugated to * fluorochrome)
Human immunoglobulins 
reactive to antigens in tissue
Tissues or cells mounted 
on glass slide
Figure 6 Principle of indirect immunofluorescence.
Human serum under investigation is incubated with tissue mounted on a glass slide. 
Unbound material is washed from the slide leaving only immunoglobulin specifically 
recognising antigens in the tissue. Bound human immunoglobulin is detected with an 
antiserum [i.e. anti-IgG as TgAb and TPOAb are mainly of IgG class (Weetman & 
McGregor, 1994)] conjugated to a fluorophore [e.g. fluorescein isothiocyanate-conjugate 
(FITC)] and visualised by fluorescence microscopy (Miles et a/., 1998).
1.8.4 Agglutination
Agglutination assays involve the cross-linking of specific antigen-coated 
particles by an antibody directed against that antigen, to form large 
macroscopic aggregates (Miles et a/., 1998). Boyden (1951) discovered that 
red blood cells pretreated with tannic acid ('tanned' red cells), passively 
absorbed exogenous antigens. After absorption of antigen by the tanned red 
cell, haemagglutination of these cells was a measure of antibodies specific to 
the absorbed antigen (Edwards, 1985). Bird & Stephenson (1973), Amino et 
a/. (1976) & Cayzer et a/. (1978) described agglutination assays for MicAb 
using 'tanned' red blood cells as the antigen carrier (coated with human
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thyroid microsomal proteins). This technique was termed indirect or passive 
haemagglutination (PH).
Sheep erythrocytes, initially used, were replaced by avian (turkey) cells as 
the carrier particle, as they demonstrated advantages of increased specificity 
(by reducing non-specific agglutination), which varied from species to 
species (Cayzer et al., 1978). Problems encountered with leaching of antigen 
from the surface of tanned red cells and non-specific adsorption were 
overcome with the use of milder and more efficient covalent coupling 
procedures (i.e. using chromic chloride and glutaraldehyde) (Edwards, 1985). 
The fragility of prepared red blood cells also resulted in poor storage 
capacity, with a relatively short shelf-life of 2-3 weeks (Edwards, 1985). 
However, the stability was increased up to six months at 4°C with the use of 
formaldehyde-preserved turkey erythrocytes (Cayzer et al., 1978).
Testing was done in the U-shaped wells of agglutination plates so that the 
pattern could be easily visualised in the bottom of the well. Serial dilutions of 
samples were made to eliminate problems associated with antigen excess 
exemplified by the 'prozone' effect encountered in immunoprecipitation 
techniques. The titre of the antibody was given by the subjective estimation 
of the highest dilution demonstrating agglutination (Miles et al., 1998).
Haemagglutination assays demonstrated a high degree of non-specific 
binding on turbid or microbially contaminated sera (Cayzer et al., 1978). High 
titres of thyroglobulin autoantibodies were also prone to giving false-positive 
results, which were overcome by adding free thyroglobulin to the microsomal 
(TPO) diluent (Cayzer et al., 1978; Mariotti et al., 1990). In addition, low titre 
cross-reacting IgM antibodies, or classic IgM rheumatoid factors, were a 
potential source of interference (Miles et al., 1998).
Antigen-sensitised turkey thyrocytes, coloured gelatin particles [used in the 
Serodia®-AMC kit for this project, see Appendix 2:8] or latex were adopted in 
commercial assays, with the latter options providing more inert, stable 
systems than the earlier haemagglutination methods. In these assays 
uncoated particles or cells were used as an internal control to identify
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interference from heterophilic antibodies (Miles et a/., 1998). However, 
although agglutination techniques were simple, semi-quantitative and could 
be used without any sophisticated instrumentation, they were time- 
consuming, laborious and they lacked the sensitivity of later immunoassays 
(Mariotti et a/., 1990). The subjective evaluation of results (prone to variability 
in scoring titres) also required experienced interpretative skills as in IMF 
(Miles et a/., 1998). Consequently, agglutination techniques were largely 
superseded by RIA and ELISA.
1.8.5 Radioimmunoassay (RIA)
The potential advantages of radioimmunoassay (RIA) were sensitivity, 
specificity, simplicity and a universal application (Edwards, 1985). The 
background measurement for the radiosotope [125 I] in almost all biological 
samples is virtually zero, giving high sensitivity, and radioactive disintegration 
is unaffected by changes in physico-chemical parameters such as pH, 
concentration, or temperature, therefore providing high specificity (Edwards, 
1985). The purity of the label needed to be high to enhance the sensitivity 
and precision of the immunoassay and this was achieved using 
chromatographic techniques, which produced pure and stable radiolabelled 
antigens/antibodies (Edwards, 1985). Analagous labelling and purification 
procedures were used for antigen and antibody, (i.e. using the Chloramine T, 
Lactoperoxidase, lodogen and Conjugation labelling procedures and 
subsequently purified using molecular exclusion chromatograpy) (Edwards, 
1985).
The classical, competitive radioimmunoassay (RIA) was based on the 
reaction of a limited concentration of antibody (reagent) with varying 
concentrations of antigen and radiolabelled antigen (Edwards, 1985). The 
converse of this being evident when measuring MicAb/TPOAb i.e. a labelled 
antibody species would compete with the sample autoantibody for a 'limited' 
amount of microsomal/TPO antigen [usually immobilised on a plastic support 
(Mariotti et a/., 1987)]. The reaction is allowed to come to a state of
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equilibrium, resulting in a mixture of free and bound antibody. The final 
radioactivity detected in the 'bound' fraction is inversely proportional to the 
concentration of analyte i.e. MicAb/TPOAb being measured [see Figure 7].
Figure 7 Radioimmunoassay for measuring serum TPOAb.
The sample (TPOAb-S) competes with a radioactively-labelled antibody 
(Ab-R) for the TPO antigen, usually immobilised on a suitable support. The 
radioactive counts attached to the support via TPO are indirectly proportional 
to sample TPOAb.
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A potentially limiting factor in most radioimmunoassays was the separation of 
the bound and the free fractions and their subsequent discrimination, which 
determined the specificity of the assay (Edwards, 1985). This was overcome 
with the use of pre-formed materials such as tubes and microplates, which 
greatly improved washing and separation procedures and obviated the need 
for centrifugation (Voller etal., 1979).
Radioimmunoassays for MicAb/TPOAb required antigenic preparations of 
sufficiently high purity. In contrast to Tg, TPO being a membrane protein, 
could only be obtained free of contamination in small quantity (Ruf et a/., 
1988). This conferred the drawbacks of low specific signal and high non- 
specific interference from serum components such as Tg with the less pure 
microsomal preparations (Ruf et a/., 1988). This was exemplified in the RIA 
described by Mariotti et a/. (1987), to measure the microsomal autoantibody 
(MicAb) which involved the competition of sample microsomal autoantibody 
and [125l]-anti-microsomal IgG with human thyroid microsomes coated onto 
microtitre plates. Similarly, a competitive radioassay was used to measure 
thyroid peroxidase (TPOAb), which involved the competitive inhibition of 
[125l]-anti-TPO monoclonal antibody and sample autoantibody for the coated 
microsomes. The competitive radioimmunoassays demonstrated that TPOAb 
and MicAb were virtually identical, but they lacked the sensitivity and 
specificity of the corresponding immunoradiometric assay (IRMA) methods 
also investigated (Mariotti etal., 1987).
Methods using monoclonal-assisted RIA, based on the competitive inhibition 
of the binding of [125l]-labelled TPO (by sample autoantibody) to the solid- 
phase monoclonal TPOAb coated onto plastic tubes or micro-titre plates 
have also been described (Ruf et a/., 1988; Mariotti et a/., 1990). These 
methods were claimed to overcome the limitations of the previously 
described competitive radioimmunoassay, being sensitive, specific and easy 
to perform (Ruf et a/., 1988; Mariotti et a/., 1990). The measurement of 
MicAb and TPOAb using the competitive inhibition of TPO antigenic activity, 
provided assays of increased sensitivity as compared with measurement by 
passive haemagglutination (Ruf et a/., 1988; Mariotti et a/., 1990; Roti et a/.,
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1992). The method also obviated the need for large quantities of purified 
microsomal TPO, as required for an existing IRMA (Mariotti et al., 1987; Ruf 
etal., 1988).
However, a prerequisite for using a monoclonal antibody preparation is that it 
can compete effectively for the TPO binding, with virtually all TPOAb present 
in patients' sera [i.e. encompassing all the autoantibodies produced against 
each of the epitopes, as described in 1.4.1]. Massart et al. (1991) compared 
a competitive inhibition assay which was developed by Ruf et al. (1988) for 
measuring TPOAb, with a commercial IRMA MicAb kit (which used tubes 
coated with microsomal antigens and a preparation of Protein A labelled with 
[125I] as antibody reagent) and showed that the assays were comparable in 
analytical reliability.
1.8.6 Immunoradiometric Assay (IRMA)
The conventional immunoradiometric (IRMA) (for antigen measurement) 
consisted of a two-step, non-competitive binding system in which the 
antibody was radioactively labelled instead of the antigen, and provided 
results directly proportional to the 'bound' radioactivity (i.e. complexed 
radiolabelled antibody) (Edwards, 1985). The measurement of autoantibody 
(i.e. MicAb/TPOAb) via IRMA would require labelled TPO antigen and an 
'excess5 amount of antibody reagent. The IRMA assay represented the use 
of another concept, i.e. immobilisation (covalent bonding) of antibody to a 
solid phase (Edwards, 1985).
There are a number of general ways in which IRMAs may be performed (i.e. 
the basic immunometric reaction, the 'two-site' method, and the indirect 
labelling [i.e the labelling of a second antibody] approach (Edwards, 1985). 
The IRMA used in this project, based on a method described by Beever et al. 
(1989) [see 2.4] for measuring TPOAb, was via the 'two-site' immunometric 
method, whereby the complex of radiolabelled TPO antigen and TPOAb was 
precipitated from the reaction mixture by the addition of a solid-phase 
antibody (magnetic particles coupled to Protein A), directed towards a
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second antigenic binding site on the TPOAb. Protein A (SpA) is a 42 kDa 
cell wall constituent of Staphylococcus aureus (Potter et a/., 1996), and has a 
high affinity and high specificity for IgG (Bottomley et a/., 1995).
Although, reagent preparation is technically more demanding for the IRMA, it 
is often easier to perform (Edwards, 1985), and is frequently more precise 
with greater sensitivity than the competitive RIA and may be accompanied by 
enhanced specificity, but earlier methods required large amounts of the TPO 
antigen (Mariotti et a/., 1987). For optimal use in IRMAs, different reagents 
are often added sequentially, allowing time for each reagent to react and the 
excess removed before the addition of the next reagent. IRMAs almost 
invariably use solid-phase separation techniques to distinguish between the 
complexed or bound antibody and the unreacted or free antibody (Edwards, 
1985). This makes the sequential additions technically very simple with the 
reduction of side-chain reactions, which could compromise the potential 
sensitivity and specificity of the assay system (Edwards, 1985). The IRMA 
can however, demonstrate the effects of 'non-specific' binding of the 
radiolabelled species, which can reduce the sensitivity of the assay. The 
washing of the solid-phase, radiolabelled TPO complex to remove any 'non- 
specific' interference can serve to enhance sensitivity.
The IRMA has a higher detection limit at high concentrations, giving overall a 
much wider working range, obviating the need for repeat analysis with 
dilution. The general, biphasic response (analagous to the 'prozone' effect in 
the precipitin test) is exemplified by the 'hook' effect in the 
immunoradiometric assay. The 'hook' effect takes place when the species 
being measured (i.e. TPOAb), is at a high concentration in reaction terms, 
and erroneously low results can be produced (Edwards, 1985).
Radioactive labelling provided assays with a very high level of sensitivity and 
reproducibility, which were amenable to automation for large scale 
processing (with the introduction of automated multi-well gamma counters for 
the detection of the low energy gamma-rays). However, the use of isotopes 
posed problems, including costly reagents with short shelf-lives, complex 
equipment for processing the results, and special safety measures to be
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observed in the handling, storage and disposal of the reagents. These 
factors prompted the search for alternative, non-radioactive methodologies 
equivalent to their radioactive counterparts.
1.8.7 The Enzyme-labelled Assay
Enzyme-linked Immunosorbent Assay (ELISA)
The enzyme-labelled assay may be categorised into either immunoassay 
(limited reagent) or immunometric (excess reagent) techniques. Enzyme- 
immunoassays may be carried out without the use of separation techniques 
(i.e. homogeneous) (which is not applicable to radioactive labels) or with 
heterogeneous techniques, which utilise separation techniques (Edwards, 
1985). Heterogeneous enzyme-immunoassays depend on the assumption 
that either an antigen [see 2.5] or antibody can be linked to an enzyme whilst 
retaining both immunological and enzymic activity in the resultant conjugate. 
As with radioimmunoassays, labelling the antigen with an enzyme, usually 
requires the availability of highly purified antigen (Edwards, 1985).
Enzyme-labelled immunometric assays using enzyme-labelled antibodies are 
invariably heterogeneous, requiring a separation stage, where the reacted 
enzyme-labelled component is separated by washing from the unreacted 
enzyme-labelled material, conventionally carried out with a solid-phase 
component. This basic immunometric assay, pioneered by Engvall et al. 
(1972) and Van Weemen & Schuurs, (1971) is usually referred to as 
Enzyme-linked immunosorbent assay (ELISA) and has been successfully 
applied to measuring large molecular weight substances (MWt over 10,000) 
such as antibodies in biological fluids, especially in blood. It was based on 
the principle that soluble antigens or antibody can be linked to an insoluble 
solid phase with the retention of reactivity of the immunological component 
(Vollerefa/., 1979).
In the variant of ELISA used for measuring MicAb, the immunosorbent i.e. 
the microsomal antigen is attached to the solid phase. After reacting the 
immobilised antigen with the varying concentrations of antibodies present in
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samples, and removal of unbound antibodies by washing, the bound 
antibodies are detected following a subsequent reaction with an enzyme- 
labelled anti-immunoglobulin antibody [see Figure 8 for a diagrammatic 
representation of the ELISA].
1 Antigen adsorbed to plate
wash
2 Add serum : any specific antibody attaches to antigen
wash




Amount hydrolysed = amount antibody present
Figure 8 The Indirect Method for Assay of Antibody (Voller ef a/., 1976: Bull. Wld. 
Hlth.Org.) Taken from The Enzyme-linked immunosorbent assay (ELISA): 
A guide with abstracts of microplate application' by Voller, Bidwell, & Bartlett, 
1979, Nuffield Laboratories of Comparative Medicine, The Zoological Society 
of London, London.
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Unlike in immunoradiometric assays, semi-purified antibodies, or even 
unpurified antibodies, have been used successfully in applications of the 
ELISA technique. However, this is probably a reflection of the fact that 
enzyme-labelled assays are generally not as sensitive as their radioisotope- 
labelled equivalents (Edwards, 1985).
ELISA consists of a series of incubations of different reagents separated by 
washing steps, which must be carried out in such a manner that there is no 
carry-over from one step to the next. The solid phase permits the separation 
of immunologically reacted from unreacted material during the test, and it is 
imperative that the solid phase should take up an adequate amount of the 
reactant in a reproducible manner. The variability at this stage is a major 
factor in determining the precision of all solid phase immunoassays (Voller et 
a/., 1979). Microplates made of polystyrene are easy to use and give 
adequate, reproducible uptake of most antigens merely by passive 
adsorption in alkaline solution (Miles et a/., 1998). The microplate format 
used in the ELISA is very convenient allowing the simultaneous washing of 
96 wells, whereas the sequential washing of individual tubes, beads or discs 
can be very cumbersome by comparison. Fully automated ELISA systems, 
including washing arrangements are available, with the results being read 
photometrically, with rapid microplate readers capable of reading a whole 
ELISA plate in seconds (Voller et a/., 1979).
It is essential to include a reference positive and negative sample on each 
plate. The substrate reaction is stopped when the reference positive 
absorbance reaches a predetermined value. This enables valid comparisons 
to be made between tests on different occasions and in different laboratories.
The enzyme should have a high turnover rate of substrate product in order to 
provide a good final signal, and be minimally susceptible to interference from 
factors likely to be present in the sample e.g. enzyme cofactors (Edwards, 
1985). The enzymes most favoured in the ELISA method have been alkaline 
phosphatase and in particular horseradish peroxidase, because of its low 
cost, easy conjugation and wide variety of substrates (Voller et a/., 1979).
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In addition, a convenient substrate detector system must be available, which 
should be cheap, safe and easy to use. The chief requirement of a substrate 
is to provide a sensitive detection method for the enzyme in the conjugate. 
Ideally the substrate should initially be colourless which upon degradation 
gives a strong colour, and also produce completely soluble products with a 
high absorbance (Voller et a/., 1979). A wide variety of peroxidase substrates 
oxidised by H2O2 are available, but care must be taken to choose one with 
adequate solubility. ABTS (2-2-azino-di-(3-ethyl benzothiazolin sulphone-6) 
(diammonium salt) has been used in ELISA (Groves et a/., 1990), and yields 
a final green colour with an Amaxat 410 nm, but gives a poor dose response 
curve. Ortho-phenylenediamine dihydrochloride (OPD) is considered to be by 
far the best peroxidase substrate. The product is completely soluble and has 
a high absorbance at 492 nm, yielding an orange colour after stopping with 
H2SO4 [as used in the enzyme-immunometric assay described in 2.5]. OPD, 
however, is photosensitive so that reasonable care is required when it is 
used, and OPD along with some other peroxidase substrates has been 
reported as being mutagenic (Voller et a/., 1979).
ELISA can exhibit the 'high dose hook' effect as exemplified in the 'IRMA', 
i.e. when antigen levels are extremely high and give falsely low absorbance 
values. ELISA can also be prone to interference by other serum components 
(e.g. specific for IgG antibody), which become fixed to the sensitised solid 
phase giving false positive results (as evident in the agglutination assay) 
(Voller et a/., 1979). Thyroglobulin contamination of microsome preparations 
(still present after filtration) has also caused problems in designing an 
antimicrosomal antibody ELISA (Weetman et a/., 1983).
Many ELISA methods have been developed for measuring thyroid 
autoantibodies (Schardt et a/., 1982; Weetman ef a/., 1983; Roman et a/., 
1984; Groves et a/., 1990). A micro-ELISA method which measured MicAb 
and TgAb simultaneously was also described by Ng et a/. (1987). Groves et 
a/. (1990) demonstrated that the determination of TgAb and MicAb (TPOAb) 
by ELISA showed superiority in both speed and sensitivity over the traditional 
passive haemagglutination, but the introduction of ELISA into routine use
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was initially hampered by the lack of primary standardisation, and different 
means of the quantitation and reporting of results (Groves et al., 1990; Feldt- 
Rasmussen, 1996; Miles et al, 1998).
Autozyme  TAB describes a commercial enzyme immunoassay (ELISA) for 
the screening and detection of autoantibodies against human thyroid 
peroxidase (TPO) in human serum. It employs horseradish peroxidase- 
conjugated anti-human antibodies and ABTS as its conjugate-substrate (Amax 
at 405nm), and is similar to the ELISA described by Groves et al. (1990). 
The Autozyme  TAB Anti-TPO assay however, uses recombinant human 
thyroid peroxidase which does not contain contaminating thyroglobulin and/or 
mitochondria found in other microsomal antigen preparations.
Ng et al. (1987) described a combined enzyme immunoassay (micro-ELISA) 
technique for the simultaneous measurement of autoantibodies against 
thyroglobulin and thyroid microsome. It involved the use of an immuno-dot 
blot technique which was developed by Hawkes et al. (1982), and used 
nitrocelluose membrane filter discs and a conjugate consisting of anti-human 
immunoglobulin labelled with horseradish peroxidase, and diaminobenzidine 
as chromogenic substrate. The results correlated well with 
immunofluorescence and as is true of other conventional ELISA techniques, 
was found to be superior (i.e. more specific and sensitive) to 
haemagglutination (Ng et al., 1987).
Heterogeneous enzyme-immunoassays combined the advantages of 
immunofluorescence and radioimmunoassay and overcame many of their 
disadvantages. Enzyme-labelled reagents are cheap to prepare, and are 
highly stable with long shelf lives. They also yield assays which approach the 
sensitivity of radioimmunoassay, and give objective results that can be 
determined, either visually, or with simple equipment (Voller et al., 1979).
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1.9 Chemiluminescent Immunoassay (CIA/ILMA)
On completion of this project, no references were cited in the world literature 
for the measurement of TPOAb/MicAb utilising a Chemiluminescent label. 
Luminescence is defined as the emission of light resulting from the 
dissipation of energy from a substance in an excited state. 
Chemiluminescence is defined as 'a type of luminescence in which the light 
emission is caused by the products of a specific chemical reaction'. In 
response to the need for non-isotopic labels, interest was renewed in 
Chemiluminescent molecules as an indicator of the antigen-antibody reaction. 
The phenomenon of light-emitting chemical reactions (chemiluminescence, 
CL) and (bioluminescence, BL) has been recognised for over 100 years. 
Although they have a diverse range of analytical applications, it is only in the 
last 10 years that they have made the transition from laboratory curiosities to 
core technologies and used in routine clinical laboratory investigations 
(Campbell, 1988).
Chemiluminescent molecules exploited as labels include luminol, isoluminol, 
acridinium esters, thioesters and sulphonamides, and phenanthridinium 
esters (Kricka, 1991). Various derivatives of luminol and isoluminol have 
been used for the Chemiluminescent labelling of proteins. However, the 
quantum yield of emission of these compounds decreased after coupling, to 
produce labelled proteins of relatively low specific activity and sensitivity. The 
requirement of a catalyst in the reaction also led to a high Chemiluminescent 
background and potential interference (Weeks et a/., 1983; Nelson & Kacian, 
1990).
The basic acridine molecule was discovered as early as 1870 (Nelson & 
Kacian, 1990). Derivatisation of acridine at the 9 position (which possessed a 
quartemary nitrogen centre at the 10 position) yielded labile phenyl ester 
moities such as A/-methyl acridinium esters (Weeks et a/., 1983). The A/- 
methyl acridinium ester reacted with dilute alkaline hydrogen peroxide to 
yield /V-methyl acridone in the excited state which then emitted light at 430 
nm, in the form of a rapid flash [see Figure 9] (Weeks et a/., 1983). This 
chemiluminescence was elicited simply without the need for a catalyst for the
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oxidation reaction to occur, thus alleviating problems encountered due to 
background and interference (Weeks et al., 1983).
CH 3 CH 3
Nt
^r ^ HO"
Figure 9 Chemiluminescent reaction of acridinium esters
I = Acridinium salt
II = N-methylacridone (Weeks et al., 1983).
Weeks et al. (1983) reported the synthesis of a stable chemiluminescent 
acridinium ester derivative that was capable of spontaneous, covalent 
association, under mild, aqueous conditions with antibodies to yield stable, 
immunoreactive derivatives of high specific, chemiluminescent activity. The 
acridinium phenyl ester contains an /V-hydroxysuccinimide (NHS) group 
which reacts specifically and covalently with primary amines, providing an 
easy way to directly label amine-containing compounds (Nelson & Kacian, 
1990). This provided an easy and effective way for the direct and 
reproducible labelling of proteins (primary and secondary aliphatic amines) 
under aqueous conditions to predetermined specific activities which could be 
detected at lower concentrations than that of the corresponding [125I] 
derivatives (Weeks et al., 1983). The detection limit is approximately 
5 x 10~19 mol (measured in a standard, commercially available luminometer), 
thus providing superior sensitivity to radiolabels, with detection linear to a 
concentration over more than 4 orders of magnitude (Weeks et al., 1983; 
Nelson & Kacian, 1990).
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The acridinium ester (AE) labels can be used in either a competitive, 
chemiluminescent immunoassay (CIA) or in the immunochemiluminometric 
(ILMA) ('sandwich') assay (Edwards, 1985). The ILMA can exhibit the 'high- 
dose hook' effect as is evident in its radioactive counterpart (IRMA).
The dissociative nature of the chemiluminescent reaction of this particular 
acridinium ester renders the emission characteristics of the molecule 
insensitive to microenvironmental changes (Weeks et a/., 1983). Assays are 
not prone to interference from many components of complex biological 
samples which can effect enzyme reactions, however, pH and temperature 
can influence luminescent reactions (Edwards, 1985). In the equilibrium 
reaction involving AE, the electronically excited /V-methylacridone is formed 
in favour of pseudo-bases when at a low pH (approximately pH 5.0) (Weeks 
etal., 1983).
The turbidity of the reaction is not usually a problem with a high tolerance of 
haemolysed, lipaemic and icteric samples evident, but interference from 
heterophilic antibodies and other autoantibodies (e.g. rheumatoid factor) still 
can present problems. More general interference can result from the effect 
of fluorescent lights in cuvettes or plastic tubes, and from minute amounts of 
impurities in the water, thus requiring maximally purified water supplies 
(Edwards, 1985).
The chemiluminescent AE can be detected rapidly and with high sensitivity 
(Edwards, 1985) and as the label reacts under mild conditions it has a 
universal application to protein immunoassay and represents a practical 
alternative to [125 I] (Weeks et a/., 1983). In chemiluminescent reactions, 
chemical energy generated as a result of the decomposition of a molecule 
produces excited-state intermediates that decay to a ground state with the 
emission of photons of light. The overall quantum yield of a CL reaction (the 
number of photons emitted/number of molecules reacting) is generally in the 
range 1-10% (Kricka, 1991). The photomultiplier tube (PMT), a 
photodetector, detects the photons of light emitted and converts them into 
electrical impulses (Parlett, 1978). The rapid reaction kinetics of acridinium 
esters result in improved sensitivity, since the short read time limits the
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contribution of background noise and allows the reading of a large number of 
samples within a short time. A wide range of luminometers are now available 
for use for chemiluminescent reactions, including manual single-tube 
instruments and automated luminometers based on tubes, microtitre strips or 
plates as the reaction vessels (Kricka, 1991).
The AE labels avoid the hazards, restrictions and inconvenience of dealing 
with radioisotopes while affording equal or greater sensitivity, with 
subpicomolar detection limits. Reagents have good stability with shelf-lives 
up to six months stored at 4°C (Weeks et a/., 1983), and procedures are 
quick and simple and are amenable to automation (Kricka, 1991). With its 
Magic® Lite assays, [Bayer/Chiron Diagnostics (formerly Ciba Corning 
Diagnostics)] was the first to offer immunoassays utilising this 
chemiluminescent technology (Boland et a/., 1990) and now provides a vast 
array of clinical analyses via sophisticated immunoassay systems, with a 
method for the measurement of TPOAb, using paramagnetic particles as the 
solid phase and AE as the chemiluminescent label currently in its 
developmental stages.
1.10 The Aim of the Project
The aim of the study was to develop a non-radioactive immunoassay, which 
demonstrated comparable assay characteristics to its radioactive 
counterpart, and which could eventually be adapted to a more sophisticated, 
automated system, amenable to the screening for thyroid peroxidase 
autoantibodies (TPOAb) in human serum, to identify individuals with 
subclinical autoimmune thyroid disease (AITD) in 'high-risk' groups.
An attempt was made to develop an enzyme-immunometric assay and 
subsequently, three other immunoassays which utilised acridinium ester 
(AE), a highly sensitive and versatile chemiluminescent label. The thyroid 
peroxidase (TPO) used in these assays was derived from the microsomal 
fraction of the preparation described by Groves et al. (1990).
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• Method 1: The immunoradiometric assay (IRMA) was based on a 
method described by Beever et al. (1989), and used a commercial 
preparation of TPO labelled with [ 125I]. Magnetic particles coupled to 
Protein A were used to effect the separation of the final antibody-antigen 
radioactively labelled complex, which provided a direct measurement of 
the sample TPOAb.
• Method 2: The enzyme-immunometric assay involved the use of a 
preparation of microsomal TPO labelled with horse-radish peroxidase 
(HRP), and the magnetic Protein A suspension (which had been 
successfully applied as the separation phase in the IRMA). The final, 
spectrophotometic quantitation of TPOAb utilised the TPO-catalysed 
conversion of ortho-phenylenediamine (OPD), and provided a direct 
relationship with the sample TPOAb.
• Method 3 (System 1): This chemiluminometric assay used a microsomal 
preparation of TPO labelled with acridinium ester (AE). The separation 
medium consisted of magnetic particles coupled to anti-human IgG, with 
the final direct quantitation of TPOAb accomplished by the measurement 
of the AE [in relative light units (RLU)] attached to the magnetic particles.
• Method 3 (System 2): This competitive, assay system involved the use 
of a biotinylated preparation of microsomal TPO, and a purified 
preparation of human IgG (containing anti-TPO antibodies) labelled with 
AE. The separation of the acridinium-labelled complex was effected with 
streptavidin-labelled magnetic 'Dynabeads®1 , which exploited the biotin- 
streptavidin interaction, with the AE (measured in RLUs) being indirectly 
proportional to the sample TPOAb.
• Method 3 (System 3): This solid-phase system (which mimicked the 
ELISA), involved the immobilisation/coating of the microsomal TPO 
antigen onto plastic tubes. A commercial source of sheep anti-human IgG 
labelled with AE provided a direct quantitation of sample TPOAb via the 
me asurement of the RLUs attached to the tubes.
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CHAPTER
Chapter 2: Materials and Methods
2.1 Samples
Serum samples were obtained from patients, in which a normal (or borderline 
low) thyroxine (FT4) result was accompanied by an unexplained elevated 
thyroid-stimulating hormone (TSH) level in routine thyroid function tests, 
which could indicate an underlying predisposition to developing hypothyroid 
autoimmune thyroiditis (HAT). Both FT4 and TSH were measured via the 
Bayer/Chiron 'Chemiluminescent Immunoassay System' (ACS-180).
Samples were also obtained from patients with suspected autoimmune 
thyroid disease (AITD) upon clinical presentation and examination i.e. mainly 
Graves' disease (GD) or Hashimoto's thyroiditis (HT).
In addition, samples were obtained from patients visiting ante-natal clinics as 
part of the 'Wales Automated Follow-up Register* (WAFUR), in which female 
subjects were screened and monitored ante-natally and post-natally for post- 
partum thyroiditis (PPT).
A range of microsomal (TPO) autoantibody titres, including 20 'normal' titres 
[determined using an ELISA (Groves et a/., 1990) see Appendix 2:7] were 
studied. Samples (serum) were stored at -20°C prior to analysis (as 
recommended for long term storage) and to avoid microbial contamination 
(Miles et al., 1998). Precautions were taken for the handling of human tissue 
samples in accordance with laboratory 'Health and Safety' guidelines.
2.2 Reference Material
2.2.1 Reference Material Used in the ImmunoradiometricAssay 
(IRMA) and the Enzyme-immunometric Assay
The 'Anti-thyroid Microsome Serum NIBSC Research Standard' (NIBS 
66/387) was used (obtained from the 'National Institute for Biological 
Standards and Control', Hertfordshire, U.K.), which had an assigned nominal 
unitage of 1000 units per ampoule. The lyophilised contents were 
reconstituted in 1 ml of Tris HCI, pH 7.5 [see Appendix 1:1 for formulation],
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and then 100 ul aliquots were 'snap-frozen' to -50°C in solid CO2 and 
isopentane and stored at -20°C. The stock, standard aliquot was diluted 1 in 
20, and further 1 in 10 dilutions were made to provide standard 
concentrations of 1000, 100, 10, and 1 U/L with the blank consisting of Tris 
HCI, pH 7.5.
2.2.2 Reference Material Used in the Chemiluminescent Immunoassays 
and the Enzyme-linked Immunosorbent Assay (ELISA)
An 'in-house1 reference material was used which consisted of pooled serum 
samples of high microsomal thyroid peroxidase autoantibody (MicAb/TPOAb) 
activity, which had been calibrated against the 'Anti-thyroid Microsome 
Serum NIBSC Research Standard' (NIBS 66/387). The stock standard 
(20,000 klU/L) [solubilised with 1% deoxycholic acid (DOC)] was diluted with 
phosphate-buffered saline (PBS), pH 7.5 [Appendix 1:5] to give 
concentrations of 100, 50, 25, 12.5, 6.25 and 3.125 klU/L (klU/L = U/L 
described previously).
2.3 Quality Control
The quality control used in the immunoradiometric assay (IRMA), (Method 1), 
consisted of serum from patients who had 'normal' and 'high' titres of 
microsomal autoantibody (MicAb) as determined by indirect agglutination 
using the Serodia®- AMC kit, Fujirebio INC. [Appendix 2:8].
Similarly, serum of known 'normal' and 'high' MicAb activities [assayed by 
the established ELISA methodology used by Groves et al. (1990)] were used 
in the Chemiluminescent immunoassays (Method 3: Systems 1, 2 and 3) and 
the ELISA. These controls were stored in frozen aliquots prior to analysis 
and were diluted by a factor of 100 for analysis with PBS, pH 7.4. The high 
control 'L4' used (also derived from patient serum), was stored in aliquots 
(diluted 1:10 with PBS, pH 7.4), which required a further 1:100 dilution for 
use.
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Unless stated otherwise, all chemicals were purchased from 'British Drug 
House Ltd., (BDH), Poole, Dorset., U.K. [see Appendix 4 for the list and 
addresses of suppliers], and were handled in accordance with the 'COSHH' 
(Control of Substances Hazardous to Health) regulations.
2.4 Method 1
Immunoradiometric Assay (IRMA) Using a Commercial Preparation 
of Thyroid Peroxidase (TPO) Labelled with [125I] and Magnetic 
Particles Coupled to Protein A
2.4.1 Principle of Assay
The diluted serum sample containing the microsomal (TPO) autoantibody 
(MicAb/TPOAb) to be measured was incubated with the [ 125 l]-radioactively 
labelled TPO, resulting in the formation of antibody-antigen labelled 
complexes. The magnetic solid-phase consisted of magnetic particles 
coupled to Protein A (MPA) which effected the separation of the labelled 
complex and the immobilised radioactive counts were measured. The counts 
were directly proportional to the sample autoantibody concentration [see Fig 
10].
2.4.2 Thyroid Peroxidase (hTPO)-[12Sl] Label
A commercial preparation of human thyroid peroxidase (hTPO), radioactively 
labelled with [ 125I] was used (obtained from RSR Ltd., Avenue Park, 
Pentwyn, Cardiff., U.K.). The lyophilised material required reconstitution with 







Figure 10 Diagrammatic Representation of the Immunoradiometric Assay (IRMA).
The radioactive counts attached to the final Antigen/Antibody/Protein A complex in this non- 
competitive immunoassay are directly proportional to the sample thyroid peroxidase 
autoantibody concentration (TPOAb).
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2.4.3 Protein A Suspension
Procedure for Coupling Magnetic Particles to Protein A
The preparation of the solid-phase was based on that used in an 'in-house' 
ferritin immunoradiometric assay which involved the coupling of BioMag® 
4100 magnetic particles to a mouse anti-serum (i.e. anti-ferritin antibody).
BioMag® 4100 magnetic particles (Advanced Magnetics Inc., Cambridge., 
U.K.) consisted of a suspension of magnetic iron oxide particles coated to 
provide primary amino groups for the covalent attachment of proteins.
Well-mixed BioMag® magnetic particles (6 ml), were washed twice, by adding 
20 ml of coupling buffer (0.1M phosphate buffer, pH 7.4), [Appendix 1:1], and 
thoroughly mixed on a roller mixer for 30 minutes.
The preparation was centrifuged and the supernatant carefully removed and 
the pellet resuspended in 12 ml of 0.1 M phosphate buffer, pH 7.4 and 12 ml 
of 5% glutaraldehyde (stock 25% glutaraldehyde reagent diluted with double- 
distilled water) and then mixed 'end-over-end' overnight at room temperature. 
(The 5% glutaraldehyde solution was added in order to activate the BioMag® 
magnetic particles for coupling to the Protein A). The mixture was 
centrifuged, the supernatant aspirated to remove any unreacted 
glutaraldehyde and the particles were resuspended in 20 ml of coupling 
buffer. The preparation was then mixed 'end-over-end' for 1 hour, 
centrifuged and the supernatant removed. This wash procedure was 
repeated five times.
To the pellet of 4 ml of washed magnetic particles, 2.5 ml of the Protein A 
solution (Staphylococcus aureus I Extracellular P.6031) (Sigma-Aldrich Co. 
Ltd., Dorset., U.K.) was added. This was prepared by dissolving 1 mg in 5 ml 
of 0.1 M phosphate buffer, pH 7.4). The particles were gently resuspended, 
and the contents were mixed 'end-over-end', overnight at room temperature. 
(N.B. A 200 ul aliquot of the Protein A solution had been removed in order to 
estimate its protein content prior to coupling).
To protect reactive groups and remove uncoupled protein, the particles were 
washed in 0.1 M phosphate buffer, pH 7.4, and then resuspended in 20 ml of
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0.1M phosphate buffer, pH 7.4 containing 0.3 g (0.2M) glycine (quenching 
solution), and mixed 'end-over-end' for 2 hours at room temperature. The 
protein content of this supernatant was measured together with the aliquot of 
the pre-coupling supernatant in order to calculate the percentage uptake of 
Protein A by the magnetic particles and determine the coupling efficiency. (A 
micro-method for the determination of protein in cerebrospinal fluid and urine, 
using Ponceau S as the stain was used (Pesce et a/., 1973), [see Appendix 
2:2 (b) for details on procedure].
The particles coupled to Protein A were washed 3 times each with 20 ml of 
0.1M phosphate buffer, pH 7.4 containing 1M and then 0.15M sodium 
chloride (NaCI) respectively, in order to remove or reduce non-covalently 
adsorbed protein on the magnetic particles.
The particles were resuspended in 5 ml of 0.1 M phosphate buffer, pH 7.4 
and then appropriately diluted in the same buffer for use. The particles were 
stored at 2-6°C [see Appendix 2:1 for further details on the BioMag® 4100 
magnetic particles].
2.4.4 Immunoradiometric Assay Procedure
Aliquots (50 ul), of the TPO autoantibody standards (i.e. 0, 1, 10, 100 and 
1000 U/L) [see 2.2.1], or quality control diluted 1:100, [see 2.3] were 
incubated in plastic 5 ml Sarstedt tubes for 1 hour at room temperature, with 
50 pi of the reconstituted [125l]-labelled TPO [see 2.4.2]. The Protein A 
Suspension (100 ul) (diluted to an optimal concentration ratio of 1:5, with 
0.1M phosphate buffer, pH 7.4) [see 2.4.3] was added to each tube and then 
incubated for a further 1 hour at room temperature. The final magnetic, 
radioactively-labelled antibody complex was precipitated out in the pellet and 
separated using a magnetic rack. The pellet was then washed with the 
addition of 1 ml of the Tris HCI buffer, pH 7.5, magnetised down and the final 
supernatant decanted. The radioactivity in the final pellet of magnetic 
particles was counted for 2 minutes using the LKB: Wallac 1260 Multigamma 
Counter System and the RIACALC software package.
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Various experiments were carried out to determine optimum assay conditions 
as described in 3.1.
2.4.5 Determination of the Assay Sample Recovery
The recovery of the assay was determined by diluting a serum sample (which 
contained a high titre of microsomal autoantibody) 20-fold to 20,000-fold with 
Tris HCI, pH 7.5 and assayed (as described in 2.4.4), with the Protein A 
suspension diluted in the ratios of 1:5 and 1:2.5. The results of the sample 
dilutions were then interpolated from the sigmoidal standard curve and the 
logarithmically converted data plotted against the sample dilution ratio.
2.4.6 Comparison of IRMA with Indirect Agglutination
Ten samples (diluted 1:20 and 1:50, using the Tris HCI diluent, pH 7.5) were 
assayed with the magnetic particles diluted in a ratio of 1:5 (using the assay 
procedure described in 2.4.4). The results were compared with those 
obtained via indirect agglutination (Serodia®-AMC).
45
2.5 Method 2
Enzyme-immunometric Assay Using Microsomal TPO 
Labelled with Horseradish Peroxidase (HRP) and Magnetic 
Particles Coupled to Protein A
2.5.1 Principle of Assay
The TPO labelled with horseradish peroxidase (HRP-TPO) reacted with the 
TPOAb in the sample to form an enzyme-labelled-antigen-TPOAb complex. 
Magnetic particles coupled to Protein A (MPA) were used (as in the IRMA, 
Method 1) in order to effect the separation of this final complex. The final 
quantitation involved the reaction of HRP (labelled with TPO), with o- 
phenylenediamine dihydrochloride (OPD), which produced an orange colour 
and was measured colorimetrically at 492 nm, the final intensity of which 
being directly proportional to the sample (microsomal) thyroid peroxidase 
autoantibody (TPOAb) concentration [see Fig 11].
2.5.2 Horseradish Peroxidase / Thyroid Peroxidase Label (HRP-TPO) 
Procedure for Labelling TPO with Horseradish Peroxidase (HRP)
Thyroid microsomes (solubilised with 1% deoxycholic acid) [Appendix 2:4] 
were coupled with HRP via the 'Periodate' method as described by Wilson & 
Nakane (1978), which was claimed to produce a higher yield of label as 
compared with coupling procedures employing glutaraldehyde (Voller et a/., 
1979). Sodium periodate, a cross-linking agent, was employed to activate the 
peroxidase enzyme for labelling, to produce a HRP-TPO label which affords 
a maximum retention of reactivity of both the HRP and TPO. The aim was to 
couple 3 nmoles of HRP to 2 nmoles of TPO.
HRP (3.6 mg) (Sigma-Aldrich Co. Ltd., Dorset., U.K.), was dissolved in 0.6 
ml of double-distilled water; (a 100 ul aliquot of this preparation was removed 
and frozen at -20°C, for future estimation of the pre-coupling activity of the 
HRP). A freshly prepared solution of 0.1 M sodium periodate (100 ul) was
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Figure 11 Diagrammatic Representation of the Enzyme-immunometric Assay.
The final absorbance at 492 nm being directly proportional to TPOAb-S in this non- 
competitive immunoassay.
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added to the remainder of the HRP dilution (giving a HRP concentration of 5 
mg/ml), and was mixed for 30 minutes at room temperature.
The mixture was then dialysed overnight at 4°C (in visking, dialysis tubing; 
8/32: Size: 1: Medicell International Ltd.,) against 1 litre of 1mM sodium 
acetate buffer, pH 4.4 [Appendix 1:2]. Then, 1.4 ml of 0.2M carbonate buffer, 
pH 9.5, containing 0.4% deoxycholate [Appendix 1:2], was added to the 
dialysate, and 100 ul of this was added to 200 pi of the solubilised TPO. The 
mixture was mixed 'end-over-end' at room temperature for 2 hours.
A fresh preparation of 0.1 M sodium borohydride (10 ul), was then added, in 
order to inactivate any uncoupled peroxidase and this was left to stand at 
room temperature for 2 hours at 4°C. The mixture was then dialysed twice 
against 1 litre of 0.5M phosphate buffered saline (PBS), pH 7.4, containing 
NaCI (0.09%) and sodium deoxycholate (0.4%), [Appendix 1:2]. Finally, 40 
ul of a 1% solution of human serum albumin (Sigma-Aldrich Co. Ltd., U.K.) 
(stock solution diluted in 0.5M PBS, pH 7.4), was added to the dialysate, to 
block any free binding sites and the label was stored at 4°C prior to use.
2.5.3 Protein A Suspension
The Protein A suspension (MPA) was as used in the immunoradiometric 
assay [see 2.4.3 for preparation details].
2.5.4 Enzyme-immunometric Assay Procedure
The NIBSC standardised TPO auto-antibody was diluted (as in the IRMA, 
Method 1, using 0.5M PBS, pH 7.4), to give the concentrations (0, 1, 10, 
100, 1000 U/L). Each dilution (50 ul), was incubated for 2 hours at room 
temperature in the dark with 50 pi of the HRP-TPO label (diluted 1 in 200 
with 0.5M PBS, pH 7.4).
Then, 100 ul of Protein A suspension (diluted in a ratio 1:2.5 with 0.1M 
phosphate buffer, pH 7.4) (as used in Method 1), was added and further 
incubated in the dark for 1 hour at room temperature. The magnetic particles
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were separated and washed with 1 ml of 0.1 M phosphate buffer, pH 7.4, and 
the supernatant removed. Then, 1 ml of freshly prepared OPD substrate 
reagent [o-phenylenediamine dihydrochloride and 10 ul of hydrogen peroxide 
in phosphate/citrate buffer, pH 5.0], was added to the particles, (substrate 
reagent as used by Voller et a/., 1979) [Appendix 1:2], and incubated at room 
temperature in the dark for 30 minutes. The reaction was stopped by the 
addition of 50 ul of 10M NaOH and the orange supernatant removed, the 
intensity of which was measured colorimetrically at 492 nm.
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2.6 Method 3 (System 1)
Non-Competitive Chemiluminometric Assay Using TPO Labelled 
with Acridinium Ester (AE)
2.6.1 Principle of Assay
This assay was based on the same principle as Methods 1 and 2, but instead 
a chemiluminescent label was employed, i.e. acridinium ester [4-(2- 
succinimidyloxycarbonylethyl)phenyl-10-methylacridinium-9-carboxylate 
fluorosulphonate] to label the microsomal TPO. Magnetic particles coupled to 
anti-human IgG (MAb-Anti-IgG) were used to effect the separation of the 
antigen-antibody complex labelled with acridinium ester. The /V-methyl 
acridinium esters react with hydrogen peroxide in base to yield A/-methyl 
acridone in the excited state which then emits light at 430 nm, measured as 
Relative Light Units (RLU) [see Figs 9 & 12].
2.6.2 Thyroid Peroxidase / Acridinium Ester Label (Acrid-TPO) 
Procedure for Labelling TPO with Acridinium Ester
The TPO protein [prepared as described by Groves et al. (1990)] [Appendix 
2:4] was labelled using a kit from Molecular Light Technology Research 
Limited, Cardiff, U.K. Varying ratios of acridinium ester (AE) to TPO protein 
content were investigated in the labelling procedures, and a comparison 
between crude preparations and those solubilised with 1% deoxycholic acid 
was made.
The TPO preparation was diluted in labelling buffer [Appendix 1:3] to give a 
protein content of 150 ug/ml. The protein preparation (30 ug), was added to 
a vial which contained 5 ug of succinimidyl activated AE and the contents 
were mixed well and incubated for 15 minutes at room temperature in the 
dark (as the activated AE is photosensitive).
Then, 100 ul of quenching buffer (DL-lysine monohydrochloride, 10 mg/ml) 
[Appendix 1:3] was added to the vial and gently mixed and stored in the dark, 













Figure 12 Diagrammatic Representation of the Chemiluminometric Assay (System 1)
The acridinium ester (AE) (in RLUs) attached to the final magnetic complex are directly 
proportional to sample thyroid peroxidase autoantibody (TPOAb-S) in this non-competitive 
immunoassay.
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quenching buffer was subsequently removed during the gel filtration 
purification process [see 2.6.4].
Following this, 30 ul of a 10% solution BSA in 0.1 M phosphate buffer, pH 
8.0, was added to the vial in order to block any existing free sites and reduce 
non-specific binding of interfering proteins. The protein/label mix was stored 
at 4°C prior to loading onto the column.
2.6.3 Varying the Ratio of Acridinium Ester to TPO in the Labelling 
Procedure
Varying concentrations of AE to TPO protein content were obtained, by 
diluting the contents of one vial with 100 ul of acetonitrile (methyl cyanide). 
An appropriate aliquot was removed to give the required 
percentage/concentration [i.e. 10% (0.5 ug) and 50% (2.5 ug)] and 
transferred into a small glass vial and concentrated down. The diluted TPO 
protein was then added and the labelling procedure continued (as described 
in 3.6.2). For 1% of a vial, (i.e. 0.05 ug of AE), 10 ul of a vial (diluted with 
100 ul of acetonitrile) was taken and further diluted with 90 ul of acetonitrile. 
A 10 ul aliquot was then removed and concentrated down and the diluted 
TPO protein was then added and the labelling procedure continued.
2.6.4 Purifying the Acridinium/TPO Label Using Gel Filtration
Sephadex  G25 (Medium) (Pharmacia Fine Chemicals) was hydrated 
according to the manufacturer's instructions and a column of 10 ml volume 
prepared. The column was equilibrated with 30 ml of elution buffer [Appendix 
1:3]. The AE-labelled TPO was applied to the top of the column and fifteen 1 
ml aliquots of eluate were collected. Each fraction was mixed, and 10 ul of 
each was diluted with 1 ml of elution buffer. Then, 10 ul of this dilution was 
transferred to plastic tubes and the total Relative Light Units (RLUs) in each 
tube were measured using the Bayer/Chiron Magic® Lite Chemiluminescent 
Luminometer. This involved the addition of 300 ul of hydrogen peroxide 
solution which oxidises the ester, followed by the addition of 300 ul solution
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of sodium hydroxide which was added to adjust to the necessary reaction 
pH, accelerating the oxidation process. The light energy emitted (measured 
in RLUs) at 430 nm was proportional to the acridinium content.
The fractions which contained the labelled TPO (i.e. with the highest RLUs 
signals) were retained for use. (The fractions collected were the ones on the 
ascending side of the elution peak, which would hopefully provide a label of 
a high purity and specificity). The fractions were then stored in the dark at 
-20°C.
2.6.5 Magnetic Separation Phase
The separation phase consisted of magnetic particles coupled to anti-human 
IgG (MAb-Anti-IgG) [see Appendix 2:5 for preparation].
2.6.6 Chemiluminometric Assay : System 1
The 'in-house' MicAb/TPOAb standard (calibrated against the NIBSC 
Standard) was diluted with assay diluent (PBS, pH 7.4), to give final 
concentrations of 100, 50, 25, 12.5, 6.25 and 3.125 klU/L. The control sera 
and patient samples were diluted by 100 with assay diluent. Aliquots, each of 
100 ul of the diluted standards, controls and patient sera were incubated in 5 
ml Sarstedt plastic tubes, with 100 ul of TPO labelled with AE [diluted 1:2000 
with label diluent (i.e. PBS, pH 7.4 containing 1% sheep serum)]. The sheep 
serum was added to reduce the effects of non-specific adsorption to the 
plastic tubes or other support in the assay system. The tubes were vortex 
mixed and then incubated for 2 hours at room temperature.
Then, 500 ul of the magnetic antibody suspension (MAb-Anti-IgG) (washed 4 
times with assay diluent) [Appendix 2:5] was added to each tube. [The stock 
preparation of MAb-Anti-IgG was diluted by 20 with assay diluent (PBS, pH 
7.4) for use]. The tubes were vortex mixed and further incubated for 1 hour 
at room temperature.
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The magnetic particles were then separated, decanted and washed four 
times using the ELISA wash solution [Appendix 1:5], (using a Bayer/Chiron 
magnetic separator). The RLUs associated with each pellet was measured 
as described previously [see 2.6.4]. The logarithmically transformed data 
(logio RLU versus log  TPOAb standard concentration) was plotted using 
the Excel Version 5 Statistical Software Package.
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2.7 Method 3 (System 2)
Competitive Immunoassay Using TPO Labelled with Biotin, Human 
IgG Labelled with Acridinium Ester and Magnetic Beads Coupled 
to Streptavidin
2.7.1 Principle of Assay
System 2 involved the labelling of an antibody to TPO from a patient sample 
with a high anti-TPO titre with acridinium ester. This was incorporated into an 
assay system using TPO labelled with biotin and a separation stage using 
magnetic beads coupled to Streptavidin.
In this system there was competition between the thyroid peroxidase 
autoantibody (TPOAb) in the sample and the acridinium-labelled-IgG (Acrid- 
IgG), for the biotinylated TPO (Biotin-TPO). The higher the TPOAb in the 
sample, the less Acrid-IgG will be bound to the Biotin-TPO, and 
subsequently to the Streptavidin beads. The separation of the Biotin-TPO- 
antibody-acridinium complexes was effected via the magnetic beads labelled 
with Streptavidin, with the sample TPOAb concentration being inversely 
proportional to the final RLUs of the acridinium ester attached to the beads 
[see Fig 13].
2.7.2 (i) Biotinylation of Microsomal Thyroid Peroxidase (TPO) in 
Solution Using the ECL Protein Biotinylation Module
The ECL Protein Biotinylation Kit was supplied by Amersham Life Science 
and had the capability of labelling primary amino groups on proteins using an 
N-hydroxysuccinimide-biotin ester. The high affinity binding of the small water 
soluble vitamin biotin, to the bacterial Streptavidin was then exploited to 
effect the separation of the biotin-labelled immune complex.
A 100 ul aliquot of crude microsomes (10mg/ml) was diluted with 900 ul of 
coupling buffer (SOOmM bicarbonate buffer, pH 8.6). Deoxycholic acid (DOC) 
(1%), was added to the crude TPO dilution in order to solubilise the cell 
membranes to avoid aggregation. The solubilisation of the crude TPO
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Figure 13 Diagrammatic Representation of the Chemiluminescent Immunoassay 
(System 2). The AE attached to the Biotin-TPO- Acrid-lgG-Streptavidin-labelled complex is 
inversely proportional to sample thyroid peroxidase autoantibody (TPOAb).
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causes the formation of micelles which results in the charged groups of the 
proteins being relocated on the inner of the micelles, thus eliminating any 
aggregation. Biotinylation reagent (40 ul), (equilibrated to room temperature 
before use), was slowly added via a syringe to the 1 ml of diluted protein (40 
ul of biotin reagent is required per 1 mg of protein). The biotin reagent 
(supplied ready for use in the kit) was added centrally to avoid contact wth 
the plastic tube.
The biotin/TPO solution was mixed for 2 hours at room temperature, and a 
further 1 ml of coating buffer was added, (reducing the TPO protein 
concentration to 0.5 mg/ml), and providing 2 ml of biotin/TPO protein 
solution, the minimum volume that could be used in this biotinylation 
procedure.
2.7.2 (ii) Purification of the Biotinylated TPO (Biotin-TPO) via Gel- 
Filtration Using Sephadex™ Gel 25
The 5 ml columns containing Sephadex  Gel 25 were supplied ready for 
use with the ECL Biotinylation kit. The 2 ml of the biotin/TPO solution was 
carefully applied to the column which had been equilibrated with 5 ml of PBS 
/1% BSA and then washed with 20 ml PBS, pH 7.5 [Appendix 1:4].
The Biotin-TPO label was eluted off the column, with 5 ml of PBS buffer, pH 
7.5, and the eluate was collected in 1 ml fractions. UV absorbance at 280 nm 
verified the fraction number in which the eluted protein was present. The 
Biotin-TPO label was eluted in the first 3 ml which agreed with the 
manufacturers findings. The unbound biotin was also removed by gel 
filtration as the presence of 'free' biotin will interfere in the interaction of the 
streptavidin beads with the Biotin-TPO label. The two fractions containing the 
Biotin-TPO label were then stored at 4°C, with the addition of sodium azide 
(0.02%).
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2.7.3 Labelling of Purified IgG Sample (Containing A High Level of 
Microsomal Autoantibody) with Acridinium Ester (AE)
A sample containing high microsomal antibody activity (determined by 
ELISA), was purified via the salting out procedure using ammonium sulphate 
[Appendix 2:6]. The purified IgG sample (2 mg/ml), was appropriately diluted 
to give a final concentration of 50 ug of immunoglobulin G (IgG) in a volume 
of 200 pi, (the concentration recommended by 'Molecular Light Technology 
Research Limited' for the labelling procedure). The 200 pi aliquot of sample 
was then added to a vial containing the acridinium ester (AE) (5 ug), and the 
same labelling and purification procedure was carried out as for the 
preparation of the Acrid-TPO label (described in 2.6.2 & 2.6.4). The 1 ml 
aliquots containing the label were then stored frozen at -20°C prior to 
analysis.
2.7.4 Preparation of the Dynal 'Dynabeads®'
Dynabeads® M-280 Streptavidin (obtained from 'Dynal' U.K. Ltd.,) consisted 
of beads covalently labelled with Streptavidin, a protein of molecular weight 
(MWt) 66,000 consisting of 4 identical subunits which have a high affinity for 
biotin (Kd = 10"15M). The superparamagnetic, polystyrene beads were 
supplied as a suspension containing a 6.7x108 concentration of Dynabeads® 
/ ml (10 mg/ml), dissolved in PBS, pH 7.4, containing 0.1% BSA and 0.02% 
sodium azide.
The Dynabeads® were gently resuspended to obtain a homogeneous 
suspension and were washed before use to remove the sodium azide 
preservative. The appropriate volume required for the assay was removed 
and transferred to a plastic tube and placed on the Dynal MPC (magnetic 
separator). The supernatant was removed and the beads resuspended in 2 
ml of PBS, pH 7.5, and washed on the roller-mixer for 15-30 minutes. The 
particles were magnetised down and the supernatant removed and the wash 
procedure repeated. The particles were separated and resuspended in PBS, 
pH 7.5 diluent to the original volume and were ready for use.
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An equivalent of approximately <1 M | of biotin solution (assuming 100% 
recovery of biotin in the 2 fractions after gel filtration) would be in a 100 ul 
aliquot of the Biotin-TPO label (diluted 1:100). Thus, using this rough 
estimation, 10 pi of beads per assay tube should be sufficient and in excess. 
['Dynal' quote an uptake ratio of 1 (mg/ml) of streptavidin beads to 4 (mg/ml) 
of biotin].
2.7.5 Assay System Using Biotin-TPO and Human Anti-TPO Labelled 
with Acridinium Ester (AE)
Standards and quality control (100 ^l aliquots), [diluted with PBS as in 
Method 3 (System 1)], were pipetted into plastic Sarstedt tubes. To each 
tube 100 jul of Biotin-TPO label [diluted accordingly with (TBS)/1% sheep 
serum], plus 100 jul of IgG labelled with AE (Acrid-IgG) (diluted appropriately 
with PBS/1% sheep serum, as described later) was added, the contents 
vortex mixed and incubated at room temperature for 2 hours.
The washed Dynabeads® (M-280 Streptavidin) (10 jal), were added to each 
tube, vortex mixed and further incubated for 1 hour at room temperature. The 
beads were then separated from the supernatant using a Bayer/Chiron 
Magnetic Rack and the supernatant decanted. The beads were washed and 
decanted four times using ELISAwash solution [Appendix 1:5] and the RLUs 
of the acridinium ester attached to the beads were measured via the 
luminometer as before.
Standard curves were set up using the Biotin-TPO label diluted 1:1000 and 
1:2000, with the Acrid-IgG label initially diluted 1:2000. A series of dilutions of 
the high 'L4' control were also assayed using the Biotin-TPO diluted 1:10, 
1:100 and 1:1000 and the Acrid-IgG label diluted both 1:1000 and 1:2000.
Results indicated a problem with the Acrid-IgG label, therefore it was decided 
to further purify the preparation using affinity chromatography, as described 
below.
59
2.7.6 Affinity Chromatography Using Cyanogen Bromide (CNBr)- 
Activated Sepharose™ 4B Gel
2.7.6 (i) Preparation of CNBr-Activated Sepharose™ 4B Gel Column
CNBr-activated Sepharose  4B provides the most convenient way to 
immobilise ligands containing primary amino groups, by the cyanogen 
bromide method. The coupling reaction is spontaneous, rapid, safe and easy 
to carry out and the amount of coupled ligand can be reproducibly controlled 
(Pharmacia Fine Chemicals, 1983).
CNBr-activated Sepharose  4B gel was rehydrated according to the 
manufacturer's instructions [Appendices 1:4 & 3]. Following rehydration the 
gel was filtered and immediately added to a solution containing the dialysed 
TPO protein which was diluted in approximately 3 ml of coupling buffer, pH 
8.3 [Appendix 2:4]. This stage should be completed without delay since 
reactive groups on the gel hydrolyse at the coupling pH.
The crude TPO sample (500 jul, providing a protein content of 5 mg of 
protein), which had been dialysed overnight in bicarbonate buffer [Appendix 
2:4], was added to the CNBr gel and roller mixed for 2 hours at room 
temperature, checking that all the gel was in suspension. (For protein ligands 
a concentration of 5-10 mg of protein per ml of CNBr Gel was 
recommended).
The suspension was then spun down and the protein content of the 
supernatant estimated spectrophotometrically at 280 nm. The percentage 
uptake of protein (by the gel) from the initial dialysate was calculated to 
assess the efficiency of the labelling procedure.
The gel was then transferred to 1M ethanolamine, pH 8.0, and the contents 
were roller-mixed for a further 2 hours at room temperature. The 1M 
ethanolamine acts as a blocking agent and helps minimise non-specific 
adsorption to immunoadsorbents.
The next stage involved washing the gel 5 times in alternating high and low 
pH buffers, (i.e. between coupling buffer, pH 8.0 and acetate buffer, pH 4.0) 
[Appendix 2:4]. This procedure ensures that no free ligand remains ionically
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bound to the immobilised ligand. After the final wash, the gel was 
resuspended in 5 mis of TBS Azide, pH 7.4 [Appendix 2:4], and stored at 
4°C prior to use.
2.7.6 (ii) Purification of Acrid-IgG Label Using Affinity Chromatography
The TPO gel was transferred to a suitable support system (e.g. 5 ml plastic 
pipette tip), with the end being plugged with cotton wool. The gel was 
washed with approximately 4 times the bed-volume (i.e. 10 ml), with elution 
buffer (TBS Azide, pH 7.4, 0.1% BSA [Appendix 2:4]. The column was not 
allowed to dry.
The 1 ml of Acrid-IgG label (labelled as described in 2.6.2 & 2.7.3), was 
carefully transferred to the top of the gel. The column was eluted slowly with 
15 ml of elution buffer to allow adequate time for the Acrid-IgG label to 
specifically bind to the TPO gel. The eluate was collected in fifteen 1 ml 
fractions and 10 jul of each fraction was diluted in 1 ml of TBS /1% BSA and 
the RLUs of a 10 |ul aliquot of this dilution was measured as before.
The non-specifically bound substances were eluted in the first 3 fractions 
with TBS / Azide, pH 7.4 [see Fig 42 for the elution profile]. The purified 
Acrid-IgG label was finally eluted in 3M sodium thiocyanate solution in 
fractions 2 and 3 [indicated as fractions 16 and 17 in elution profile: see Fig 
43]. Previous fractions 1 to 14 represented the failed attempt to elute the 
label in 2M NaCI. The fractions containing the Acrid-IgG label were dialysed 
(in visking tubing, Size 1-8) overnight against TBS/Azide, pH 7.4 and the 
dialysate of each fraction stored frozen until use.
2.7.7 Assay Using the Further Purified Acrid-IgG Label
Standards of the 'in-house' MicAb/TPOAb preparation were diluted to give 
concentrations ranging from 3.125 to 100 klU/L [see 2.2.2] and appropriately 
diluted quality control [see 2.3] were assayed [see 2.7.5] using the Biotin- 
TPO label (100 jal), (both diluted 1:100 and 1:1000 using TBS / 1% sheep
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serum); 100 |nl of the further-purified Acrid-IgG label (diluted 1:100 with PBS / 
1% sheep serum) and 10 pi of the Dynabeads®. A range of 'L4' control 
dilutions from 1:10 to 1:10,000 were also assayed, with the same Biotin-TPO 
and Acrid-TPO label dilutions.
62
2.8 Method 3 (System 3)
Solid-Phase, Non- Competitive Immunoassay Using Sheep Anti- 
Human IgG Labelled with Acridinium Ester (Coated-Tube Assay)
2.8.1 Principle of Assay
This was a solid-phase, heterogeneous (sandwich) assay system, in which 
the TPOAb in the sample reacted with the TPO antigen coated on the tube, 
and then binds to the sheep anti-human IgG labelled with acridinium ester 
(Acrid-Anti-IgG) to form a labelled complex. This was a non-competitive 
assay system resulting in a direct correlation between the RLUs attached to 
the tube and the concentration of TPO autoantibodies in the sample, i.e. the 
sample antibody concentration is proportional to the final RLUs [see Fig 14].
2.8.2 Procedure for Labelling Sheep Anti-Human IgG with Acridinium 
Ester
A preparation of sheep anti-human IgG (Sheep Anti-Human IgG [Gamma 
Chain] obtained from Serotec Ltd.,) (with an approximate concentration of 
0.5 - 1 mg/ml), was used. A 200 ul aliquot of the diluted sheep anti-human 
IgG (40 ul of the anti-serum diluted with 180 pi of phosphate buffer, pH 7.4), 
was added to a vial of acridinium ester (5 ug) and the labelling and 
purification procedures carried out as described in 2.6.2, 2.6.4 & 2.7.3).
2.8.3 Assay Using Tubes Coated with TPO and Sheep Anti-Human 
IgG Labelled with Acridinium Ester
Sarstedt tubes were coated with 100 pi of TPO (solubilised with 1% 
deoxycholic acid and diluted with coating buffer, pH 9.3 [Appendix 1:5] to 
give a concentration of 1 ug TPO/ml. The tubes were incubated overnight at 
4°C, the supernatant decanted and the tubes drained thoroughly. The tubes 
were washed four times using the ELISA wash [Appendix 1:5], and 
thoroughly drained. To duplicate coated tubes, 100 ul of each of the 
standards [diluted as for Method 3 (Systems 1 & 2) and ELISA], and quality
63
Immobilized TJ>0
' J- * ' '± v N 'I • .
Figure 14 Diagrammatic Representation of Coated-Tube Assay (System 3).
Microsomal TPO immobilised on plastic support, reacted with sample 
thyroid peroxidase autoantibody (TPOAb-S), which then reacted with 
sheep anti-human IgG labelled with AE. The final RLUs attached to the 
tube provided a direct relationship with TPOAb-S.
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control and samples (diluted 1:100 with PBS diluent, pH 7.4) [Appendix 1:5], 
were added and incubated at room temperature for 2 hours. The tubes were 
decanted and again washed four times. The Acrid-Anti-IgG label was diluted 
1:1000 with PBS, pH 7 with 1% sheep serum and added to the tubes which 
were incubated at room temperature for a further hour. The tubes were finally 
decanted and washed a further four times before measuring the RLUs 
attached to each tube as described previously.
Assays were set up using different dilutions of the Acrid-Anti-IgG label and 
different incubation periods. Precision and comparison studies were carried 
out, together with experiments to determine the analytical sensitivity and 
specificity and also the 'high-dose hook' effect [see 3.5].
2.8.4 Estimation of the Analytical Sensitivity of the Coated-Tube Assay
Blank samples consisting of PBS, pH 7.4, were assayed (as described in 
2.8.2) and the analytical sensitivity was calculated. The definition and 
subsequent calculation of analytical sensitivity used was as defined by 
Bayer/Chiron Diagnostics in their Chemiluminescent automated assays, i.e. 
the concentration of analyte that corresponds to the RLUs that are two 
standard deviations greater than the mean RLUs of 'x' replicate 
determinations (20 replicates used in this study).
2.8.5 Statistical Analyses
The logarithmically converted data for the standard curves for Method 3 
(CIA): Systems 1-3, were graphically plotted, and the correlation coefficient 
(r) for each assay was derived, (which indicated the closeness of the 
transformed data to a linear response). The closer (r) is to 1.0 the closer the 
'fit' of data to a straight line.
The logarithmically converted results of the coated-tube assay and the 
ELISA were statistically compared using the 'least squares' method of 
regressional analysis (using Microsoft® Excel: Version 5). The 'Deming Plot' 
and 'Passing & Bablok' Regression Models were also applied (using 'Analyse
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It': Version 1.28). The results of the agglutination assay had to be 'rank- 
transformed' for statistical analysis, and a semi-log regression plot was used 
to compare this method with the coated-tube assay and the ELISA [see 3.5 
for results]. The non-parametric 'Wilcoxon Mann-Whitney 'U' Test' was also 






Immunoradiometric Assay (IRMA) Using TPO Labelled with [125I] 
and Magnetic Particles Coupled to Protein A
A limited study only was carried out for the IRMA [see 2.4], with the primary 
aim being to assess the viability of the magnetic particles coupled to Protein 
A, which were to be subsequently incorporated as the separation phase in an 
enzyme-immunometric assay [see 2.5].
The percentage uptake of Protein A by the magnetic particles (estimated 
using differential protein measurements of the supernatants before and after 
coupling) [see Appendix 2:2 for further details], achieved an average uptake 
of 94% on separate preparations, which indicated a successful and 
reproducible coupling procedure.
3.1.1 Experiments to Determine the Percentage Uptake of IgG by the 
Protein A Suspension
Experiment 1
Aliquots (100 nl) of the Protein A Suspension (i.e. neat and diluted in a range 
from 2-fold to 20-fold with 0.1M phoshate buffer, pH 7.4) [Appendix 1:1], 
were incubated with 100 ul of a serum diluted in Tris HCI, pH 7.5 [Appendix 
1:1] to give a final concentration of 0.98 g/L immunoglobulin G (IgG) per 
tube. The tubes were incubated overnight (with the experiment being carried 
out at room temperature and at 37°C). The IgG present in the separated 
supernatant was estimated using a turbidimetric method (for the routine 
determination of immunoglobulins), in which the immunoglobulin G was 
mixed with its specific anti-IgG anti-serum (obtained from Dako Ltd.,) and the 
resulting turbidity measured spectrophotometrically on the Cobas Fara II 
centrifugal analyser at 340 nm [see Appendix 2:3 for a description of the 
method].
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The uptake of immunoglobulin G (IgG) by the neat Protein A suspension 
(with overnight incubation) was 0.56 g/l (57%) at room temperature and 0.49 
g/l (49%) at 37°C, (an average of 53% of the quoted uptake of 9 mg of IgG 
per 1 mg of Protein A). The greater uptake of IgG was evident at room 
temperature for all Protein A concentrations [see Figs 15 & 16].
Figure 15
Uptake of IgG by the Protein A Suspension 
(Overnight Incubation: At Room Temperature
1 in 20 1 in 10 1 in 5
Protein A Dilution
1 in 2 Neat
Figure 16
Uptake of IgG by the Protein A Suspension 
(Overnight lncubation^At370C)
1 in 20 1 in 10 1 in 5 1 in 2 
Protein A Dilution
Neat
Figures 15 & 16: The uptake of IgG with different concentrations of the Protein A 
suspension at different temperatures.
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Experiment 2
A further experiment to investigate the percentage uptake of the Protein A 
suspension, involved the overnight incubation, at room temperature of 
different dilutions of serum IgG (50-fold, 100-fold and 200-fold) with various 
dilution ratios of the Protein A suspension (1:10, 1:2.5 and neat).
Figure 17
Uptake of Different Concentrations of the Protein A 
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Protein A Suspension Dilution Ratio
Fig 17 shows that the neat Protein A suspension was completely successful 
in removing all the IgG from all of the sample dilutions. The magnetic 
particles diluted in a ratio 1:10, were less effective and only succeeded in 
removing all the IgG when the sample was diluted 1:200. The magnetic 
particles diluted in a ratio 1:2.5 exhibited complete uptake of the IgG when 
the sample dilution was 1:100 or 1:200.
3.1.2 Experiments Varying Incubation Periods
Assays were carried out varying the initial (i.e. 1 hour and overnight) and the 
final (i.e. 1 hour and 30 minutes) incubation periods (all at room 
temperature), with various dilutions of the Protein A suspension (i.e. 1:10, 1:5 
and 1:2.5). However, varying either of the incubation periods did not 
significantly affect assay results.
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The first incubation period was compared overnight and for 1 hour, with the 
final incubation period of 1 hour (using the Protein A suspension diluted 1:10 
and 1:2.5.
The assays with the initial incubation period of 1 hour, exhibited a 
progressive decrease in counts at the upper TPOAb standard 
concentrations, with the decrease being not as pronounced with the 
overnight incubation, which generally exhibited a levelling off in the final 
response after an initial decline. The Protein A suspension diluted 1:10, 
demonstrated the 'high-dose hook' effect, (in which there was the 
paradoxical decrease in radioactive counts at very high serum autoantibody 
concentrations), which was not as pronounced using the suspension diluted 
1:2.5 [see Fig 18].
Figure 18
Standard Curves Using Different Concentrations of 
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Similarly, the assay was carried out with an initial incubation period of 1 hour 
and the final incubation of both 1 hour and 30 minutes (using the Protein A 
suspension diluted in a ratio 1:5 and 1:2.5). All incubations were at room 
temperature. A slight final decline in response was evident with the Protein A 




Standard Curves with Final Incubation Periods of 30
Minutes (30M) and 1 Hour (60M): Using Different
Concentrations of Protein A Suspension
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1000
The final assay conditions consisted of both incubation periods of 1 hour at 
room temperature, with an optimum Protein A suspension dilution ratio of 
1:5. The graphs shown in Figs 18 & 19 indicated that 10 U/L was the 
effective top of the working range. In future assays the stock standard was 
further diluted 20-fold to provide a working range [see 2.2.1 & Fig 20].
Figure 20
Graph of Assays (Using the TPOAb Standard Further 
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A sample (T1) containing a high thyroid peroxidase autoantibody (TPOAb) 
activity (diluted from 20-fold to 2000-fold) was assayed [see 2.4.5], and the 
results obtained were read off the standard curve. The results indicated an 
excellent recovery, and the logarithmic conversion of the interpolated data 
produced an initial linear response up to a dilution of 200-fold, with a 
subsequent decrease in counts representing the manifestation of the 'high- 
dose hook' effect. The experiment was carried out using the magnetic 
particles diluted in a ratio 1:2.5 and 1:5 and both gave a similar response 
[see Fig 21].
Figure 21 
Graph of Results of Recovery Study for Sample T1
1.5 -r




A set of 10 samples were all diluted 1:20 and 1:50 and the results were 
interpolated from a standard curve and compared with the results obtained 
by indirect agglutination (InAg) [see 2.4.6]. The limited data indicated a good 
correlation between the two methodologies. Further sample dilution would be 
required to provide absolute values for those analyses which exceeded the 
top standard [see Table 1].
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Enzyme-immunometric Assay Using TPO Labelled with 
Horseradish peroxidase (HRP) and Magnetic Particles Coupled to 
Protein A
3.2.1 Experiments to Determine the Enzyme Activity of the HRP Pre- 
and Post-Coupling with TPO
The initial HRP dilution and the HRP-TPO label were both diluted 1 in 1000, 
and 1 in 10,000 with double-distilled water. A 10 ul aliquot of each of the 
dilutions were added to 1 ml of freshly prepared o-phenylenediamine 
dihydrochloride (OPD) substrate reagent [Appendix 1:2], and the enzyme 
activity was monitored spectrophotometrically, by measuring the rate of 
change in absorbance at 492 nm. A 22% retention only of the initial HRP 
activity was demonstrated in the post-coupling HRP-TPO preparation.
A series of dilutions of the HRP-TPO label (250-fold, 500-fold and 1000-fold), 
were prepared using 0.5M PBS, pH 7.4, and 100 ul each of the dilutions 
were incubated with 1 ml of OPD substrate reagent [Appendix 1:2] for 30 
minutes in the dark, at room temperature. The reaction was stopped by the 
addition of 50 ul of 10M NaOH and the absorbance of the supernatants was 
measured at 492 nm and the results, which were graphically represented 
demonstrated a linear response [see Fig 22].
The enzyme-immunometric assay (described in 2.5.4) produced a 'blanket' 
response with similar absorbances at 492 nm for all standard TPOAb 
concentrations (the results were confirmed by repeat analysis with the 
repreparation of all assay components) [see Fig 23].
The OPD substrate was replaced with 1 ml of 5 mM potassium iodide (Kl) and 
the reaction stopped by the addition of 15 ul of 30% hydrogen peroxide 
(H202) and the optical density was measured at 350 nm, but again a similar 
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Figure 23
Graph of Standard Curves for the Enzyme-lmmunometric 
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3.3 Method 3 (System 1)
Chemiluminometric Assay Using TPO Labelled With Acridinium 
Ester and Magnetic Particles Coupled to Anti-Human IgG
The Acrid-TPO label (labelled as described in 2.6.2) was consistently eluted 
in fractions 5 and 6 on all preparations [see Fig 24].
Figure 24
Graph Showing the Elution Profile of the Acrid-TPO
Label350 -r—
5 6 7 8 9 10 11
Tube (Fraction) Number
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3.3.1 Experiment to Assess Whether the Antigenic Properties of TPO 
are Modified After Coupling To Acridinium Ester
An assay was set up using the ELISA system (Groves ef a/., 1990) to 
compare the antigenicity of the TPO labelled with AE (Acrid-TPO) with that of 
the original crude microsomal preparation. Increasing concentrations of 
Acrid-TPO label (from 0 to 160 ul/ml) were added in a final volume of 100 pi 
per well, across an ELISA plate [coated with 1 ug/ml TPO (solubilised with 
1% deoxycholic acid)]. The label was diluted in a sample containing a high 
TPOAb titre (diluted 1:100 in PBS, pH 7.4). The crude TPO (diluted 1:10) 
and PBS diluent (as the blank) were similarly diluted and assayed and their 
response compared with that of the Acrid-TPO label.
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The experiment indicated that no apparent change or loss of antigenicity of 
the TPO had occurred upon labelling with acridinium ester (AE) as compared 
with the unlabelled TPO [see Fig 25].
Figure 25
Graph Comparing the Antigenic Response of the 
Acrid-TPO Label with Unlabelled (Crude) TPO
4 8
Addition per Well (Ml/ml)
16 32
The results of an initial assay using a label prepared with 5.5 |jg of AE and a 
solubilised preparation of TPO produced a correlation coefficient (r) of 0.99 
upon regression curve analysis (with the mean of triplicate analyses used). A 
lack of precision was demonstrated with the overlapping of consecutive 
standard data points, with the error bars being defined as 1 standard 
deviation (S.D.) of the mean. A plot of relative light units (RLU) instead of 
Log™ RLU (on y-axis) is shown to illustrate the assay imprecision [see Fig 
26]. In addition, only an uptake of 0.5% of AE measured in RLUs was 





































































































































































3.3.2 Experiments Varying Acrid-TPO Label Dilutions
Varying the ratios of AE to TPO protein in the preparation of the labels [see 
2.6.3] produced no improvement in results. Inferior results were produced for 
all labels [i.e. prepared with 5 ug (100%), 2.5 ug (50%), 0.5 pg (10%) and 
0.05 ug (1%) of AE], as compared with the standard curve using 5.5 ug, with 
correlation coefficients (r) values of between 0.88 and 0.97 produced on 
regression curve analysis of the mean of duplicate analyses. Variable 
precision was still evident over the standard data points [see Figs 27-30: 
error bars defined as 1 S.D.].
A greater uptake of AE for each standard was produced with increasing 
amounts of AE in the label. The greatest percentage uptake of AE by the top 
standard was achieved with the label containing 1% AE, but then only with 
an uptake of 1.1%. In addition, a poor curve response was produced with the 
1% label [see Fig 30], with no apparent uptake of AE and no discrimination 
between consecutive standards.
A deterioration in assay performance was demonstrated with labels prepared 
with crude TPO as compared with TPO solubilised with 1% deoxycholic acid. 
A label prepared with 5 ug (100%) of AE produced a correlation coefficient (r) 
of 0.96 (upon regression analysis) for the crude TPO as opposed to 0.98 for 
the solubilised TPO. However, labels prepared with 0.5 ug of AE produced 
similar correlation coefficient (r) values of 0.94 and 0.96 for the solubilised 
and crude TPO respectively. A greater uptake of AE was exhibited across 












































































































































































































































































































A series of dilutions of the high 'L4' control (100-fold to 12800-fold, diluted in 
sample diluent), were assayed (as described in 2.6.5), using different dilution 
ratios of the Acrid-TPO label (prepared using 5.5 ug of AE). The label was 
diluted (in label diluent) to give the ratios 12,000-fold, 6,000-fold, 3,000-fold 
and 2,000-fold and assayed using the MAb-Anti-IgG diluted 1:20 [see Fig 
32].
Figure 32
Graph of 'L4' Control Dilutions Using Different 
Concentrations of the Acrid-TPO Label
25000 T- ~\
12800fold 6400-fold 3200-fold 1600-fold 800-fold 400-fold 200-fold 100-fold
'L4' Control Dilution Ratio
Increased imprecision was demonstrated in the duplicate analyses with 
increasing Acrid-TPO label concentration, with very little discrimination 
between consecutive '14' dilutions using the Acrid-TPO diluted 12,000-fold. 
Although imprecision obscured the results, there was an indication of the 
'high-dose hook' effect for all the other Acrid-TPO label dilutions at an 800- 
fold dilution of the 'L4' control with the MAb-Anti-IgG diluted 1:20 [see Fig 
32].
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3.3.3 Experiments to Investigate the Efficacy of the MAb-Anti-IgG
Standard curves were set up using double the concentration of magnetic 
antibody (i.e. stock diluted 1:10) and the Acrid-TPO label prepared with 5.5 
ug of AE, demonstrated no improvement in assay results (data not shown).
The 'L4' control dilutions were also assayed using the Acrid-TPO label 
(prepared with 5.5 ug) and the MAb-Anti-IgG diluted both 1:10 and 1:20. The 
results indicated the 'high-dose hook' effect at an 'L4' dilution of 800-fold with 
the magnetic antibody diluted 1:20, and at a dilution of 400-fold for the 
particles diluted 1:10 [see Fig 33].
Figure 33
Further Investigation of the 'High-dose Hook' Effect 
Using the Magnetic Particles (MAb-Anti-IgG) Diluted
1:10 and 1:20
o>
12800-fold 6400-fold 3200-fold 1600-fold 800-fold 400-fold
'L4' Control Dilution Ratio
200-fold 100-fold
Another experiment involved the dilution of the high 'l_4' control both 400-fold 
and 800-fold in both sample diluent and in a TPOAb positive sample and 
assayed (as described in 2.6.6) with MAb-Anti-IgG diluted both 1:20 and 
1:10.
In the first set of tubes, Tubes 1 and 3 consisted of the high TPOAb positive 
'L4 1 control diluted 800-fold [(with a TPOAb negative sample (determined via 
an ELISA) [Appendix 2:7] (which had also been diluted 800-fold with assay 
diluent)]. Tubes 1 and 3 were assayed with the MAb-Anti-IgG diluted 1:20
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and 1:10 respectively. Tubes 2 and 4 consisted of the 'L4' control diluted 
400-fold with assay diluent, with the MAb-Anti-IgG diluted 1:20 and 1:10 
respectively [see Table 2 (i)].
In the second set of tubes, Tubes 2 and 4 were as the first set, but Tubes 1 
and 3 consisted of the 'L4' control diluted 800-fold with a TPOAb negative 
sample (which had been pre-diluted 400-fold with assay diluent), with the 
MAb-Anti-IgG diluted 1:20 and 1:10 respectively [see Table 2 (ii)]. The latter 
dilution resulted in a greater final sample protein concentration.
Table 2


























A similar response was produced for the 'L4' control diluted 800-fold for both 
magnetic antibody concentrations. However, the magnetic antibody diluted 
1:20 appeared to be rate-limiting for the 'L4' control diluted 400-fold, with 
RLUs of 8,380 as compared to 17,570 RLUs produced for the 1:10 dilution 
ratio, thus, demonstrating the 'high-dose hook' effect with low RLUs for a 
high TPOAb titre [see Table 2 (i)]. Similar results were produced with the 
dilutions which incorporated different sample protein dilution ratios of a 
TPOAb negative sample [see Table 2 (ii)].
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3.4 Method 3 (System 2)
Competitive Immunoassay Using TPO Labelled with Biotin, Anti- 
Human TPO Labelled with Acridinium Ester and Magnetic Beads 
Coupled to Streptavidin
The preparation of the Biotin-TPO label (using the ECL Protein Biotinylation 
Module) [see 2.7.2 (i)] appeared to be successful with a >50% uptake of the 
solubilised TPO (estimated by spectrophotometric measurement at 280 nm). 
The biotinylated TPO label (Biotin-TPO) purified from the 'free biotin' via gel
TM
filtration using Sephadex Gel 50M [see 2.7.2 (ii)], was eluted within the first 
five fractions, which agreed with ECL's protocol [see Fig 34].
Figure 34





3.4.1 Experiments to Investigate the Antigenicity of the Biotin-TPO 
Label
Experiment 1
The antigenicity of the Biotin-TPO label was similarly investigated as 
described for the Acrid-TPO label [see 3.3.1], with increasing amounts of 
label (diluted in a high TPOAb sample) being added across an ELISA plate 
and comparing its response with with an equivalent concentration of the
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crude microsomes and PBS diluent (as blank). The Biotin-TPO produced a 
similar response (with a decrease in absorbance with increasing TPO added) 
as compared with the crude unlabelled TPO, which indicated no apparent 
loss of antigenicity of the TPO upon labelling [see Fig 35].
Figure 35
Graph of Experiment to Investigate Any Change in 
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Experiment 2
An alternative experiment to investigate any change or loss in the antigenicity 
in the TPO after biotinylation was also set up by coating the upper section 
(rows A-D) of an ELISA micro-titre plate with 1 jag/ml crude TPO per well as 
is used in the ELISA (Groves et ai, 1990). The crude TPO (approximately 10 
mg/ml) was diluted accordingly with coating buffer for use. The lower section 
(rows E-H) of the micro plate was coated with the Biotin-TPO label, similarly 
diluted with coating buffer. The ELISA was then carried out [Appendix 2:7], 
and the response of the labelled and unlabelled TPO preparations compared.
The logarithmically converted data was plotted and results compared [see 
Fig 36]. The Biotin-TPO label produced a response comparable with that of 
the unlabelled TPO [correlation coefficient (r) = 0.99], which again indicated 
no apparent loss of antigenicity. However, the Biotin-TPO label produced
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higher blank values and also falsely elevated values (almost double) as 
compared with the unlabelled TPO for a 'Normal' control. The anomalous 
reponse was confirmed by repeat analysis for this particular 'Normal' quality 
control sample, but was not evident in an alternative 'Normal' control.
Figure 36
Graph of ELISA Comparing TPO (Unlabelled) and the 
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Experiment 3
The Biotin-TPO label was also used as the coating antigen replacing the 
solubilised TPO in the coated tube assay [see 2.8.3]. The Biotin-TPO and 
solubilised TPO were diluted as described in Experiment 2 above. The 
coated-tube assay was carried out using the sheep anti-human IgG 
acridinium label (diluted 1:1000) and a good curve response was produced 
[correlation coefficient (r) of 0.98 (on two separate assays)], indicating the 
viability of the Biotin-TPO label in this assay also [see Fig 37]. 
A similarly anomalous result was produced for the 'Normal' control in this 
experiment, again indicating that an acquired cross-reactivity of the TPO 
could have occurred upon biotinylation.
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Figure 37
Graph of Coated-Tube Assay: Comparing the Biotin- 
46lPÔ Lab®Lvvith Solubilis_ed TPO as the Coating Antigen
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The IgG was labelled with AE [see 2.7.3 and purified via gel filtration using 
Sephadex™ G-50M and eluted in fractions 5 and 6, which was consistent 
with previous TPO labelling procedures [see Fig 38 for the elution profile].
Figure 38
Graph Showing the Elution Profile of IgG Labelled with 
Acridinium Ester (Acrid-IgG)
100 -r
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Tube (Fraction) Number
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89
The results indicated the assay system to be non-functional with a non- 
uniformity of reponse of the standards which exhibited substantial oscillation 
with the Biotin-TPO labels (1:1000 and 1:2000) and the Acrid-IgG label 
initially diluted 1:2000 [see Fig 39]. A series of 'L4' control dilutions also 
assayed using the Biotin-TPO label (diluted 1:100 and 1:1000) and the Acrid- 
IgG label (diluted both 1:1000 and 1:2000) exhibited a 'blanket' response 
with very little difference in the RLUs between the different dilutions (data not 
shown).
Figure 39
Graph of Assay Method 3 (System 2): Using Biotin-TPO
and Acrid-IgG Label
30000
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3.4.2 Experiments to Investigate the Viability of Assay Components
Experiment 1: Investigation of the Competitive Reaction between the 
Acrid-IgG Label and Sample MicAb/TPOAb
This experiment involved incubating 100 nl of the Biotin-TPO label (diluted 
1:100 with TBS, containing 1% sheep serum) [Appendix 1:4] with increasing 
amounts of Acrid-IgG label, (i.e. 1, 3, 10, 30, 100 ^l) (diluted in a a high 
TPOAb titre sample, prediluted 1:100) being added to each tube in a total 
volume of 100 /J. Similarly, another set of tubes was set-up with increasing 
amounts of Acrid-IgG label, but the label was diluted in diluent excluding the
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high TPOAb sample. The tubes were incubated at room temperature for 2 
hours, and then 20 ul (in excess) of the washed streptavidin beads were 
added and the tubes were incubated for a further hour at room temperature. 
The separated beads were washed and decanted 4 times with ELISA wash 
solution [Appendix 1:5], and the RLUs attached to the beads were measured 
on the Bayer/Chiron Magic Lite Luminometer.
The two sets of tubes exhibited a similar response, indicating that the 
addition of the high TPOAb sample had no or little effect/interference on the 
interaction of the components within the experimental system [see Fig 40].
Figure 40
Graph Showing the Effect of the Addition of a High 
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Experiment 2: Investigation of the Uptake of the Biotin-TPO Label by 
the Streptavidin-labelled Beads
The Biotin-TPO label was diluted 1:100 with TBS/1% sheep serum, and 250 
^il of the diluted label was placed into a plastic tube. An excess of 80 nl of 
washed streptavidin-labelled beads was added and the contents vortex 
mixed and incubated at room temperature for 1 hour. The resulting 
supernatant was diluted (in a serum sample containing a high TPOAb 
concentration), so that increasing concentrations of the supernatant were
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added across an ELISA plate. The experiment was carried out on two 
separate Biotin-TPO label fractions, and a PBS blank and 'normal' and 'high' 
QC were included to ensure optimal ELISA assay conditions.
There was no decrease in absorption at 410nm with increasing addition of 
supernatant and this indicated that the streptavidin beads had successfully 
removed the Biotin-TPO from the supernatants (data not shown).
Experiment 3: Experiment to Further Investigate the Functional 
Capacity of the Streptavidin-labelled Beads
Appropriately diluted standards, quality controls plus a PBS blank [see 2.7.5], 
were pipetted in 100 jxl aliquots (in duplicate) into plastic Sarstedt tubes. To 
each tube, was added 100 jul each of the Biotin-TPO and Acrid-IgG label 
(both diluted 1:100 in label diluent). The tubes were incubated for 2 hours at 
room temperature and then 20 jj,l of washed streptavidin beads were added 
and further incubated for 1 hour. The beads were decanted and washed four 
times with ELISA wash [Appendix 1:5].
Then, instead of measuring the RLUs of the acridinium ester (attached to the 
beads), the final ELISA quantitation stage for the measurement of TPOAb 
was applied, using the colorimetric antibody/substrate reaction as described 
next.
To each tube containing the washed magnetic particles, 100 nl of freshly 
prepared conjugate solution (i.e. peroxidase conjugated sheep anti-human 
IgG antibody), (sheep antiserum obtained from Serotec, Oxford, U.K.) was 
added [Appendix 1:5]. The tubes were vortex mixed and then incubated at 
room temperature for 30 minutes at room temperature. The particles were 
washed 4 times with ELISA wash [Appendix 1:5], and then 100 ^l of the 
ELISA substrate solution ABTS [2,2' Azino-bis(3-ethylbenzthiozoline-6- 
sulphonic acid)] (Boehringer Mannheim) was added. The tubes were then 
incubated at room temperature with the top standard being carefully 
monitored and the reaction stopped by adding 50 jul of stopping reagent [2% 
sodium fluoride (NaF)], when the colour intensity appeared to be comparable
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with that of the ELISA. The green supernatant (140 nl) was then removed 
from each of the tubes and pipetted into an ELISA microtitre plate and the 
absorbances read at 410 nm on the Dynatech (MR5000) Multi-plate reader. 
[The ELISA method used was as described by Groves et a/., 1990, which in 
turn was based on the method of Volier et a/. (1980), see Appendix 2:7]. The 
logarithmically converted absorbances measured at 492 nm produced a good 
regression curve response [correlation coefficient (r) of 0.98] [see Fig 41], 
and the 'Normal' control produced an erroneously high result as 
demonstrated before [see 3.4.1: Experiments 1 & 2].
Figure 41
Graph of Method 3 (System 2) with the Final 
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The results obtained, implicated the source of the problem as being the lack 
of purity of the IgG (purified as described in Appendix 2:6] used in the 
preparation of the Acrid-IgG label [see 2.7.3, 2.6.2 & 2.6.4]. The label did not 
appear to be competing effectively in the assay system, so it was decided to 
further purify the Acrid-IgG label using CNBr-activated Sepharose™ 4B [see 
2.7.6]. The non-covalently bound components were eluted in TBS azide [see 
Fig 42] and the final elution of the label achieved using a 3M sodium 
thiocyanate solution [see Fig 43] (an initial attempt to elute the purified label 
with 2M NaCI was unsuccessful). The label was identified by measuring the 
RLUs of each of the diluted 1 ml fractions.
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Figure 42
Graph Showing the Elution of Non-Specifically-Bound 
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Figures 42 & 43 The elution profile of the further purified Acrid-IgG label.
The label was not eluted in 2M NaCI (Fractions 1 to 14), but in 3M 
sodium thiocyanate (Fractions 16 and 17) [see Fig 43].
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Two attempts were made to further purify the Acrid-IgG label, with an 
apparently improved yield on the second attempt [see Fig 43]. However, 
assays using this purified label [see 2.7.7], served to provide no 
improvement in the assay, with no apparent uptake of AE by the magnetic 
beads at all, resulting in little difference (in RLUs) with consecutive standards 
[see Fig 44].
Figure 44
Graph of Standard Curve for Method 3 (System 2) 
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3.5 Method 3 (System 3)
Solid-Phase Chemiluminometric Assay Using Sheep Anti-Human 
IgG Labelled With Acridinium Ester (Coated-Tube Assay)
This assay procedure [see 2.8.3] with the immobilisation of the solubilised 
TPO antigen onto plastic tubes, provided a direct quantitation of the sample 
TPOAb in RLUs, using the sheep anti-human IgG acridinium label (Acrid- 
Anti-IgG). The Acrid-Anti-IgG label was prepared via the same procedure as 
used for the Acrid-IgG label [see 2.7.3 & 2.8.2] and was eluted in fraction 6 
(data not shown).
This assay demonstrated superior precision (analyses in duplicate) as 
compared with the other chemiluminescent assay systems. Assays were 
carried out using the Acrid-Anti-IgG label initially diluted 1:1000 [see Fig 45 
for the standard curve of Relative Light Units versus Log™ TPOAb 
concentration (error bars being defined as 1 S.D.) and Fig 46 for the 
logarithmic plot].
Assays using the Acrid-Anti-IgG label diluted 1:2000 [correlation coefficient 
(r) of 0.98], indicated a slight compromise in assay performance with an 
uptake at best of 18,880 RLUs (i.e. logic value = 3.5) by the top standard 
[see Fig 47], as compared with an uptake of 53,900 RLUs (i.e. log™ value = 
4.73) by the top standard with the 1:1000 dilution ratio [coefficient correlation 
(r) of 0.99].
Assays with the final incubation reduced from 1 hour to 30 minutes (Acrid- 
Anti-IgG label diluted 1:1000) produced comparable correlation coefficient (r) 
value of 0.99 upon regression curve analysis, but again a reduced uptake of 
24,570 RLUs (i.e. log™ value = 3.65) was demonstrated by the top standard 
[see Fig 48]. Therefore, in future studies a 1:1000 dilution of the Acrid-Anti- 







































































Graph of Coated-Tube Assay Using the Sheep Anti-human 
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Graph of Coated-Tube Assay with a Final Incubation
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3.5.1 Experiment to Determine the 'High-Dose Hook' Effect
The 'high-dose hook' effect was investigated by assaying different dilutions 
of the high 'L4' control (analyses in duplicate) and was found to manifest at a 
200-fold dilution (i.e. an approximate mean TPOAb value of 172 klU/L) for 
the coated-tube assay, but increased imprecision was evident at the higher 
TPOAb concentrations which slighlty obscured results [see Fig 49].
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Figure 49
Graph of 'L4' Control Dilutions to Investigate the 'High- 
dose Hook 1 Effect for the Coated-Tube Assay
200
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'L4' Control Dilution Ratio
200-fold 100-fold
A series of 'L4' control dilutions were also assayed via the ELISA [see Fig 
50].
Figure 50
Graph of 'L4' Control Dilutions to Investigate the 'High-Dose 











12800fold 6400-fold 3200-fold 1600-fold 800-fold 400-fold
'L41 Control Dilution Ratio
200-fold 100-fold
The threshold for the 'high-dose hook' effect in the ELISA was demonstrated 
to be higher than in the coated-tube assay, with no effect exhibited at an 'L4' 
dilution ratio of 100-fold, as compared with 200-fold for the coated-tube
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assay. The ELISA demonstrated better precision at higher TPOAb 
concentrations.
3.5.2 Determination of the Analytical Sensitivity
The 'analytical sensitivity' was derived using the criteria used by 
Bayer/Chiron Diagnostics [see 2.8.4]. An analytical sensitivity of 1.8 klU/L 
was calculated using 20 replicates of the PBS diluent 'blank 1 assayed within 
the same run.
However, 'blank' values from 13 consecutive assays ('between-run' data) 
gave an analytical sensitivity of 2.46 klU/L. This value would encompass the 
'between-run' or 'batch to batch' variation demonstrated in the 'blank' 
measurements.
3.5.3 Estimation of the 'Within-Run' (Intra-Run) Precision and 
'Between-Run' (Inter-Run) Precision
The 'within-run' precision was determined by assaying 20 replicates each of 
a 'Normal' control and a 'High' control in the same coated-tube assay and the 
standard deviation (S.D.) and the coefficient of variation (C.V.) for each 
control was calculated [see Table 3].
Similarly, the S.D. and C.V. was calculated for the 'Normal', 'High' and 'l_4' 
quality control data produced from 13 consecutive assays, to determine the 
'between-run' precision [see Table 3]. Precision studies were also performed 
for the ELISA [see Table 4].
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3.5.4 Assessment of Assay Interferences (Assay Specificity)
Various antibodies were measured via the coated-tube system to see if they 
caused any significant interference. They included, anti-nuclear factor (ANF), 
smooth-muscle antibody (SMA), and varying titres of rheumatoid factor (RF).
Samples with different degrees of positivity of rheumatoid factor did not 
appear to cause any significant interference with the coated-tube assay or 
the ELISA. Anti-nuclear factor (antibody) (ANF/ANA) and smooth-muscle 
antibody (SMA) also did not cause any significant interference in the coated- 
tube assay. SMA interference was evident in the ELISA, but its interference 
could be attributed to the highly icteric nature of the sample, which interfered 
with the ELISA colorimetric measurement.
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Grossly haemolysed, lipaemic, and icteric (jaundiced) samples were 
investigated for any significant interference in the coated-tube assay [see 
Table 4]. The samples were assayed (in duplicate) both neat and diluted by 
50% with a TPOAb negative sample (with the latter TPOAb sample 
demonstrating a mean RLU value of 2000 on duplicate analyses). The 
samples were diluted 100-fold with PBS, pH 7.4, as for patient samples and 
assayed. No significant effect was demonstrated in the coated-tube assay, 
indicating no (positive) interference of any of the samples studied. However, 
the icteric sample (which was also MicAb/TPOAb negative via indirect 
agglutination), did cause positive interference in the ELISA, giving a TPOAb 
titre of 39 klU/L.






































(i) Coated-Tube Assay versus ELISA
The data obtained from 100 patient sera were compared for the coated-tube 
assay and the ELISA. The samples were obtained from a biased population, 
which inferred that the population would be of non-Gaussian distribution (i.e. 
a Gaussian distribution is when 95% of the values are between +/- 1.96 
S.D.).
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This was confirmed by the analysis of the data using Minitab: Version 9. 
Coated-Tube Assay: Std. Dev = 78.89, Mean = 86.8, n = 100 
ELISA: Std. Dev - 76.33, Mean = 89.7, n « 100
The data were analysed using three statistical models and the 
logarithmically-transformed data indicated a very good correlation between 
the coated-tube assay and ELISA for all statistical models used. A correlation 
coefficient (r) of 0.96 and (P= <0.001) was produced using the 'least squares' 
regression method [see Fig 51]. The data was also evaluated using the 
Deming Method and the Passing & Bablok Method. Similar slope values of 
1.04 and 1.01 (with ranges of 0.99 to 1.08 and 0.96 to 1.05) were achieved 



























































































































































Figure 52 (i) 
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Deming Method Comparison of Coated-Tube Assay with 
















Passing & Bablok Method Comparison of Coated-Tube
Assay and ELISA
100
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Clinical Specificity / Sensitivity of the Coated-Tube Assay
One discordant result was produced which gave a borderline positive result 
for the chemiluminescent coated-tube assay as compared with a borderline 
negative result in the ELISA (assuming a 'cut-off value of 19.6 klU/L, as 
used in the ELISA for both assays) [Table 6].
Table 6
100 samples were compared with ELISA







Sensitivity of CIA = 100%; Specificity of CIA = 95 %
(ii) Comparison of the ELISA and Coated-Tube Assay with Indirect 
Agglutination
Only 37 samples were compared in this study with the agglutination assay 
values being rank ordered as follows for graphical representation:
1 - Negative; 2 - 1:100; 3 - 1:400; 4 - 1:1,600; 5 - 1:6,400; 6 - 1:25,000; 
7-1:100,000 and 8-1:500,000.
The logarithmically converted data for both the coated-tube assay and the 
ELISA compared well with the indirect agglutination assay, with correlation 
coefficients (r) values of 0.80 and 0.85 respectively [see Figs 54 & 55]. The 
application of the "Wilcoxon-Mann-Whitney U Test' indicated that the 
correlation of data for both the coated-tube assay and ELISA with indirect 
agglutination was significant (P = <0.0001). However, the graphs indicated a 
tendency for the indirect agglutination assays to underestimate at high 
concentrations and be less sensitive at lower concentrations (with three 
samples giving negative titres for the indirect agglutination assay, but
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positive titres for both the coated-tube assay and the ELISA) (with a titre of 
1:100 considered negative in the indirect agglutination assay, and a 'cut-off 
value of 19.6 klU/L being applied in the other assays) [Table 7].
Table 7











As CIA was identical to ELISA for these samples both agglutination and CIA 










































































































































































The discussion will commence with a summary of the results of the five 
assays investigated, followed by a further detailed discussion of the various 
assay components and their viability within the assays.
The Immunoradiometric Assay (IRMA) [2.4: Method 1]
This assay involved the use of a commercial preparation of hTPO labelled with
15A
[ I], and a Protein A magnetic suspension to effect the separation of the 
radiolabelled TPO-TPOAb complex. The assay system was based on the 
direct interaction between the [125l]-labelled TPO autoantigen and 
autoantibody (TPOAb) (similar to an IRMA described by Beever et a/., 1989) 
and succeeded in overcoming the limitations of indirect measurement as used 
in agglutination, radioimmunoassay (RIA) and enzyme-linked immunosorbent 
assay (ELISA). A full evaluation of the IRMA was not performed, as the 
primary aim was to demonstrate the efficacy of the Protein A suspension, 
which could subsequently be applied to a non-radioactive enzyme- 
immunometric assay system [2.5: Method 2].
The magnetic particles were successfully coupled with Protein A, with an 
average uptake of 94% being achieved on two preparations. No advantage 
was gained for the further uptake of IgG by the suspension with incubation 
overnight at 37°C as compared with incubation at room temperature [Figs 15 
& 16]. The Protein A suspension exhibited a high uptake of the total 
radioactive counts for the top standard in the IRMA (60%), a favourable assay 
characteristic, which augured well for a reliable, clinical assay. Results 
indicated that hourly incubation periods at room temperature were optimal 
conditions for both the initial interaction (between TPO and TPOAb), and for 
the final incubation period with the Protein A suspension [Fig 20]. The 'high- 
dose hook' effect was demonstrated with the Protein A suspension dilution 
ratio of 1:10, which produced the paradoxically low (and misleading) results for 
high TPOAb concentrations [Fig 20]. An optimum Protein A suspension assay 
dilution ratio of 1:5 was indicated (with a 200-fold sample dilution) [Fig 21].
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The limited results compared favourably with indirect agglutination [Table 1: 
3.1] endorsing the findings of Beever et af. (1989). The TBS blank consistently 
demonstrated values significantly lower than the lowest TPOAb standard (of 1 
U/L), which indicated a low degree of non-specific binding and hence a high 
assay sensitivity. This was exemplified in Sample 5, with the IRMA identifying 
low TPOAb titres in contrast to negative litres by indirect agglutination. A 
discordant negative result was also reported in the IRMA for Sample 1, as 
opposed to a positive titre of 1:400 for indirect agglutination [Table 1: 3.1]. 
This could indicate an increased assay specificity as compared with the 
indirect agglutination microsomal assay. Sample 1 was accompanied by a high 
thyroglobulin autoantibody (TgAb) titre of 1:12,000 and the presence of TgAb 
in serum has been reported as causing positive interference in certain indirect 
methodologies for MicAb, including passive haemagglutination (PH) 
microsomal assays (Cayzer et al., 1978; Weetman & McGregor, 1983; Roman 
etal., 1984; Ruf etal., 1988; Mariotti et al., 1990).
Although the IRMA demonstrated very good assay characteristics, due to the 
economic implications and restrictions of supporting the use of isotopes, 
radioactive methodologies in the routine laboratory environment have been 
widely abandoned and limited to a more specialised use, prompting the search 
for non-radioactive alternatives.
The Enzyme-immunometric Assay [2.5: Method 2]
This unsuccessful, non-competitive system involved the labelling of a crude 
(solubilised) preparation of TPO with HRP. Although, HRP activity was 
demonstrated in the HRP-TPO label [Fig 22], and the Protein A suspension 
was proved to be functional by reacting with the HRP-TPO-labelled complex 
(indicated by the HRP activity associated with the suspension), no 
discrimination between consecutive TPOAb standard dilutions was exhibited 
[Fig 23]. All the assay components were reprepared, but the same 'blanket' 
response was produced upon repeat analysis. The same response was 
exhibited when potassium iodide was used as the HRP substrate.
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Chemiluminescent Assay [2.6: Method 3 (System 1)]
This assay involved labelling the crude (solubilised) TPO with the 
Chemiluminescent label acridinium ester (AE), again resulting in a non- 
competitive assay system. The final RLUs attached to the magnetic particles 
(coupled to anti-human IgG) were directly proportional to the TPOAb 
concentration. This system was inferior to the IRMA, but did demonstrate an 
improvement over the enzyme-immunometric assay, and was capable of 
distinguishing between high and low TPOAb titres. The standard curve, 
however, lacked precision (especially at the higher TPOAb titres), and 
exhibited considerable overlapping of consecutive data points.
Varying the ratio of TPO to AE in the labelling procedure [see 2.6.3] did not 
improve the uptake of the top standard, with the maximum uptake of only 
1.1% being exhibited with the label prepared using 0.05 ug of AE. The best 
standard curve parameters were achieved with the solubilised TPO label 
containing 5.5 ug of AE with correlation coefficients (r) of 0.99 and 0.98 being 
achieved on two separate assay attempts, but with the uptake of the top 
standard being only 0.4% and 0.5% respectively [Fig 26]. The lowest 
concentration of AE was accompanied by little difference in consecutive data 
points [Figs 27-30].
Little difference was exhibited when labels were prepared from either crude or 
TPO solubilised with 1% deoxycholic acid. A slight improvement was shown 
with the solubilised TPO label over the corresponding crude label when 
prepared with 5 ug of AE, but no improvement was shown at all using 0.5 ug 
of AE [Fig 31J. In addition, no significant difference in the results was evident 
using the magnetic particles diluted 1:10 instead of 1:20, with perhaps a slight 
improvement in precision seen at the lower TPOAb levels (data not shown).
Using different dilutions of the 5 ug AE label did not produce any improvement 
in assay results, with increased imprecision evident with increased AE 
concentration. The 'high-dose hook' effect (with the paradoxical decline in 
RLUs at the higher TPOAb concentrations) was demonstrated at an 'L4' 
control dilution of 800-fold, but results were slightly obscured by imprecision 
[Fig 32]. The 'high-dose' hook effect was again illustrated at an 'L4' control
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dilution ratio of 1:800 and 1:400 with the magnetic particles diluted 1:20 and 
1:10 respectively [Fig 33]. These results were further endorsed by the 
experiment [see 3.3.3] which demonstrated that the magnetic particles (diluted 
1:20) were rate-limiting with the high 'L4' control diluted 400-fold [see Table 2: 
3.3.3].
The Chemiluminescent Immunoassay [2.7: Method 3 (System 2)]
This assay involved the labelling of the anti-TPO antibody, resulting in a 
competitive assay, in which the RLUs were inversely proportional to TPOAb, 
in contrast to Method 3 (System 1) which involved labelling the TPO antigen 
with AE, resulting in a non-competitive immunoassay. This proved to be the 
least viable of the Chemiluminescent assays and produced similar results to 
the enzyme-immunometric assay [3.2], with very little difference being shown 
between consecutive standard absorbances [Fig 38]. A series of 'L4' dilutions 
which provided a wide range of TPOAb titres were also assayed with various 
dilutions of the Biotin-TPO label (from 10-fold to 1000-fold) and the Acrid-IgG 
label diluted both 1:1000 and 1:2000, but still no improvement was 
demonstrated (data not shown). The further purification of the Acrid-IgG label 
[2.7.6] resulted in no uptake of RLUs by the standards at all [Fig 44]. The 
results perhaps, reflecting the increased biochemical complexity of this 
method.
The Solid-Phase Coated-Tube Assay [2.8: Method 3 (System 3)]
This sandwich assay mimicked the ELISA, with the solubilised TPO antigen 
immobilised onto plastic tubes. A commercial preparation of sheep anti-human 
IgG labelled with AE, complexed with the TPOAb (attached to the immobilised 
TPO) providing a direct quantitation of the TPOAb.
The results indicated a considerable improvement in response as compared 
with Method 3: Systems 1 & 2, with a very good correlation of results with the 
ELISA and indirect agglutination (as discussed later). The logarithmically 
transformed assay data, was graphically represented [Fig 46]. The new Acrid- 
Anti-IgG label diluted 1:1000 provided a slightly improved response, as
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compared with a dilution of 1:2000 and a good response was still produced 
after reducing the final incubation (with label) to 30 minutes. However, a lower 
uptake of RLUs was evident in both these experiments, which could 
compromise assay sensitivity [Figs 47 & 48]. Thus, optimal assay conditions 
consisted of an intial 2 hour incubation for the interaction for the sample 
TPOAb and the immobilised TPO, followed by a 1 hour incubation with the 
Acrid-Anti-IgG, diluted 1:1000 [Figs 45 & 46]. The 'high-dose' hook effect 
was demonstrated at an 'L4' control dilution of 200-fold (approximately 172 
klU/L) [Fig 49], which exceeded that shown in Method 3 (System 1) [Fig 33]. 
However, the threshold was not as high as that shown with the ELISA, which 
did not exhibit the effect, even at a 'L4' dilution of 100-fold [Fig 50].
The enzyme-immunometric assay (Method 2) and the chemiluminometric 
assay [Method 3 (System 1)] did not produce the same successful response 
as exhibited with the IRMA (Method 1). As the Protein A suspension had been 
successfully applied to the IRMA, this inferred that it should not be the 
dysfunctional assay component. This indicated the source of the problem as 
being the HRP-TPO label. Similarly, with Method 3 (System 1) the magnetic 
particles coupled to anti-human IgG had been used in a similar assay system 
to measure TgAb [Appendix 5], which produced a far superior assay (with an 
uptake of 17% of AE for the top standard), which implicated the source of the 
problem as being the Acrid-TPO label. However, these findings warrant further 
investigation, as they are based on the assumption that both of the magnetic 
solid-phases used, had an equal affinity and avidity for IgG, but an actual 
direct comparison of each, in each of the assay systems had not been made.
A modest uptake of 22% of the initial HRP activity by the TPO was 
demonstrated. However, the experiment [see 3.2.1] indicated that HRP activity 
was present in various dilutions of the HRP-TPO label when incubated with 
the OPD substrate [Fig 22]. The elution profile of the Acrid-TPO label 
demonstrated a high uptake of AE [Fig 24] and similarly, a >50% uptake of 
biotin was also demonstrated upon the biotinylation of TPO [Fig 34], which 
indicated that TPO could be successfully labelled with both AE and biotin.
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Further Discussion of Assay Components and their Viability 
(i) The Size of the TPO Molecule
The Tg molecule being a larger molecule of 660,000 kDa (Williams & 
Goodburn, 1983, Premawardhana et a/., 1994) as compared to TPO of 
average 103-117 kDa (Banga et a/., 1984; O'Connor & Davies, 1990; Banga 
et a/., 1991; Weetman & McGregor, 1994) had a greater uptake of AE upon 
labelling, which would afford greater assay sensitivity. The top standard in the 
Tg assay (using Acrid-Tg) [Appendix 6] had an uptake of AE with RLUs in the 
order of 106 as compared with 104 for the equivalent TPO standard. As TPO is 
a smaller molecule than Tg, it perhaps has less surface area for the interaction 
with the AE, with steric hindrance possibly preventing the appropriate 
interaction with the anti-human IgG labelled magnetic particles. However, the 
commercial [125l]-labelled TPO proved to be functional in the IRMA (Method 1), 
which indicated that TPO could be effectively radiolabelled and used in a 
similar assay using a magnetic antibody suspension.
(ii) Loss or change in TPO Antigenicity upon Labelling
A possible explanation for the lack of response in the assays, could be a loss 
or modification in the antigenicity of the TPO (perhaps associated with steric 
hindrance) after coupling to the AE or biotin label. No methodology was 
currently available to investigate whether the TPO had retained its original 
antigenic properties after labelling with HRP, but the other TPO labels (i.e. 
Acrid-TPO and Biotin-TPO) were investigated for any change in their antigenic 
response as compared with the unlabelled, microsomal preparation.
An initial experiment involved adding increasing amounts of the TPO label 
(diluted in a high TPOAb titre sample) across an ELISA plate [see 2.6.5 & 
2.7.3 (i)] and the response compared with the unlabelled TPO and the PBS 
blank. The TPO in the sample added, would compete with the solubilised TPO 
coated on the plate for the TPOAb (present in the patient serum used to dilute 
the TPO). The more active the TPO added, the greater would be the 
competition for the TPOAb, therefore less TPOAb will bind to the coated well, 
resulting in a decrease in absorbance at 410 nm with increasing TPO activity
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added. The results showed the same decrease in absorbance at 410 nm with 
the crude TPO and the labelled TPO, indicating that there did not appear to be 
a loss of antigenicity of the TPO after labelling with the AE [Fig 25] or biotin 
[Fig 35].
However, an alternative experiment [3.4.1: Experiment 2] in which the Biotin- 
TPO was immobilised onto an ELISA microtitre plate, indicated that although 
the antigenic properties had not been lost, a subtle modification in the 
antigenicity of the TPO had manifested upon biotinylation. The Biotin-TPO 
label produced a good standard curve response [Fig 36], however, the Biotin- 
TPO produced higher blank values than its unlabelled counterpart, which 
indicated increased non-specific binding and also produced an erroneously 
high result for a 'Normal' control, again not demonstrated in unlabelled TPO.
The erroneous 'Normal' result was also produced in the coated-tube assay, 
using Biotin-TPO as the coating-antigen [Experiment 3: 3.4.1], and in another 
experiment [Experiment 3: 3.4.2] in which the peroxidase conjugate/substrate 
system was used instead of measuring the RLUs of the AE attached to the 
final magnetic pellet. This acquired cross-reactivity indicated a modification in 
the antigenic properties of the TPO upon biotinylation, not revealed in the 
initial antigenicity check.
The ECL protein biotinylation system has been designed to label primary 
amino groups, including enzymes. The biotin ester used in the ECL kit has 
been synthesised incorporating a 'spacer arm' which ensures that the protein 
linked biotin is freely accessible to bind streptavidin. The incorporation of a 
'spacer arm' should overcome the associated problems of steric hindrance 
and possibly result in a more stable streptavidin-biotin complex.
Although the biotinylation of a protein is a relatively mild chemical reaction, the 
number and location of biotin-moieties coupled to the amino groups of a 
protein can alter its physico-chemical properties and impair biological activity 
(Mirallesef a/., 1991; Higashi etal., 1992; Jokiranta & Men, 1993; Muzykantov 
et al., 1995). A remarkable increase in hydrophobicity of the biotinylated 
protein has been demonstrated as compared with its unlabelled counterpart by 
Storm et al., (1996) who recommend a biotin optimum for a given protein, in
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order to yield a high detection signal without loss of biological function. In this 
study 40 pi of biotin solution (concentration not stated) per 1 mg of protein was 
used as defined by ECL.
(iii) The Purity of the TPO
In addition to TPO being a smaller molecule than Tg, it is a more complex 
transmembrane protein (Banga et a/., 1991; McLachlan & Rapoport, 1995), 
which has proved to have been difficult to obtain free of contamination of 
serum components such as Tg (Ruf et a/., 1988, Feldt-Rasmussen, 1996). 
The less pure microsomal TPO preparation (and labelled counterpart) was 
successfully applied and proved to be viable in the ELISA and coated-tube 
assay, but was proved to be less viable in the enzyme-immunometric and 
chemiluminometric assays, which strongly implicated the purity of the TPO as 
being the source of the problem. The Tg and TPO used in this study were 
produced at different stages within the same preparation procedure (Groves et 
a/., 1990). The purity of the Tg, however, was sufficient for use in both Method 
3 (System 1) and the ELISA (Groves et a/., 1990), whereas the TPO, although 
of adequate purity for use in the ELISA (Groves et al., 1990), possibly lacked 
the necessary purity for the more random assay system [Method 3 (System
1)1-
The label used in the IRMA was a commercial preparation of TPO labelled 
with [125I], which guaranteed a pure source of TPO antigen, which probably 
accounted for the higher sensitivity and specificity demonstrated. The label 
was produced from the same source as the [125 I] label used by Beever et a/., 
1989 which consisted of an 'in-house' preparation of labelled TPO, obtained 
from the microsomal fraction of homogenised thyroid tissue (prepared by 
differential centrifugation similar to the procedure described by Groves et al. 
(1990). Beever et al. (1989) used a further purified TPO preparation (which 
included the use of affinity chromatography) labelled with [125I], which resulted 
in an assay of high sensitivity and specificity. Thus, the TPO used in the non- 
radioactive methods, in this project's assays, appeared to be of insufficient 
purity, which introduced a high degree of non-specific binding caused by other
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interfering species [such as thyroglobulin (Tg)] which had also been labelled 
together with only a small percentage of TPO.
As TPO does not lend itself favourably to an effective purification procedure 
(Ruf et a/., 1988) being time-consuming, and both technically and biologically 
difficult, and not amenable to the development of a robust assay for routine 
use, it was not attempted within the present project. The preparation of 
recombinant TPO is again a very lengthy and involved procedure and was not 
a viable option in this study, and in any event even if a source was available 
there are theoretical reasons why recombinant TPO might not be suitable. 
Sera containing human thyroid autoantibodies display a variety of antigen- 
specific immunoglobulins of different classes and subclasses with different 
affinity and avidity in their epitope reaction (Feldt-Rasmussen, 1996). Reports 
have been made of up to six (Hamada et a/., 1987; Weetman et a/., 1987; 
Doble et a/., 1988; Banga et a/., 1991) or seven epitopes (Ruf et a/., 1989), 
with some patients having autoantibodies raised against more than one of the 
epitopes (Yokoyama et a/., 1989). This imposes a problem on deciding upon 
which section/epitope of the TPO molecule should act as the target for the 
TPOAb, against which the recombinant TPO can be raised. The ideal label 
would be able to encompass all the possible epitopes for interaction, so as to 
measure all the possible autoantibodies which may be present in the human 
population. Therefore, because of the varying antigenic sites on the TPO 
molecule investigators must decide which epitope(s) of TPO antigen are the 
most important in the autoantibody reaction, [with a sequence C2 thought to 
harbour a major epitope (Ludgate et a/., 1989)]. Attempts have been made to 
produce recombinant TPO of both full length and truncated forms (Feldt- 
Rasmussen, 1996).
However, the ELISA and the coated-tube assay, used in this study, also 
cannot guarantee the identification of all the various epitopes, as the different 
thyroid tissue used to prepare the TPO can confer immunological variation 
upon the assay system, with even slight differences in its preparation capable 
of affecting its performance.
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The Purified IgG (containing Anti-TPO Antibody): Used in Method 3 
(System 2)
The Biotin-TPO label appeared to be functional in the coated-tube assay 
Method 3 (System 3) [2.7] and in the ELISA [Appendix 2:7], but its viability in 
Method 3 (System 2) was questionable. However, experiments indicated that 
the lack of response (using the biotin-streptavidin interaction) could also be 
attributed to a lack of purity of the IgG labelled with AE.
The results of Experiment 1 [described in 3.4.2] confirmed the efficacy of the 
Acrid-lgG-Biotin-TPO-Streptavidin magnetic bead interaction, with the 
demonstration of a proportional uptake of AE with increased Acrid-IgG label 
added. However, graphical representation of the final RLUs indicated that the 
addition of a sample with a high TPOAb titre to a second set of tubes 
appeared to have no effect on the amount of Acrid-IgG label being taken up by 
the beads [Fig 39], inferring that the Acrid-IgG label was not competing 
effectively with the high TPOAb sample for the Biotin-TPO label. The TPOAb 
in the sample should compete with the Acrid-IgG label, which would result in 
less Acrid-IgG label being bound to the Biotin-TPO label and subsequently 
less RLUs bound to the streptavidin beads, which was not shown.
The streptavidin beads were demonstrated as being functional as described in 
Experiment 2 [3.4.2]. Supernatant obtained from incubating the Biotin-TPO 
label with streptavidin beads and subsequently diluted in a sample containing 
a high TPOAb titre, was added in increasing amounts across an ELISA plate. 
Any TPO present remaining in the supernatant, would have competed with the 
immobilised TPO, resulting in less TPOAb binding on the plate, producing a 
decreased absorbance with increasing TPO concentration added. As there 
was no difference in response between the label and the blank, this strongly 
suggested that the Biotin-TPO label had been effectively removed from the 
supernatant by the streptavidin beads (data not shown).
The results of Experiment 3 [3.4.2], (in which the final Biotin-TPO- 
Streptavidin-Acrid-lgG/TPOAb complex was quantitated using the ELISA 
peroxidase conjugate/substrate reaction), inferred that the Biotin-TPO was 
functional and had reacted proportionately with the standards and in turn with
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the beads, as indicated by the final supernatants (absorbance measured at 
410 nm) [Fig 40]. This experiment endorsed the findings that the Acrid-IgG 
label was not competing effectively with the sample TPOAb for the Biotin-TPO 
label.
As the acridinium ester is designed to couple with the IgG protein component, 
the actual labelling procedure should not be a problem, thus implicating the 
purity of the original anti-TPO as the source of the problem, which resulted in 
the ineffective competition with the sample TPOAb for the Biotin-TPO label. It 
could be surmised that perhaps other non anti-TPO immunoglobulins had 
been labelled with the AE and only a very small amount of IgG specific to TPO 
was actually labelled. Even further purification by affinity chromatography did 
not apparently produce sufficient yield. However, perhaps the actual system 
was not viable due to its complexity both biochemically and technically.
The results of the project indicated that the crude TPO functioned successfully 
in the solid-phase assay systems (i.e. the coated-tube assay and the ELISA), 
which involved the immobilisation of the TPO antigen onto the solid support. 
The crude preparation (although apparently retaining its antigenicity after 
labelling) was less effective in the assays using magnetic particles to effect the 
separation of the labelled autoantigen-autoantibody complexes. This was 
apparent with the Biotin-TPO label, which produced a reasonable response 
when applied to the ELISA and the coated-tube assay, but not in the complex 
TPO-Biotin-Streptavidin system. This inferred that the former solid-phase 
assays did not rely on as high a degree of purity of TPO, and would account 
for the success of the IRMA (Method 1) which used a commercial radioactive 
label and hence, a purified TPO preparation.
The systems which utilised the magnetic particles (in homogeneous solution), 
although providing increased surface area for interaction (which should 
increase assay sensitivity), probably introduced a greater degree of variability 
in the exposure of the various antigenic sites on the TPO molecule. This 
variability is reduced in the solid-phase assays, as the TPO is immobilised 
onto the plastic surface, which serves to decrease the randomness of the 
exposed sites for interaction with the TPOAb.
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The Coated-Tube Assay
Assay systems such as agglutination, radioimmunoassay (RIA) and enzyme- 
linked immunosorbent assay (ELISA) can give useful clinical information, but 
they all depend on the indirect measurement of the interaction between 
autoantibody and autoantigen, and this can result in limitations of sensitivity, 
precision and ease of handling. The coated-tube assay provided a direct 
measurement of TPOAb, with decreased reagent manipulation as compared 
with the ELISA. However, the coated-tube assay system (with analyses set up 
in duplicate), although perhaps involving less stages, did not provide any other 
immediate advantage over the established ELISA assay (analysed in 
quadruplicate). Both the assays required special, dedicated, measuring 
systems (i.e. ELISA requires a plate reader and the coated-tube assay 
requires the Ciba Corning [now Bayer] Magic® Lite Luminometer). The ELISA 
proved to be less technically cumbersome, with the micro-titre plates easier to 
wash than the tubes, and problems were encountered on occasions with the 
ineffective draining of the tubes, which could account for the lack of precision 
evident on some assays. However, plate-readers are now comm ercially 
available which are capable of measuring luminescence in micro-titre plates 
(such as the 'Orion 1 microplate luminometer by Flowgen). Both assay systems 
can be semi-automated with the application of sample processors and 
automated wash systems.
The AE label demonstrated a long shelf-life and was still functional after six 
months, which provided a significant advantage over the use of radioactive 
reagents, also requiring no stringent storage or disposal procedures. It was 
noted in the latter stages of the study that the assay RLUs had decreased in 
the coated-tube assay as compared with the start of the study. There also 
appeared to be a greater degree of imprecision in the duplicate analyses 
(especially at high TPOAb levels), which would warrant further investigation. 
This could be accounted for by reagent deterioration, however, technical 
problems were also encountered with the Magic® Lite Luminometer, which 
could also have introduced erroneus results.
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Statistical Analysis of Data
Comparison of the Coated-Tube Assay and ELISA
Among the tests that could be applied to describe the relationship between 
results by two methods are the least-squares linear regression, Pearson 
correlation, Deming regression analysis and the Passing and Bablok's method 
(Jones & Payne, 1997).
The Least-Squares Linear Regression
The least-squares linear regression is applied to paired measurements with 
the object of fitting the best straight line which will pass through the plotted 
points to predict the average value of any one variable, the dependent variable 
(usually named y), to be expected at any value of the other independent 
variable (usually named x). The assumptions of the parametric test for 
association in least squares linear regression, are that there is a straight line 
which can be drawn through the means of the x at any y value in such a way 
that the data points have a 'Normal Distribution' about it in the y direction at 
each value of x and that the S.D.s of y are similar at all values of x (Jones & 
Payne, 1997).
Non-parametric tests should be used when the data is not normally distributed, 
however, the logarithmic transformation of the data for the coated-tube assay 
and ELISA allowed the processing of the parametric 'scatter' plot or the 'least 
squares regression analysis'. The correlation coefficient (r) derived from 
comparing the coated-tube assay and the ELISA was 0.96, which indicated a 
very close correlation between the methods, with a probability P = <0.001 [Fig 
51].
The disadvantage of using the least-squares regression to describe the 
relation between two methods is the assumption that the independent variable 
is determined without error, however, in method comparison both variables are 
measured with error. The correlation coefficient (r) (introduced by Karl 
Pearson) is a numerical way of expressing how closely the slopes of the two 
regression lines agree. The Pearson correlation coefficient gives no
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information of value in method comparison studies, because (r) can be highly 
significant when there is no obvious bias between the two methods. A 
correlation coefficient (r) near one will be obtained when the data points lie 
close to a straight line even when the slope of the line is very different from 
one. It measures the strength of association and not of agreement (Jones & 
Payne, 1997).
Deming Method
The data were also processed using the Deming Plot, which adopted the 
approach of Kummel (1879) to solve the problem of describing the relationship 
between variables both measured with error, by proposing that the sum of the 
squares of the deviation from the line should be minimised in both the x and y 
directions at the same time, taking account of the analytical imprecision of 
each method, not done in the least-squares linear regression.
The major advantage of the Deming's method is that it gives only a single 
regression line whether x or y is used as the 'independent' variable. The 
intercept is calculated as in conventional least squares regression as the 
mean of y minus the product of the slope and the mean of x or vice versa. The 
calculation provided the standard error (SE) of the slope (0.029), and of the 
intercept (3.46) (in the y direction if x is taken as the independent variable), so 
that the line can be plotted with confidence limits [Fig 52 (i)].
The disadvantage of the Deming method is that it assumes the ratio of the 
analytical variances of the two methods is constant over the range of 
measurements. Thus, the method maybe in error if the analytical S.D.s 
increase with measured values at different rates. Like the least-squares linear 
regression, Deming's method is greatly influenced by data pairs that have 
substantially higher or lower values than the bulk of the results (Jones & 
Payne, 1997).
The Deming plot [Fig 52 (i)] again demonstrated a good correlation between 
the coated-tube assay and ELISA, with the residuals demonstrating increased 
variability at the higher TPOAb assay range [Fig 52 (ii)]. The residual value is
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the term used to denote the distance between an observed value and the 
value given by the regression line known as the 'fitted' value (Altman, 1991).
Passing and Bablok Model
The data were also analysed using the 'Passing & Bablok' Model (a 
modification of Thiel's procedure adapted to method comparison studies) [Figs 
51 (i) & (ii)]. Essentially, the slopes of all the straight lines between any two 
points are used to calculate the slope. Like Deming's method, it gives only one 
regression line. The method has been well publicised in the field of clinical 
chemistry, but has not been extensively used because the method of 
calculation has not been widely available.
The method introduces a median shift which, unlike the Deming method, has 
no bias in its estimates of slope and intercept when measurement error 
increases with concentration at different rates. The method has the additional 
advantage that each pair of results is given equal weight in the calculation so 
that, unlike Deming's method, it is not unduly biased by extreme values. It has 
the disadvantage that it gives no measure of scatter (Jones & Payne, 1997).
A good comparison was again demonstrated between the coated-tube assay 
and the ELISA, by the fact that the fitted regression line is similar to the 
identity line [Fig 52 (i)]. The cumulative sum (cusum) chart [Fig 52 (ii)] shows 
the cumulative count of residuals above and below the regression line and is 
used to determine linearity. Large peaks or troughs indicate many residuals on 
the same side of the regression line and possible non-linearity. The results 
demonstrated, that there was less agreement between the assays at the 
higher TPOAb range, by the sudden trough exhibited between running 
numbers 80 and 100 [Fig 52 (ii)].
Comparison of Indirect Agglutination with the Coated-Tube Assay and 
ELISA
A comparison was also carried out for 37 samples between indirect 
agglutination and the coated-tube assay and ELISA [Figs 54 & 55 
respectively]. As the data was non-parametric, and the data for the indirect
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agglutination had to be rank-ordered, the Wilcoxon Mann-Whitney Ranked 
Statistical test was applied to investigate the differences between two 
independent samples. This test is the non-parametric equivalent of the paired 
T test, and assigns the results in each category in ascending numerical 
values, and is used to test the null hypothesis that the distribution of two 
variables are the same (Jones & Payne, 1997). In this study the data obtained 
in the indirect agglutination assay was ranked from 1 to 8, which represented 
the result titres from negative to 1:500,000. The ELISA and coated-tube assay 
data was logarithmically transformed for the statistical comparison. A good 
correlation was demonstrated between the coated tube and indirect 
agglutination (r = 0.80, P = <0.001, n = 37) and also with ELISA and indirect 
agglutination (r = 0.85, P= <0.001, n = 37).
For the comparison of quantitative methods, measurements should be made 
in duplicate as in the coated-tube assay (with the ELISA performed in 
quadruplicate). This allows the calculation of the imprecision of each method 
at a range of levels and the assessment of whether outliers are due to 
imprecision (when the duplicates are likely to differ widely) or to a difference in 
specificity or susceptibilty to analytical interference between methods (when 
the duplicates are likely to give similar values). The outliers in the coated-tube 
assay were produced predominantly due to the imprecision of measurements, 
suggestive of a processing problem rather than an intrinsic methodological 
problem. The imprecision was more evident at higher TPOAb activites and 
towards the end of the study, possibly attributable to reagent deterioration. 
Erroneous values were produced in the ELISA, but to a lesser extent than in 
the coated-tube assay and quadruplicate analysis tended to reduce repeat 
analysis. However, another possible source of variation could be produced by 
the difference in the antigenic determinants intrinsic in the TPO antigen itself 
and its tissue source, and also due to a lack in specificity associated with its 
degree of purity.
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Precision Studies, Analytical Specificity and Sensitivity
Precision studies indicated comparable data for the coated-tube assay and 
ELISA, with perhaps an improved 'within-run' precision seen with the ELISA 
[Tables 3 & 4: 3.5.3].
The 'detection limit1 (analytical sensitivity) (defined as the smallest value that 
can be distinguished from zero with a defined degree of confidence) was 
found to be 2.46 klU/L which did not provide the level of sensitivity offered with 
the IRMA, nor that obtained with ELISA (0.8 klU/L). This value is determined 
by the degree of non-specific binding associated with the purity of the TPO 
coating antigen.
Studies to determine the 'analytical specificity' (described as the extent to 
which substances which maybe present in a sample interfere with the 
analysis) indicated that smooth muscle antibodies (SMA) did not interfere with 
the coated-tube assay, but did exhibit positive interference in the ELISA, 
however, this could be attributed to the icteric nature of the sample which 
would interfere with the colorimetric measurement. Morita et al. (1995) also 
reported SMA interference with the earlier immunofixation (IMF) techniques. 
Positive TPOAb results were produced in the coated-tube assay and in the 
ELISA on samples positive for mitochondrial antibody (MIT) and parietal cell 
antibody (PCA). However, the results were invalidated due to the 
demonstration of incidental positivity for TPOAb when assayed by indirect 
agglutination. No interference was indicated with a range of rheumatoid factor 
(RF) titres in either the coated-tube assay or the ELISA.
The coated-tube assay proved to be superior to the ELISA and the Cambridge 
Life Sciences 'Autozyme™' kit for measuring TPOAb in serum in that 
haemolysed, lipaemic and icteric samples did not produce any false positive 
(erroneous) values in the coated-tube assay. The ELISA demonstrated 
positive interference with the icteric sample and the manufacturer's of the 
'Autozyme™' kit advise against the use of the latter three sample 
interferences.
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Determination of the Assay 'Cut-off' Value for 'Normal' versus 
'Abnormal' Results
A first line screening test should detect all disease positive cases and should 
give no false negatives. On the other hand, a test used to confirm a diagnosis 
should be maximally 'specific' and should not misclassify patients as positive 
when they do not have the disease. In addition, a test used for monitoring 
treatment or disease needs to be highly reproducible.
Various statistical methods can be applied to the determination of the 'cut-off 
value. Groves et al. (1990) used a non-parametric method, as upon carrying 
out a 'Normal probability plot' their data were skewed and the 'cut-off was 
applied manually to determine the central 95% fraction. Intuitive assessment 
can provide a rule of thumb guidance as to the expected upper and lower 
limits of a particular value, but is not recommended (Jones & Payne, 1997). 
When using the 95% percentile for healthy individuals, greatly variable values 
have been obtained, partly attributable to the selected subject population (i.e. 
differences with the age and gender ratio), differences in TPOAb affinities in 
different serum samples, the method used for TPOAb measurement [including 
differences associated with the dilution media employed (Feldt-Rasmussen, 
1996)], and also the final reporting of results.
Assessment of a reference range for TPOAb in a normal population is a 
controversial issue, mainly due to the fact that TPOAb, as well as other thyroid 
autoantibodies may be positive in a healthy person with completely normal 
thyroid function. It is a matter of much speculation as to whether the presence 
of low concentrations of TPOAb is indicative of false-positive measurements 
or may indicate individuals with a predisposition to disease. Additionally, not all 
of these individuals progress to develop disease and there is no way of 
identifying which individuals will, as a complex interplay of genetic and 
environmental factors is involved.
A useful technique advocated for determining the optimum 'cut-off level is the 
Receiver Operator Characteristic (ROC) curve analysis. It can be applied to 
clinical measurements in order to identify optimum test 'cut-off values (Jones 
& Payne, 1997) and its usefulness as a fundamental evaluation tool in clinical
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medicine was reviewed by Zweig & Campbell (1993). The test is based on a 
graphical representation of sensitivity (y-axis) plotted against 1 minus 
specificity (x-axis) for a range of threshold values. The trade-off between 
sensitivity and specificity can be appreciated visually, or the test may be 
extended by comparing derived values from the curves, including the areas 
under the curves. This analysis was not attempted in this study as access to 
all the required clinical data was not possible to associate the diseased state 
with the measured TPOAb level.
The determination of the 'cut-off value (to distinguish between 'normal' and 
'abnormal') to screen for subclinical AITD was not determined in this study, as 
to provide valid results a large population study would be required of 
apparently 'normal' individuals, as carried out by Groves et a/. (1990), who 
studied 832 blood donor samples. However, as a good correlation of results 
was evident for the coated-tube assay and the ELISA, the 'cut-off value of 
19.6 klU/L used for the ELISA was applied to the coated-tube assay and only 
one discordant result was indicated (which was borderline for both methods) 
and would warrant further investigation in both cases.
The clinical sensitivity and specificity for the coated-tube assay (n=100) was 
calculated as being 100% and 95% respectively, using the 'cut-off value of 
19.6 klU/L for both ELISA and the coated-tube assay (assuming the ELISA to 
be the 'gold standard' [Table 6: 3.5.5 (i)]. A sensitivity of 73% and a specificity 
of 100% was calculated for indirect agglutination (n=37), using the 'cut-off 
value of 19.6 klU/L in the coated-tube assay and a titre of 1:100 as being 
negative in indirect agglutination [Table 7: 3.5.5 (ii)J. The limited data indicated 
that indirect agglutination tended to underestimate at high TPOAb 
concentrations and also be less sensitive at lower TPOAb concentrations, as 
compared with the coated-tube assay and ELISA.
The field of thyroid autoantibody testing has been hampered by poor attempts 
at interlaboratory or international standardisation of the methods used in 
clinical practice. It is therefore difficult to compare the analytical sensitivity, 
accuracy and precision profiles of the various methods presented in the 
literature or by commercial companies. Thus, although there is a reference
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preparation 66/387, the results are also dependent on the method principle, 
with results being quantified in terms of immunoglobulin content, 
antigen/epitope reactivity or binding capacity (Feldt-Rasmussen, 1996). 
Additionally the various studies in the literature involve the use of purified 
human TPO, porcine TPO, and more recently recombinant TPO or truncated 
recombinant TPO, with some method principles (e.g. competitive RIA) being 
highly dependent on a very pure source of TPO, whereas some methods are 
less influenced by impurites, the latter endorsed in this study.
Screening for Subclinical Autoimmune Thyroid Disease
A screening test for a particular condition must meet certain criteria before 
implementation, and be both clinically and financially viable, satisfying the 
requirements of sensitivity and specificity. It should be easy to perform and 
cause a minimum of stress to the individuals concerned, with an appropriate 
and effective treatment regime subsequently available.
A screening test to detect thyroid peroxidase autoantibodies in asymptomatic 
individuals in 'high-risk' groups could possibly provide intervention at an earlier 
stage of the disease process, which could preclude the need for lifelong 
supplementation of thyroid hormones or surgical intervention, which in itself is 
a substantial drain on health resources, or avoid the devastating 
consequences sometimes associated with PPT (Burrow, 1993; Pop et a/., 
1995).
The presentation of an unexplained increased, isolated thyroid-stimulating 
hormone (TSH) can indicate the presence of subclinical hypothyroidism or 
hyperthyroidism (Weetman, 1997), and provides a valuable 'first-line' 
investigation, which can be followed-up with the more specific and expensive 
TPOAb assay. The population prevalence of subclinical hypothyroidism (i.e. 
isolated raised TSH) varies between studies, with a range of approximately 
1.4 - 7.8% (Weetman, 1997). The prevalence of asymptomatic autoimmune 
thyroid disease in apparently normal individuals (by measuring thyroid 
autoantibodies) ranges from 3.6 - 8.4% (Roti et a/., 1992; Sundbeck et a/., 
1995) to 15% (Weetman & McGregor 1992), reflecting the chronological
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increase in methodological sensitivity. Women are around 3 times more 
frequently affected than men, especially in elderly women (Weetman, 2000). 
Women with both a raised TSH and positive thyroid autoantibodies are at a 
greater risk of developing overt hypothyroidism than with either an isolated 
increased TSH or TPOAb, with the relative risks even higher in men 
(Weetman, 2000).
The screening of the general population for subclinical hypothyroidism using 
TSH measurement is not advocated (Helfand, 1990; Vanderpump et al., 
1996). Similarly, the general screening for subclinical AITD using TPOAb 
measurement is not considered to be a viable option, as not all TPOAb 
positive individuals progress to develop disease, but it is recommended that 
'high-risk' groups are targeted for cost effectiveness. The annual risk of 
developing hypothyroidism in women is 4.3% when both anti-thyroid 
antibodies (namely TPOAb) are present and serum TSH is raised. If a raised 
serum TSH alone is found the annual risk of developing hypothyroidism is 
2.6% and the presence of anti-thyroid antibodies or raised serum TSH alone 
was associated with a highly significantly raised risk (5% per year) of 
developing hypothyroidism at twenty years (Vanderpump et al., 1995). The 
study by Vanderpump et al. (1995) has important implications for the 
recommendation of treatment of asymptomatic women with markers of thyroid 
disease, i.e. subclinical hypothyroidism. In addition, the appearance of thyroid 
autoantibodies seemed to be coincident with the menopause (Vanderpump et 
al., 1995). Thus, focusing on women over 40 years with non-specific 
symptoms would be a favourable approach (Weetman, 1997), and also on 
patients taking lithium or amiodarone who are also at risk of developing 
hypothyroidism and thyrotoxicosis and require regular monitoring of thyroid 
function (Vanderpump et al., 199).
Weetman, (2000) still does not advocate the general screening of pregnant 
women for subclinical AITD by measuring TPOAb, as only 50% of females 
who are TPOAb positive proceed to develop disease (Weetman, 1994). 
Targeting the more vulnerable or 'high-risk' sections of the population i.e. 
young females, especially those with Type 1 Diabetes Mellitus (Bech, et al.,
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1991) or other autoimmune endocrine disorders (Weetman, 1994) and 
individuals with a family history of disease, would prove to be more beneficial. 
It is recommended that women who are Type 1 Diabetes Mellitus antepartum 
should have thyroid antibody measurements in the first trimester, with careful 
follow up of those with positive results. Also, any women who develops PPT 
should be offered annual follow-up as about a quarter of these women will 
develop overt hypothyroidism within the next five years (Othman et a/., 1990). 
This approach is favoured by Weetman, (2000) who believes that the general 
screening and monitoring of TPOAb during pregnancy would result in further 
unwanted stress and anxiety, with no obvious advantage being gained.
The advent of new technology may prove that the more specific TPOAb test 
will become more cost-effective and be equally available for routine use as 
TSH measurements. The newer automated systems (with fully robotic systems 
also becoming available) are now capable of measuring chemical tests 
effectively and quickly. Bayer/Chiron are currently developing a method for 
measuring TPOAb which utilises acridinium ester and magnetic particles as 
the separation phase. Methods are also being developed for the measurement 
of TPOAb by Abbott on the 'AxSYM' Analyser, which utilises microparticle 
enhanced immunoassay (MEIA), and also by Johnson & Johnson on the 
Vitros E' Analyser which utilises solid-phase enzyme-immunoassay.
Treatment
As previously stated, before a screening programme can be introduced, an 
effective treatment regime must also be available, but controversy exists as to 
the appropriate and effective use of current treatments. An argument in favour 
of instituting thyroxine replacement is that it prevents the onset of overt 
hypothyroidism. This is particularly persuasive for people with raised thyroid 
stimulating hormone concentrations plus thyroid antibodies, who have an 
annual risk of developing overt hypothyroidism of around 5% (Vanderpump et 
a/., 1995). The detection of subclinical hypothyroidism (using a sensitive TSH 
assay) warrants further testing for thyroid peroxidase autoantibodies and if 
these are positive there is now general consensus that treatment with
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thyroxine is indicated (Weetman, 2000). For those individuals with subclinical 
hypothyroidism but negative antibodies, the need for treatment is yet to be 
established, although many endocrinologists would give a trial of thyroxine, as 
providing the TSH concentrations are restored to the reference range and 
properly monitored, no adverse effects have been indicated (Weetman, 1997).
There are modest benefits from treating subclinical hypothyroidism (Weetman, 
1997). Trials of treatment in sub-clinical hypothyroidism have shown small but 
significant benefits in symptom scores and psychometric performance, and 
there may be mild benefits with regard to lowering of cholesterol, as subclinical 
hypothyroidism is 2-3 times more common than expected in people with 
increased total plasma cholesterol concentrations (Weetman, 2000).
Reports have been made, whereby asymptomatic patients with 
autoantibodies, who are the treated with thyroxine can revert to normality, with 
no apparent recurrence of disease. Nystrom et al. (1988) have shown that 
asymptomatic female patients with subclinical hypothyroidism responded 
positively to therapy, as shown in a controlled trial in which the administration 
of L-thyroxine stopped some individuals from preceding onto developing 
autoimmune disease.
Hidaka et al. (1994) state that it may be possible that early diagnosis and the 
immediate start of appropriate drug therapy will bring a prompt remission in 
Graves' thyrotoxicosis, but no large-scale investigation had been carried out to 
substantiate their claims. Treatment of Graves' disease with antithyroid drugs 
and of idiopathic myxoedema or hypothyroid Hashimoto's thyroiditis with L-T4 
was also associated with a significant decrease in TPOAb (Jansson et al., 
1985; Mariotti et a/., 1990; Rieu et al., 1994; Takasu et al., 1990; Takasu et 
a/., 1992). In addition, Hashizume et al., 1991 and Rieu et al., 1994 agreed 
that thyroid hormonal status (changed with appropriate treatment) can 
modulate thyroid autoimmunity expression.
However, conflicting results have been reported on the effect of treatment on 
euthyroid individuals (Rieu et al., 1994). A decrease in mean levels of TPOAb 
in response to L-T4 therapy in euthyroid patients indicated by Rieu et al. 
(1994) showed discrepancies with other studies (Chiovata et al., 1986; Takasu
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et a/., 1990). This could possibly be explained by the variation introduced by 
differences in TPOAb methodology used, study-plans and treatment regimes. 
Also, PPT symptoms of depression are more common in women who have 
thyroid antibodies than in those without, irrespective of biochemical thyroid 
dysfunction. The implication being that some mood disturbance in subclinical 
hypothyroidism has an immunological rather than endocrinological basis, in 
which thyroxine treatment would not help (Weetman, 1997).
The cloning and expression of TPO as a recombinant protein has allowed 
progress on the characterisation of the autoantigenic epitopes recognised by 
autoantibodies. The main immunogenic region on the molecule recognised by 
autoantibodies has been localised to the carboxyl terminal. The availability of 
recombinant autoantigen, together with synthetic peptides derived from the 
amino acid sequence of TPO, will now facilitate the characteristics of T cell 
populations and the epitopes recognised on TPO from patients with AITD. 
This will allow therapeutic strategies at an antigen level to be addressed 
(Banga et a/., 1991).
There are reports of immunisation procedures being developed which may 
serve to prevent the onset of autoimmune disease. A number of approaches 
aimed at restoring self-tolerance in autoimmune disease are now being 
implemented in clinical trials in humans (Steinman, 1995). Oral tolerance is a 
long recognised method to induce peripheral immune tolerance and the oral 
administration of autoantigens may find a place in the treatment of human 
organ-specific inflammatory autoimmune diseases (Weiner et a/., 1994). 
Attempts to induce tolerance by feeding antigen have given encouraging 
results in small trials in patients with multiple sclerosis (MS) and rheumatoid 
arthritis (RA) (Weiner et a/., 1994) and may eventually be applied to AITD. The 
novel macrolide antibiotic, FK-506, has been found to ameliorate human AITD 
lesions in vivo by the inhibition of human intrathyroidal lymphocyte activation 
which might have central role(s) in the development and progression of human 




A follow-up option would be to attempt to label a recombinant preparation of 
TPO with AE and use in the chemiluminometric assay [Method 3 (System 3)]. 
However, although a recombinant TPO label may have the apparent 
advantage of greater precision and sensitivity, it might not have the capacity to 
identify all the autoantibodies which may present, which could result in falsely 
negative results. It would be of interest to compare the results of the ELISA 
used in this study for TPOAb measurements with an ELISA system 
(developed by Cambridge Life Sciences), called 'Autozyme™' which utilises 
recombinant TPO and employs a similar conjugate/substrate system.
It would also be of interest to adapt the coated-tube assay to a micro-titre plate 
assay, as the final results can be quantitated using plate readers capable of 
measuring luminescence in micro-titre plates, which would overcome some of 




Detection systems using chemiluminescent labels have been developed that 
are viable alternatives to radioisotopic methods. Chemiluminescence provides 
an extremely sensitive mode of detection, in which the reaction chemistry is 
typically very simple, yet very specific. The reagents require no special 
handling or disposal, and have excellent shelf-lives; and Chemiluminescence 
can be detected using a wide variety of methods from simple photographic film 
to highly sophisticated photon counting instrumentation (e.g. the Bayer/Chiron 
'Automated Chemiluminescent System 1 ). In contrast to other non-radioactive 
end-points, initiation of acridinium Chemiluminescence is extremely simple and 
robust. Quantitation is rapid (typically 2 seconds) and requires no substrate 
incubations or complex chemical manipulations prior to measurement.
The development of a viable chemiluminescent assay system using acridinium 
ester and magnetic particles as the separation medium, for the screening of 
TPOAb in human serum was not achieved in this study. However, the coated- 
tube assay, an alternative approach to the ELISA solid-phase system was 
devised, which produced acceptable assay data. The assay accommodated 
the use of the less pure TPO which could not be applied successfully to the 
other assay systems. The coated-tube assay was a direct method of analysis 
as compared to the indirect ELISA and involved less stages, but the assay 
time was only reduced by approximately 30 minutes. Acceptable precision was 
demonstrated, but the ELISA proved to be superior at the higher TPOAb 
levels. However, imprecision in the coated-tube assay could have been 
attributed to reagent deterioration in the latter stages of the study, and would 
merit further investigation to substantiate.
The provision of immunoassay reagents in the form of 'kits', sophisticated 
automated systems, and the considerable involvement of commercial 
interests, exemplifies the competitive nature in immunoassay development 
and the consequent proliferation of the methodology. However, it is apparent, 
that even in well-evaluated methods, problems can be encountered due to 
intrinsic (e.g. assay constituent changes) and extrinsic (e.g. presence of 
heterophilic antibodies) interferences, and these must be considered in an
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attempt not to report erroneous and misleading assay results, and all confirm 
that immunology tends to be a very complex and elusive science.
The selective screening for subclinical thyroid disease, including AITD, has 
been indicated to be beneficial. The earlier intervention in the disease process 
and subsequent treatment has been associated with alleviating symptoms or 
sometimes preventing the further progression of the disease. The advent of 
new, novel treatment regimes and techniques, together with the considerable 
advances evident in the field of genetics could however, ultimately result in the 
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All reagents used in the following appendix were obtained from 
BDH, unless otherwise stated in the text.
(1) Reagents, Buffers for Immunoradiometric Assay 
(Method 1)
(i) Tris HCL, pH 7.5 (Diluent for reconstituting the tracer and 
samples as described by Beever et at, 1989)
150 mmol/1 NaCl
10 mmol/1 Tris HC1
5g of BSA (Bovine serum albumin) (Sigma-Aldrich Co. Ltd.)
1 mlofTween 20
The NaCl and Tris (hydroxymetJiyl-methylamine) were weighed out 
and dissolved in approximately 600 cm3 double-distilled water 
(ddH2O) and the pH adjusted to 7.5 using concentrated HC1. BSA 
(5g) and 1 ml of the Tween 20 were added and the solution made up 
to 1 litre with ddH2O.
(ii) 2OO mmol/1 Phosphate Buffer, pH 7.4
To 161 ml of 0.2M disodium hydrogen phosphate (Na2HPO4.12H2O), 
a solution of 0.2M sodium dihydrogen phosphate (NaHaPC^) was 
added until pH 7.4.
(iii) 1OO mmol/1 Phosphate Buffer, pH 7.4
The 200 mmol/1 phosphate buffer, pH 7.4 was diluted with an equal
volume of ddH2O.
(iv) O.2M Sodium dihydrogen phosphate (NaHaPO-O (Mr=156.Ol)
15.601 g in 500 ml of ddH2O. 
(v) O.2M Disodium hydrogen phosphate (Na2 HPO4. 12H2O)
(Mr = 358.15)
35.815 g in 500 ml of ddH2O.
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(vi) 5% Glutaraldehyde (BDH)
3 ml of stock (5%) diluted with 12 ml of ddH2O.
(vii) Sigma Protein A (extracellular) Staphylococcus aureus 
(Cat N° P6O31)
Supplied as 5g of freeze-dried material.
(2) Reagents for Enzyme-immunometric Assay Using 
TPO Labelled with Horseradish Peroxidase (HRP) 
(Method 2)
(i) Acetate Buffer, pH 4.4
Anhydrous sodium acetate (8.2 g) was dissolved in approximately 
100 ml of ddHsO. Glacial acetic acid was added until pH was 4.4. 
(Acetate buffer diluted 10-fold with ddH2O for dialysis).
(ii) Sodium Deoxycholate (2O%)
4 g dissolved in 20 ml of ddF^O. 
(iii) Carbonate Buffer, pH 9.5
Sodium carbonate (0.5M) and sodium bicarbonate (0.5M) were 
prepared:-
Sodium carbonate (0.5M) (1.2 ml) was added to 10 ml of ddH20 and 
0.5 ml of 20% deoxycholate solution. The pH was adjusted to 9.5 
with 0.5M sodium bicarbonate and made up to 25 ml with ddH2O.
(iv) Sodium Periodate (O.1M)
Sodium periodate (0.0214 g) was dissolved in 1ml of ddH2O - 
prepared freshly just before use. 
(v) Phosphate-buffered Saline (PBS), pH 7.4
0.5M disodium hydrogen phosphate (35.49 g/500 ml) 
0.5M sodium dihydrogen phosphate (39.00 g/500 ml)
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Di-sodium hydrogen phosphate (0.5M) (32.1 ml), 18 g of sodium 
chloride, plus 4 ml of warmed 20% sodium deoxycholate was added 
to a beaker and the pH adjusted to 7.4 with sodium dihydrogen 
phosphate (0.5M). Then, 20 ml of 1% thiomersal was added and the 
solution made up to 2 litres with ddH2O.
(vi) OPD Substrate (Voller, et aL, 1979)
25 ml of citrate-phosphate buffer (see vii)
1 OPD (ortho-phenylene diamine dihydrochloride) tablet
(Sigma-Aldrich Co. Ltd.)
10 jul of hydrogen peroxide (H2O2)
(vii) Citrate/Phosphate Buffer, pH 5.O
24.3 ml of 0.1M citric acid (2.1014g /100 ml)
25.7 ml of 0.2M phosphate (7.163g Na2HPO4.12H2O/ 100ml)
50 ml of ddH2O
(3) Reagents for Chemiluminescent Assay 
[Method 3 (System 1)]
(i) Labelling Buffer [Phosphate Buffer (O.1M)], pH 8.O
15.6 g of NaH2PO4.2H2O per litre of ddH2O. 
(ii) Quenching Buffer
Lysine monohydrochloride (10 ing/ml)- supplied with kit and
reconstituted with 5 ml of ddH2O. 
(iii) Bovine Serum Albumin (BSA)/Phosphate Mix (1% BSA
Solution)
0.11 g BSA in 11 ml of 0.1M phosphate buffer, pH 8.0.
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(iv) Elution Buffer (with O.l% BSA)
10 ml of (iii) was added to 90 ml of (i) plus sodium azide 
(200mg/L).
(v) Diluent (for Stds, Controls and Tests) (PBS)
See Appendix 1 (5) for ELISA Diluent (PBS, pH 7.4). 
(vl) ELISA Wash
See Appendix 1 (5) for ELISA Wash.
(4) Reagents Used in Method 3 (System 2)
Reagents for ECL Biotinylation Procedure 
(i) Phosphate Buffered Saline, pH 7.5
11.5 g di-sodium hydrogen orthophosphate (anhydrous) (80mM) 
2.96 g sodium dihydrogen orthophosphate (20mM) 
5.84 g sodium chloride (lOOmM)
- the above were dissolved in approximately 800 ml of ddH2O, the 
pH adjusted to 7.5 and the solution made up to a final volume of 1 
litre.
(ii) Bicarbonate Buffer (4OmM), pH 8.6
Stock SOOmM supplied with kit, diluted 1 in 20 for use with 
ddH2O.
(iii) Wash Reagent 2 : O.1M Acetate Buffer, O.5M NaCl, pH4.O
Sodium acetate (4.101 g) and sodium chloride (14.61 g) were 
dissolved in approximately 400 ml of ddH2O, the solution was 
adjusted to pH 4.0 with HC1, and then made up to a final volume of 
500ml.
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Reagents for CNBr-activated Sepharose  4B 
Affinity Chromatography 
(i) Coupling Buffer
NaHCOs (0.1M), NaCl (0.5M), pH 8.3 - requires to be 
freshly prepared.
(ii) Tris-Buffered Azide, pH 7.4
10 mM Tris
150 mM NaCl
200 mg/1 Sodium Azide
5 ml of 2M Tris, 9g of NaCl and 200 mg of sodium azide were 
dissolved in 800 ml of ddH2O, the pH was adjusted to 7.4 and the 
solution made up to 1 litre. (TBS, pH 7.4 also used with 1% BSA in 
the dilution of the Biotin-TPO label).
(ill) 2M Sodium Chloride
58.44 g NaCl in 500 ml of ddH2O. 
(iv) 3M Sodium Thiocyanate (NaSCN)
2.43 g sodium thiocyanate (anhydrous) in 10 ml of 
TBS/Azide, pH 7.4.
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(5) Reagents for ELISA 
(i) Coating Buffer
4.2 g of sodium bicarbonate 
0.2g of sodium azide
-800 ml of ddH2O was added, the pH adjusted to 9.3 and the 
solution made up to 1 litre with ddHsO.
(ii) ELISA Wash
87.66 g NaCl
24.33 g Tris (Hydroxymethyl methylamine)
5 ml Tween Detergent
Approximately 600 ml of ddH2O was added to the above, the pH 
adjusted to 7.4 and then made up to a final volume of 10 litres with 
ddH2O.
(iii) Diluent (PBS) Phosphate-Buffered Saline, pH 7.4
1.56 g sodium dihydrogen phosphate (NaH2PO4.2H2O)
(Mr=156g)
9 g NaCl
0.2 g sodium azide
0.5 ml Tween
The above were dissolved in approximately 800 ml of ddHhO, the pH 
adjusted to 7.4 and then made up to 1 litre with
(iv) Antibody /Conjugate Reagent
25 ml of 0.9% saline (isotonic)
0.5 ml of sheep serum
25 nl of anti-human IgGrc Peroxidase
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(v) Substrate
0.01 g ABTS (2-2 1 Azino-di-(3-ethylbenzothiazolin sulphone-6
diammonium salt)
25 ml citrate phosphate buffer
10 jal hydrogen peroxide (H2O2)
(vi) Citrate Phosphate Buffer, pH 5.O
5.106 g Citric Acid
7.31 g Anhydrous disodium hydrogen phosphate (Na2PO4)
The above were dissolved in 800 ml of ddH2O, the pH adjusted to 
5.0 and then the solution made up to a final volume of 1 litre.
(vii) Stopping Reagent [can use either (a) or (b)]
(a) 0.04 g sodium fluoride (NaF) in 20 ml of ddH2O
(b) 10.5 g citric acid (i.e. 0.1M) in 500 ml of ddH2O 
0.05 g sodium azide (0.01%)
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Appendix 2
(1) Further Information on BioMag® 4100 Magnetic 
Particles Used in the IRMA (Method 1)
BioMag® 4100 consisted of a suspension of magnetic iron oxide 
particles coated to provide primary amino groups for the covalent 
attachment of proteins. The oxide particles are super-magnetic, i.e. 
they respond well to weak magnetic fields but do not become 
permanently magnetised. The amino groups are sterically 
unencumbered, permitting the covalent attachment of proteins or 
ligands (e.g. Protein A), with the retention of biological activity, (with 
a claimed coupling efficiency of 80% or greater).
BioMag® 4100 was supplied in distilled water containing ImM 
solution EDTA (ethylene diamine tetra-acetate), pH 7.0, at a 
concentration of approximately 50 mg/ml, with about 12 jjmoles of 
amine per ml in the BioMag® 4100 suspension as supplied (240 
nmoles/g). Magnetic separations are superior to conventional 
separations when biohazardous or radioactive materials are 
involved. Separation of BioMag® from solution via a magnetic rack 
eliminated the need for centrifugation, which eliminated the 
possibility of aerosol production, inherent in centrifugation and also 
the possible contamination of equipment was minimised. Further 
details can be found in the product literature from Advanced 
Magnetics Inc., [see Appendix 4 for address].
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(2) Micro Method for the Determination of Protein in 
Cerebrospinal Fluid and Urine
(a) Reagents
(i) Stock Ponceau S
0.4 g Ponceau S (BDH 'Gurr') in 19 ml of ddH2O. 
(ii) Stock TC A/Ponceau S
Trichloracetic acid (TCA) (30 g) was dissolved in 80 ml of ddH2O, 
and 2 ml of stock ponceau S (reagent 1) was added and then made 
up to 100 ml with ddH2O.
(iii) Working TCA/Ponceau S
Stock TCA/Ponceau S (reagent 2) (10 ml) was diluted to 100 
ml with ddH2O.
(iv) O.2M Sodium Hydroxide (NaOH)
8g in a litre of ddH2O.
(b) Method
The method was linear up to 2 g/1, and any proteins with a greater 
protein content required dilution with ddH2O.
1. 100 nl of each supernatant, standard and control was pipetted 
into a plastic tube and 1 ml of the working TCA/Ponceau S solution 
was added to each tube, mixed well and centrifuged at full speed for 
10 minutes.
2. The supernatant was then decanted without disturbing the 
precipitate and the tubes drained for 1 minute.
3. The precipitate was redissolved in 2.0 ml of 0.2M sodium 
hydroxide.
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4. The absorbances were read at 560 nm using water as a blank 
and then the protein concentration was calculated in g/L using the 
known protein content of the standard preparation.
The standard and quality control used in the assay procedure were 
in current routine laboratory use, to ensure that the procedure was 
acceptable.
(3) Estimation of Immunoglobulin G (IgG)
The immunoglobulin G to be measured in the supernatants, was 
mixed with its specific anti-sera (Dako Ltd) and the resulting 
turbidity measured photocolorimetrically on the Cobas Fara II 
centrifugal analyser at 340 nm. A standard curve was produced 
using SPS-01 Calibrant, obtained from The Royal Hampshire 
Hospital, Sheffield, with Behring N/T Protein Control Serum used 
as quality control.
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(4) Preparation of Thyroid Microsomes (as described 
by Groves et at, 199O)
Thyroid microsomes (containing the crude TPO antigen) were 
prepared from thyroid tissue obtained during sub-total 
thyroidectomy for primary hyperthyroidism [Graves' disease (G.D.)] 
The tissue was dissected and snap frozen in hexane, cooled over 
alcohol/CC>2 and subsequently stored at minus 80°C. Tissue was 
minced in 0.15M KC1 using a Polytron homogenizer (type PT350D, 
Northern Media Supplies Ltd., England) at full speed for 60 
seconds. The homogenate was centrifuged at 10,000 g for 15 
minutes at 4°C to remove cell debris before being recentrifuged 
(100,000; 60 minutes; 4°C). The pellet from this centrifugation, 
which represented a 'microsomaT fraction, was washed twice in 
phosphate buffered saline (PBS) (100,000 g; 4°C; 60 minutes) and 
suspended in 0.25M sucrose and solubilised using 10 volumes 
0.1% sodium deoxycholate in 0.0IM Tris, pH 8.0; insoluble material 
was removed by centrifugation (10,000g; 15 minutes; 4°C). The 
protein concentration of this soluble membrane fraction at this 
stage was found to be approximately 1 mg/ml using Folin phenol 
reagent. Human thyroglobulin (hTg) was isolated from the 
supernatant from the first 6x10 6 g/minute spin by taking an 
ammonium sulphate cut between 1.5M and 1.7M which was 
dialysed and purified on a column of Sephacryl S-300 equilibrated 
with Tris-buffered saline pH 7.0. Test analyses were carried out to 
determine the viability of the preparations for use in assays.
Appropriate precautions were taken in accordance with 'Health and 
Safety' guidelines for the handling of human tissue samples.
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(5) Preparation of Magnetic Particles Coupled to 
Anti-Human Immunoglobulin (IgG) (MAb-Anti-IgG)
(i) Preparation of IgG Protein
1. The antibody [sheep anti-human IgG (Heavy & Light Chain 
Specific)] obtained from the Scottish Antibody Production Unit, was 
reconstituted in Acetate Buffer, pH 5.5 (as described in Appendix 
1:2 but different pH).
2. Sodium sulphate was slowly added to give a final concentration 
of 180 mg/ml and mixed for 30 minutes at room temperature.
3. The mixture was centrifuged at 2000 r.p.m. for 20 minutes.
4. The pellet was redissolved in 4 ml of acetate buffer and dialysed 3 
times overnight using acetate buffer.
(ii) Coupling of IgG Protein to Magnetic Particles
1. The magnetic particles (obtained from Advanced Magnetics Inc.) 
were washed 3 times with methanol.
2. The particles were resuspended in approximately 25 ml of acetate 
buffer and shaken-mixed in a culture flask for 3 minutes, and the 
particles separated on a magnetic plate. The particles were then 
resuspended in 25 ml of acetate buffer and shaken-mixed. This was 
repeated 3 times.
3. The particles were then resuspended in approximately 8 ml of 
acetate buffer.
4. An equal volume of 12.5% glutaraldehyde was added and rotate- 
mixed for 3-4 hours. The particles were then washed 5 times each 
with 25 ml of acetate buffer.
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5. The particles were resuspended in 5 ml of acetate buffer and 5 ml 
of the antibody preparation gently added [prepared as described 
previously in (i)].
6. The mixture was gently mixed overnight at room temperature.
7. The particles were washed with PBS, pH 7.4 (see ELISA Reagents: 
Appendix 1) and then washed with 1M NaCl. This wash procedure 
was repeated 3 times.
8. The particles were then resuspended in diluent (phosphate 
buffer, pH 7.4).
9. The magnetic particle suspension coupled to anti-IgG (46 mg/ml) 
was then heat stressed for 16 hours at 50°C and subsequently 
washed 3 times with 25 ml of diluent.
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(6) (i) Preparation of Human Immunoglobulin (Ig) for 1 
Labelling with AE for Method 3 (System 2)
Ammonium sulphate was added to a serum sample containing a 
high TPOAb level to give a final concentration of 1.7M. This caused 
the Ig (containing high levels of IgG) to precipitate when left for 1 
hour at 0°C, which was subsequently isolated by centrifugation at 
>2000g. The resulting pellet was washed with 1.6M ammonium 
sulphate. The final pellet was dissolved in 1/5 volume of distilled 
water before being dialysed against three changes of Tris buffered 
saline [see Reagents (ii) next]. The optical density at 280 nm was 
measured and the protein concentration calculated using the 
extinction coefficient:-
The protein aliquots were stored at -70°C-
(ii) Reagents for Ammonium Sulphate Precipitation
Tris-Buffered Azide, pH 7.4
10 mM Tris
150 mM NaCl
200 mg/1 Sodium Azide
To 5 ml of 2M Tris, 9g of NaCl and 200 mg of sodium azide was 
added and dissolved in 800 ml of ddH2O. The pH was adjusted to 
7.4 and the solution made up to 1 litre.
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(7) Enzyme-linked Immunosorbent Assay (ELISA)
Each well of a (96-well) polystyrene, microtitre immunoassay plate 
(Dynatech Laboratories, INC.), was coated with 100 pi of human 
thyroid microsomes (10 ng/ml- diluted 1:100 in coating buffer, 50 
mM sodium carbonate, pH 9.1) to give a well concentration of 1 
Mg/ml. [The MIC preparation was solubilised with 1% deoxycholate 
(DOC) in phosphate buffered saline (PBS)]. The plates were 
incubated overnight at 4°C and then decanted vigorously. Each 
plate was washed four times with ELISA Wash Solution [see 
Appendix 1:5] and drained thoroughly between each wash.
Standards (diluted as for Method 1 (System 3); quality control and 
samples (diluted 1:100); and blanks (PBS buffer, pH 7.4), (100 nl of 
each) were added to each well (loaded vertically in quadruplicate). 
The plates were incubated at room temperature for 2 hours then 
thoroughly washed again four times with ELISA Wash.
The plates were treated with peroxidase conjugated sheep anti- 
human IgG antibody (Serotec) (100 jil of freshly-prepared conjugate 
being added to each well). The plate was then incubated for a 
further half hour at room temperature and the washing procedure 
repeated again. The autoantibody activity was quantified following 
the addition of ABTS (2,2 1 -Azino-bis(3-ethylbenzthiozoline-6- 
sulphonic acid)- [Boerhinger) and hydrogen peroxide as substrate 
reagent (with 100 nl of freshly prepared substrate being added to 
each well).
The plate was read at intervals at 410 nm using the T>ynatec' Multi- 
Plate Reader, with the colour measured spectrophotometrically at 
492 nm. When the optical density of the top standard reached 1.00, 
50 jil of stopping reagent was added across the plate. The final 
optical densities were then measured and the logarithmically 
converted standard data was plotted, and the test absorbances
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interpolated using the Olivetti M24 microcomputer using 'in-house' 
software written in Turbo Pascal'.
(8) Indirect Agglutination
The data for the indirect agglutination assays in this project, were 
provided using the Serodia®-AMC kit for the detection and titration 
of thyroid microsomal antibodies in human serum. This method 
utilised artificial gelatin particle carriers 'sensitised' with thyroid 
microsomal antigen, extracted and purified from human thyroid 
tissue. The coloured, artificial gelatin carriers are claimed to 
eliminate every possible chance for the production of 'non-specific - 
agglutination associated with passive haemagglutination (PH), and 
be easier to read than their PH counterpart (which utilised 
'erthrocytes sensitised' with thyroid microsomes as the carriers). In 
addition, results were provided in 3 hours and the final patterns 
were stable overnight.
Assay Procedure
Serum samples (appropriately diluted with kit diluent) were 
incubated with 'sensitised' particles in the *U -shaped wells of a (96- 
well) micro-titre. The contents of the wells were thoroughly mixed 
and allowed to stand on a level surface, at room temperature for 3 
hours and the patterns interpreted. TJnsensitised' particles were 
also incorporated into the assay to demonstrate any effects of 'non­ 




Affinity chromatography enables the purification of almost any 
biomolecule on the basis of its biological function or individual 
chemical structure. Affinity chromatography is a type of adsorption 
chromatography in which the molecule to be purified is specifically 
and reversibly adsorbed by a complementary binding substance 
(ligand) immobilised on an insoluble support (matrix).
It is important that the immobilised ligand retains its specific 
binding affinity for the substance of interest and that methods are 
available for selectively desorbing the bound substances in an active 
form, after washing away unbound material.
Sepharose® is a bead-formed agarose gel which displays virtually all 
the features required of a successful matrix for immobilising 
biologically active molecules. The hydroxyl groups on the sugar 
residues can be easily derivatised for covalent attachment of a 
ligand. Sepharose® 4B is the most favoured and widely-used matrix. 
The open-pore structure, and the exclusion limit of Sepharose® 4B 
in gel filtration is MWt 20xlO6 , makes the interior of the matrix 
available for ligand attachment and ensures good binding 
capacities, even for large molecules. Sepharose® 4B exhibits 
extremely low non-specific adsorption; this is essential because the 
power of affinity chromatography relies on specific interactions.
In 1972 Pharmacia Fine Chemicals developed CNBr-activated 
Sepharose® 4B, a stable ready-to-use medium for immobilising 
ligands. CNBr-activated Sepharose® 4B enables ligands containing 
primary amino groups to be safely, easily and rapidly immobilised 
by a spontaneous reaction [see Figure (i) for structure].
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Structure of Agarose gel
Agarose
HO
D-galactose 3-6 anhydro 
L-galactose










\ \ — 1*-
HO-I
isourea
Figure (i) Structure of agarose gel.
Taken from Pharmacia Fine Chemicals (Handbook), 1983, (Ch.3).
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The coupling reaction is spontaneous, rapid and easy to carry out 
and the amount of coupled ligand can be reproducibly controlled. 
Because cyanogen bromide, which is an extremely toxic and 
unpleasant chemical, is absent, the use of CNBr-activated 
Sepharose™ 4B requires no special chemicals or equipment.
CNBr-activated Sepharose™ 4B is produced by the reaction of 
Sepharose™ 4B with cyanogen bromide. The active product is freeze- 
dried in the presence of additives to preserve the bead form of the 
gel. The freeze-dried material (Ig) swells to give approximately 3.5 
ml of swollen gel. The freeze-dried material is supplied in packs of 
15 g and should be stored below 8°C. Under these conditions the 
shelf life is approximately 18 months.
The selection of the ligand for affinity chromatography (i.e. TPO in 
this method) is influenced by two factors. Firstly, the ligand should 
exhibit specific and reversible binding affinity for the substance to 
be purified. Secondly, it should have chemically modifiable groups 
which allow it to be attached to the matrix without destroying its 
binding activity.
Preparation of CNBr-Activated Sepharose™ 4B Gel
CNBr-activated Sepharose™ 4B Gel (Ig) was weighed out into an 
appropriate container (universal). Approximately 20 ml of ImM HC1 
was added in order to wash and swell the gel. The solution was then 
filtered using a Buchner filter funnel system. The gel was washed 
quickly with a further 200 ml of ImM HC1, with care being taken 
not to let the gel dry out, and then washed in a similar manner 
using 20 ml of coupling buffer (NaHCOs buffer, pH 8.3, containing 
0.5M NaCl) [see Appendix 1:4].
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Appendix 4
Suppliers: The following companies supplied equipment or 
consumables, as detailed in the text and used in this project.
Advanced Magnetics Inc., Metachem Diagnostics Ltd., 29, 
Forest Road, Piddington, Northampton, NN7 2DA.
Amersham LIFE SCIENCE, Amersham International pic., 
Amersham Place, Little Chalfont, Buckinghamshire, England, 
HP7 9NA.
Bayer pic (formerly Chiron Diagnostics), Registered Office 
Bayer House Strawberry Hill, Newbury, Berkshire, RG14 IJA.
Becton & Dickinson, Between Towns Road, Cowley, Oxford, 
OX4 3LY, England.
Boehringer Mannheim Ltd., (Diagnostics and Chemicals), 
Bell Lane, Lewes, East Sussex, BN7 1LG, England.
B.D.H. (British Drug House Ltd.), Poole, England.
Cambridge Life Sciences pic., Cambridgeshire Business Park, 
Angel Drove, Ely, Cambridge, CB7 4DT, England.
Behring (now Dade-Behring), Walton Manor, Walton, Milton 
Keynes, Buckinghamshire, MK7 7AJ.
Dynal (UK) Ltd., 10, Thursby Road, Croft Business Park, 
Bromborough, Wirral, Merseyside, L62 3PW.
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Dynatech Laboratories, INC., 14340 Sullyfield Circle, 
Chantilly, Virginia, 22021.
Fujirebio INC. (Serodia® AMC), 7-1, Nishi-shinjuku 2-chome, 
Shinjuku-ku, Tokyo, Japan.
Medicell International Ltd., 239, Liverpool Road, London, 
Nl 1LX
Molecular Light Technology Research Ltd., Cardiff Business 
Technology Centre, Senghenydd Rd., Cardiff, CF2 4AY.
National Institute for Biological Standards and Control,
Blanche Lane, South Mimms, Potters Bar, Hertfordshire, EN6 
3QG, United Kingdom.
Pharmacia LKB Biotechnology (Fine Chemicals), 23,
Grovener Road, St. Albans, Hertfordshire, AL1 3AW, England.
R.S.R. Ltd., Avenue Park, Pentwyn, Cardiff, U.K.
Sarstedt Ltd., 68, Boston Road, Beaumont Leys, Leicester, 
LE4 1AW, England.
Serotec U.K., 22, Bankside, Station Approach, Kidlington, 
Oxford, OX5 1JE, England.




The following graph is of a thyroglobulin autoantibody (TgAb) assay 
using the assay system [Method 3 (System 1)] [see 2.6] as described 
for the measurement of thyroid peroxidase autoantibodies (TPOAb) 
in human serum.
A preparation of Tg was labelled with AE using the same procedure 
employed in the preparation of Acrid-TPO (using the 'Molecular 
Light' labelling kit). The Tg used in the label was prepared at a 
different stage within the same procedure as used for the 
preparation of the thyroid microsomes (TPO) (Groves et al, 1990) 
[see Appendix 2:4]. The appropriate molar concentration (i.e. 0.3 
nmol of Tg) was used with 5 jag of AE in the preparation of the 
Acrid-Tg label. The standards (but with a different dilution regime), 
quality control and assay procedure was as used in the TPOAb 
assay.
A viable assay system was produced with a 17% uptake of AE (an 
order of 106 RLUs) exhibited by the top standard as compared with 
the meagre uptake of <2% (an order of 104 RLUs) in the assays 
using Acrid-TPO (label prepared using 5.5 jig of acridinium ester). 
Very good assay precision was demonstrated, with a correlation 
coefficient (r) of 0.99 produced [see Graph next page, error bars 
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